

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934**

For the Month of May 2025

1-15240
(Commission File Number)

JAMES HARDIE INDUSTRIES plc
(Translation of registrant's name into English)

1st Floor, Block A,
One Park Place
Upper Hatch Street, Dublin 2, D02, FD79, Ireland
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F..X.... Form 40-F.....

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Not Applicable

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Not Applicable

TABLE OF CONTENTS

Forward-Looking Statements	3
Exhibit Index	5
Signatures	6

Forward-Looking Statements

This Form 6-K contains forward-looking statements. James Hardie Industries plc (the “company”) may from time to time make forward-looking statements in its periodic reports filed with or furnished to the Securities and Exchange Commission, on Forms 20-F and 6-K, in its annual reports to shareholders, in offering circulars, invitation memoranda and prospectuses, in media releases and other written materials and in oral statements made by the company’s officers, directors or employees to analysts, institutional investors, existing and potential lenders, representatives of the media and others. Statements that are not historical facts are forward-looking statements and such forward-looking statements are statements made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.

Examples of forward-looking statements include:

- statements about the proposed merger between the Company and AZEK, including its completion, timing and anticipated benefits;
- statements about the company’s future performance;
- projections of the company’s results of operations or financial condition;
- statements regarding the company’s plans, objectives or goals, including those relating to strategies, initiatives, competition, acquisitions, dispositions and/or its products;
- expectations concerning the costs associated with the suspension or closure of operations at any of the company’s plants and future plans with respect to any such plants;
- expectations concerning the costs associated with the significant capital expenditure projects at any of the company’s plants and future plans with respect to any such projects;
- expectations regarding the extension or renewal of the company’s credit facilities including changes to terms, covenants or ratios;
- expectations concerning dividend payments and share buy-backs;
- statements concerning the company’s corporate and tax domiciles and structures and potential changes to them, including potential tax charges;
- statements regarding tax liabilities and related audits, reviews and proceedings;
- statements regarding the possible consequences and/or potential outcome of legal proceedings brought against us and the potential liabilities, if any, associated with such proceedings;
- expectations about the timing and amount of contributions to AICF, a special purpose fund for the compensation of proven Australian asbestos-related personal injury and death claims;
- statements regarding the company’s ability to manage legal and regulatory matters (including but not limited to product liability, environmental, intellectual property and competition law matters) and to resolve any such pending legal and regulatory matters within current estimates and in anticipation of certain third-party recoveries; and
- statements about economic or housing market conditions in the regions in which we operate, including but not limited to, the levels of new home construction and home renovations, unemployment levels, changes in consumer income, changes or stability in housing values, the availability of mortgages and other financing, mortgage and other interest rates, housing affordability and supply, the levels of foreclosures and home resales, currency exchange rates, and builder and consumer confidence.

Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “target,” “estimate,” “project,” “predict,” “forecast,” “guideline,” “aim,” “will,” “should,” “likely,” “continue,” “may,” “objective,” “outlook” and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Readers are cautioned not to place undue reliance on these forward-looking statements and all such forward-looking statements are qualified in their entirety by reference to the following cautionary statements.

Forward-looking statements are based on the Company's current expectations, estimates and assumptions and because forward-looking statements address future results, events and conditions, they, by their very nature, involve inherent risks and uncertainties, many of which are unforeseeable and beyond the Company's control. Such known and unknown risks, uncertainties and other factors may cause actual results, performance or other achievements to differ materially from the anticipated results, performance or achievements expressed, projected or implied by these forward-looking statements. These factors, some of which are discussed under "Risk Factors" in Section 3 of the Form 20-F filed with the Securities and Exchange Commission on 20 May 2025, include, but are not limited to: all matters relating to or arising out of the prior manufacture of products that contained asbestos by current and former Company subsidiaries; required contributions to AICF, any shortfall in AICF funding and the effect of currency exchange rate movements on the amount recorded in the Company's financial statements as an asbestos liability; compliance with and changes in tax laws and treatments; competition and product pricing in the markets in which the Company operates; the consequences of product failures or defects; exposure to environmental, asbestos, putative consumer class action or other legal proceedings; general economic and market conditions; the supply and cost of raw materials; possible increases in competition and the potential that competitors could copy the Company's products; compliance with and changes in environmental and health and safety laws; risks of conducting business internationally; compliance with and changes in laws and regulations; currency exchange risks; dependence on customer preference and the concentration of the Company's customer base; dependence on residential and commercial construction markets; the effect of adverse changes in climate or weather patterns; use of accounting estimates the proposed AZEK merger; and all other risks identified in the Company's reports filed with Australian, Irish and US securities regulatory agencies and exchanges (as appropriate). The Company cautions you that the foregoing list of factors is not exhaustive and that other risks and uncertainties may cause actual results to differ materially from those referenced in the Company's forward-looking statements. Forward-looking statements speak only as of the date they are made and are statements of the Company's current expectations concerning future results, events and conditions. The Company assumes no obligation to update any forward-looking statements or information except as required by law.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Results for Announcement to the Market
99.2	Appendix 4E - Preliminary Final Report 31 March 2025
99.3	Earnings Release
99.4	Earnings Presentation
99.5	KPMG Actuarial Report

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: 21 May 2025

James Hardie Industries plc

By: /s/ Aoife Rockett

Aoife Rockett

Company Secretary

EXHIBIT INDEX

Exhibit No.	Description
99.1	Results for Announcement to the Market
99.2	Appendix 4E - Preliminary Final Report 31 March 2025
99.3	Earnings Release
99.4	Earnings Presentation
99.5	KPMG Actuarial Report



James Hardie Industries plc
 1st Floor, Block A
 One Park Place
 Upper Hatch Street, Dublin 2
 D02 FD79, Ireland

T: +353 (0) 1 411 6924
 F: +353 (0) 1 479 1128

21 May 2025

The Manager
 Company Announcements Office
 Australian Securities Exchange Limited
 20 Bridge Street
 SYDNEY NSW 2000

Dear Sir/Madam

Results for Announcement to the Market

James Hardie announced today its results for the 4th quarter and year ended 31 March 2025 and has filed the following documents with the ASX:

- Appendix 4E: Preliminary Final Report for the year ended 31 March 2025
- Annual Report on Form 20-F, which has also been filed with the United States Securities and Exchange Commission (SEC)
- Earnings Release
- Earnings Presentation
- KPMG Actuarial Report for the year ended 31 March 2025

Copies of these documents are available on James Hardie's investor relations website at <https://ir.jameshardie.com.au/financial-information/financial-results>.

Shareholders who wish to receive a hard copy of the company's 20-F free of charge should contact the company's investor relations office on +1 312 756 9919.

Alternatively, shareholders can forward their request by email, including their mailing details, to: investor.relations@jameshardie.com.au.

Yours faithfully

Joe Ahlsmeyer, CFA
 Vice President, Investor Relations

This announcement has been authorized for release by the Board of Directors of James Hardie Industries plc.

James Hardie Industries plc is a limited liability company incorporated in Ireland with its registered office at 1st Floor, Block A, One Park Place, Upper Hatch Street, Dublin 2, D02 FD79, Ireland.
Directors: Anne Lloyd (Chairperson, USA), Peter-John Davis (Aus), Persio Lisboa (USA), Renee Peterson (USA), John Pfeifer (USA), Rada Rodriguez (Sweden), Suzanne B. Rowland (USA), Nigel Stein (UK), Harold Wiens (USA).
Chief Executive Officer and Director: Aaron Erter (USA)
Company number: 485719
ARBN: 097 829 895

Results for Announcement to the Market

James Hardie Industries plc

ARBN 097 829 895

Appendix 4E - Preliminary Final Report Year Ended 31 March 2025

Key Information (US\$ Millions, except per share data)	FY 2025	FY 2024	Movement	
Net Sales From Ordinary Activities	3,877.5	3,936.3	Down	(1)%
Profit From Ordinary Activities After Tax Attributable to Shareholders	424.0	510.2	Down	(17)%
Net Profit Attributable to Shareholders	424.0	510.2	Down	(17)%
Net Tangible Assets per Ordinary Share	US\$4.24	US\$3.50	Up	21%

Dividend Information

The Company does not propose to pay a dividend and no dividends were declared or paid for the current reporting period.

Movements in Controlled Entities

There following entities were created: James Hardie Netherlands B.V., Belgium branch (8 November 2024), Juno Merger Sub Inc. (21 March 2025) and JH North America Holdings Inc. (21 March 2025).

The following entities were dissolved: RCI Pty Limited (8 January 2025) and James Hardie Systems Pty Ltd (15 January 2025).

Associates and Joint Venture Entities

Aplicaciones Minerales S.A. (28%)

The following was sold: FELS Recycling GmbH (1 July 2024).

Other

The Consolidated Financial Statements, upon which this report is based, have been prepared using US GAAP and have been subject to an independent audit by external auditors, Ernst & Young, unless otherwise noted.

This information should be read in conjunction with the Company's 2025 Annual Report. This report can be found on the company website at <https://ir.jameshardie.com.au/financial-information/financial-results>.

This announcement has been authorized for release by the Board of Directors of James Hardie Industries plc.

James Hardie Achieves FY25 Guidance Issues FY26 Guidance for Organic Sales and Adjusted EBITDA Growth

Delivers Global and North America Results Consistent with FY25 Guidance

FY25 GAAP Operating Income of \$656 million, Adjusted EBITDA of \$1.1 billion

FY25 Adjusted EBITDA Margin of 27.8% Reflecting Hardie Operating System Savings and Cost Control

Expects Organic Sales and EBITDA Growth In Every Region for FY26

James Hardie Industries plc (ASX / NYSE: JHX) ("James Hardie" or the "Company"), a leader in providing high performance, low maintenance building products and solutions, and a company inspiring how communities design build and grow, today announced results for its fourth quarter ending March 31, 2025. Speaking to the results, Aaron Erter, CEO said, "We delivered solid business and financial results in the fourth quarter, and our FY25 performance reflects our commitment to invest to scale the organization and grow profitably even in a more challenging market environment. We are executing on our growth strategy and are confident that our actions are driving market outperformance that will enable us to sustain our strong positioning."

Mr. Erter continued, "We are winning by partnering with our customers and contractors while delighting homeowners by delivering products that are resilient and beautiful. Success across our value chain propels our organization forward and fuels my optimism about the future of James Hardie. We have the strongest team in the industry and the right strategy to go after our material conversion opportunity. Over the past five years, our North American business has grown the top line at a +10% CAGR and expanded Adjusted EBITDA margin by more than +400bps, a clear demonstration of the inherent strength of our value proposition and the underlying momentum in our strategy. Our conviction is as strong as ever in achieving our long-term aspirations¹ for North America Fiber Cement, namely to grow revenue double-digits, expand EBITDA margins by another +500 basis points, and triple our EBITDA. I am confident in the future of James Hardie as we continue building on these successes and accelerate our growth strategy."

Rachel Wilson, CFO said, "We achieved each of our FY25 guidance metrics despite a more challenging macro environment as compared to May of last year, when we initially provided this outlook. In North America, our team delivered a solid fourth quarter and we achieved our guidance points, both in our second half and full year, for volume and EBIT Margin. Our mid-thirties EBITDA margin for the full year demonstrates diligent cost control and full delivery of HOS savings, which together, helped mitigate unfavorable volume leverage from softer end markets."

1) For additional information regarding the Company's Long-Term Aspirations, see the Company's Earnings Presentation for the fourth quarter ended March 31, 2025.

Fourth Quarter Highlights

- Net Sales of \$972 million, down (3%) comparing vs. the all-time quarterly record
- GAAP Operating income of \$62 million; GAAP Operating margin of 6.4%; GAAP Net income of \$44 million; and GAAP Diluted EPS of \$0.10
- Adjusted EBITDA of \$269 million, down (4%) with Adjusted EBITDA margin of 27.6%, down (30bps), both comparing vs. record 4Q results
- Adjusted Net Income of \$156 million, down (10%)
- Adjusted Diluted EPS of \$0.36, down (9%)

Fiscal Year 2025 Highlights

- Net Sales of \$3.9 billion, down (1%) comparing vs. record results in FY24
- GAAP Operating income of \$656 million; GAAP Operating margin of 16.9%; GAAP Net income of \$424 million; and GAAP Diluted EPS of \$0.98
- Adjusted EBITDA of \$1.1 billion, down (4%) with Adjusted EBITDA margin of 27.8%, down (80bps), both comparing vs. record results in FY24
- Adjusted Net Income of \$644 million, down (9%) comparing vs. record results in FY24
- Adjusted Diluted EPS of \$1.49, down (7%) comparing vs. record results in FY24

Proposed Transaction with The AZEK Company Inc (AZEK)

In March, the Company announced entry into a definitive agreement under which James Hardie will acquire AZEK for a combination of cash and James Hardie shares, with the transaction expected to close in the second half of calendar year 2025. Speaking to the combination, Mr. Erter said, "This combination with AZEK is an extraordinary opportunity to accelerate our growth strategy, deliver enhanced and differentiated solutions to our customers and drive shareholder value. We are uniting two highly complementary companies with large material conversion opportunities and shared cultures centered around providing winning solutions to our customers and contractors. Together, we will be well positioned to drive sustained above-market growth as a leader across exterior building products. The combination will further accelerate our sales growth by an incremental two and a half percentage points on top of our double-digit trajectory due to AZEK's faster growth profile, and delivery of \$500 million of run-rate commercial synergies over the next five years. We also expect that the transaction will be accretive to our organic margin expansion target of +500 basis points, driven both by AZEK's own organic margin improvement potential, as well as by the \$125 million of run-rate cost synergies that we expect to achieve over the next three years. Our combined business will be an engine of tremendous cash flow generation, and once run-rate cost synergies are achieved, we expect to generate robust annual free cash flow of greater than a billion dollars."

Segment Business Update and Results

North America Fiber Cement

In North America, the Company is outperforming its end markets through a superior value proposition and driving leading margins despite raw material headwinds. James Hardie's significant material conversion opportunity and investments across the North American manufacturing footprint have positioned the Company well to capitalize as the market returns to growth and the long-term housing fundamentals play through. The Company is investing across the value chain and growing its contractor base to capture the repair & remodel opportunity. Similarly, in new construction, efforts to deepen exclusivity and increase trim attachment rates support growth and share gain with large homebuilders. Over the last year, in a clear demonstration of the appreciation for James Hardie's innovative product solutions and unrivaled business support, the Company has announced multi-year, national hard siding and trim exclusivity agreements with Meritage Homes, M/I Homes, David Weekley Homes, Stanley Martin Homes, CastleRock Communities, Trumark Homes, CBH Homes, Davidson Homes and McKinley Homes.

During the quarter, net sales decreased (2%). Volumes declined (3%) due to continued market weakness, particularly in multi-family, partially offset by efforts to gain share in single-family new construction and repair & remodel. Sales also benefited from a higher average net sales price, resulting from the January 2025 price increase. Volume of Exterior products declined low single-digits, and were up slightly sequentially. Volume of Interior products declined low double-digits. EBIT margin decreased (350bps) to 28.2%, due to higher pulp and cement costs as well as unfavorable production cost absorption, partially offset by Hardie Operating System (HOS) savings. Excluding depreciation and amortization expense, which rose +32% to \$45 million, EBITDA declined (7%) to \$248 million with EBITDA margin of 34.4%, a decrease of (190bps) attributable to similar drivers of EBIT margin.

Asia Pacific Fiber Cement

In Australia & New Zealand, the Company is increasing share through new customer acquisitions and project conversion enabled by customer integration. The Company is influencing how homeowners build, and driving growth through Co-Creation and leveraging the James Hardie brand. The teams are innovating to accelerate material conversion with a key focus on new construction, specifically the conversion of brick & masonry. Overall, while market demand remains challenged, the Asia Pacific team is focused on finding further efficiencies and driving HOS savings to underpin the segment's consistent profitability.

During the quarter, net sales decreased (13%) in Australian dollars, due to lower volumes of (31%) partially offset by a higher average net sales price of +25%. Adjusted EBIT margin rose +330bps to 30.5%, and excluding depreciation and amortization expense, which increased +7% to \$5 million, adjusted EBITDA declined (5%) to \$41 million with adjusted EBITDA margin of 34.5%, an increase of +410bps. The decline in volumes, increase in average net sales price and improvement in margins were each primarily attributable to the closure of the Philippines manufacturing and commercial operations. Australia & New Zealand together saw a low single-digit decrease in volume and a low single-digit increase in average net sales price, leading to a slight increase in net sales. Margins also rose modestly in Australia & New Zealand, due primarily to slightly positive average net sales price and HOS savings.

Europe Building Products

Markets across Europe remain challenged, particularly in Germany, our largest European market, where improvement is anticipated to be more gradual, while in the UK, the Company is well-positioned to capture potential improvement in residential construction. Growth in high-value products remains a strategic priority, as leveraging a broader and deeper product portfolio should accelerate share gains and customer wins. Recently designated as the fiber gypsum Brand of the Century by Deutsche Standards, pioneering innovations such as Therm25 have made fermacell® a European market leader for high-quality building products.

During the quarter, net sales increased +8% in Euros, including a higher average net sales price of +7%, driven by the price increases earlier this fiscal year. EBIT margin decreased (40bps) to 9.9% due to higher energy and raw material costs and higher employee costs related to increased headcount for our high value product sales force. Excluding depreciation and amortization expense, which rose +4% to \$9 million, EBITDA increased +2% to \$22 million with EBITDA margin of 16.2%, a (50bps) decrease attributable to similar drivers of EBIT margin.

Outlook

FY26 Guidance

Speaking to the Company's market outlook, Mr. Erter said, "As we turn our focus towards continuing our material conversion mission, I reflect with pride on the resilience our teams have shown as our industry faces persistent headwinds. More recent, broader macroeconomic uncertainty could further impact the cost of home construction and weigh on consumer sentiment, influencing demand. As a result, in North America, which represents approximately three-quarters of our total net sales we are prudently planning for market volumes to contract in FY26, including a fourth consecutive year of declines in large-ticket repair & remodel activity. Despite these near-term headwinds, our brand and the attractiveness of our value proposition to customers has and will enable James Hardie to structurally grow through expansions and contractions. We will continue to navigate through the current backdrop, focusing on outperforming our end-markets to drive top- and bottom-line in FY26, consistent with our prior planning assumptions."

Mr. Erter continued, "Across our businesses, we remain committed to outperforming the markets in which we participate and have purposeful strategies that ensure we deliver on these commitments year in and year out. These plans are grounded in capturing the material conversion opportunity and driving value for our customer partners."

Ms. Wilson added with respect to financial planning assumptions, "We are committed to driving profitable growth and are reaffirming our previously stated business planning assumptions for organic sales and EBITDA growth in every region. Furthermore, we remain aligned as an organization around delivering strong cash flows not only to fund growth investments but also to ensure a strong balance sheet and enable return of capital to shareholders within our deleveraging targets. We expect to grow our free cash flow by +30% to at least half a billion dollars in FY26 by virtue of our profitable growth, stewardship of working capital, and reduction in our capital expenditures."

- North America Net Sales Growth: **Up Low Single-Digits**
- North America EBITDA Margin: **~35.0%**
- Total Adjusted EBITDA Growth: **Up Low Single-Digits**
- Free Cash Flow: **At least \$500 million, Up +30%**

FY26 Modeling Assumptions

- Total Capital Expenditures: **~\$325 million**
- Total Depreciation & Amortization Expense: **~\$225 million**
- Adjusted Effective Tax Rate: **Relatively Flat** vs. 23.5% in FY25

Note: Planning and modeling assumptions reflect only the standalone James Hardie business and exclude any impacts of acquisitions that have not closed. Free Cash Flow is defined as net cash provided by operating activities less purchases of property, plant and equipment.

Cash Flow, Capital Investment & Allocation

Operating cash flow totaled \$803 million for FY25, driven by \$955 million of net income, adjusted for non-cash items, partially offset by higher working capital of \$26 million and \$114 million of asbestos claims and handling costs paid. Capital expenditures were \$422 million.

During FY25, the Company invested \$165 million related to capacity expansion, with key milestones including commencement of production at the Company's Westfield, Massachusetts ColorPlus® facility in April, as well as the Company's Prattville Alabama facility, specifically on Sheet Machine 3 in September. The Company also completed installation of Sheet Machine 4 at the Prattville facility during the fiscal year. Looking to FY26, the Company expects investment in capacity expansion projects to moderate as several projects approach or reach completion, including at Prattville and Orejo.

The Company repurchased 4.5 million shares for a total of \$150 million over the course of FY25, completing the previously-announced repurchase program. In November, the Company's Board of Directors approved a new repurchase program, under which the Company is authorized to purchase up to \$300 million of shares through October of 2025. Due to regulatory and other considerations, the Company is not expected to repurchase stock until after it closes the AZEK transaction.

Key Financial Information

	Q4 FY25	Q4 FY24	Change	Q4 FY25	Q4 FY24	Change
Group (US\$ millions, except per share data)						
Net Sales	971.5	1,004.9	(3%)			
EBIT	62.1	84.0	(26%)			
Adjusted EBIT	209.2	232.5	(10%)			
EBIT Margin (%)	6.4	8.4	(2.0 pts)			
Adjusted EBIT Margin (%)	21.5	23.1	(1.6 pts)			
Adjusted EBITDA	268.6	280.8	(4%)			
Adjusted EBITDA Margin (%)	27.6	27.9	(0.3 pts)			
Net Income	43.6	55.6	(22%)			
Adjusted Net Income	156.1	174.2	(10%)			
Diluted EPS - US\$ per share	0.10	0.13	(20%)			
Adjusted Diluted EPS - US\$ per share	0.36	0.40	(9%)			
North America Fiber Cement (US\$ millions)						
Net Sales	718.9	735.2	(2%)			
EBIT	202.4	233.0	(13%)			
EBIT Margin (%)	28.2	31.7	(3.5 pts)			
EBITDA	247.6	267.2	(7%)			
EBITDA Margin (%)	34.4	36.3	(1.9 pts)			
Asia Pacific Fiber Cement (US\$ millions) (A\$ millions)						
Net Sales	118.1	141.5	(17%)	188.1	215.2	(13%)
EBIT	43.0	38.5	12%	68.4	58.6	17%
Adjusted EBIT	36.0	38.5	(6%)	57.3	58.6	(2%)
EBIT Margin (%)	36.4	27.2	9.2 pts	36.4	27.2	9.2 pts
Adjusted EBIT Margin (%)	30.5	27.2	3.3 pts	30.5	27.2	3.3 pts
Adjusted EBITDA	40.8	43.0	(5%)	64.9	65.4	(1%)
Adjusted EBITDA Margin (%)	34.5	30.4	4.1 pts	34.5	30.4	4.1 pts
Europe Building Products (US\$ millions) (€ millions)						
Net Sales	134.5	128.2	5%	127.7	118.0	8%
EBIT	13.3	13.1	2%	12.6	12.1	4%
EBIT Margin (%)	9.9	10.3	(0.4 pts)	9.9	10.3	(0.4 pts)
EBITDA	21.8	21.3	2%	20.7	19.7	5%
EBITDA Margin (%)	16.2	16.7	(0.5 pts)	16.2	16.7	(0.5 pts)

	FY25	FY24	Change	FY25	FY24	Change
Group	(US\$ millions, except per share data)					
Net Sales	3,877.5	3,936.3	(1%)			
EBIT	655.9	767.4	(15%)			
Adjusted EBIT	863.2	940.8	(8%)			
EBIT Margin (%)	16.9	19.5	(2.6 pts)			
Adjusted EBIT Margin (%)	22.3	23.9	(1.6 pts)			
Adjusted EBITDA	1,079.4	1,125.8	(4%)			
Adjusted EBITDA Margin (%)	27.8	28.6	(0.8 pts)			
Net Income	424.0	510.2	(17%)			
Adjusted Net Income	644.3	707.5	(9%)			
Diluted EPS - US\$ per share	0.98	1.16	(16%)			
Adjusted Diluted EPS - US\$ per share	1.49	1.61	(7%)			
Operating Cash Flow	802.8	914.2	(12%)			
North America Fiber Cement	(US\$ millions)					
Net Sales	2,863.3	2,891.4	(1%)			
EBIT	840.9	921.1	(9%)			
EBIT Margin (%)	29.4	31.9	(2.5 pts)			
EBITDA	1,001.6	1,054.9	(5%)			
EBITDA Margin (%)	35.0	36.5	(1.5 pts)			
Asia Pacific Fiber Cement	(US\$ millions)			(A\$ millions)		
Net Sales	519.9	562.8	(8%)	795.0	856.3	(7%)
EBIT	111.0	166.1	(33%)	172.7	252.7	(32%)
Adjusted EBIT	161.3	166.1	(3%)	246.3	252.7	(3%)
EBIT Margin (%)	21.7	29.5	(7.8 pts)	21.7	29.5	(7.8 pts)
Adjusted EBIT Margin (%)	31.0	29.5	1.5 pts	31.0	29.5	1.5 pts
Adjusted EBITDA	180.5	183.1	(1%)	275.7	278.5	(1%)
Adjusted EBITDA Margin (%)	34.7	32.5	2.2 pts	34.7	32.5	2.2 pts
Europe Building Products	(US\$ millions)			(€ millions)		
Net Sales	494.3	482.1	3%	460.6	444.5	4%
EBIT	38.0	45.0	(16%)	35.4	41.5	(15%)
EBIT Margin (%)	7.7	9.3	(1.6 pts)	7.7	9.3	(1.6 pts)
EBITDA	70.4	74.7	(6%)	65.6	68.9	(5%)
EBITDA Margin (%)	14.2	15.5	(1.3 pts)	14.2	15.5	(1.3 pts)

Further Information

Readers are referred to the Company's Consolidated Financial Statements and Management's Analysis of Results in Section 2 of James Hardie's Annual Report on Form 20-F for the year ended March 31, 2025 for additional information regarding the Company's results.

All comparisons made are vs. the comparable period in the prior fiscal year and amounts presented are in US dollars, unless otherwise noted.

For more information on the proposed transaction with The AZEK Company Inc please see jameshardieandazek.com.

Conference Call Details

James Hardie will hold a conference call to discuss results and outlook Wednesday, May 21, 2025 at 8:00am AEDT (Tuesday, May 20, 2025 at 6:00pm EST). Participants may register for a live webcast and access a replay following the event of the event on the Investor Relations section of the Company's website (ir.jameshardie.com).

About James Hardie

James Hardie Industries plc is the world's #1 producer and marketer of high-performance fiber cement, and in Europe, fiber gypsum building solutions. James Hardie markets its fiber cement products and systems under the Hardie™ brand, such as Hardie® Plank, Hardie® Panel, Hardie® Trim, Hardie® Backer, Hardie® Artisan Siding, Hardie™ Architectural Collection. James Hardie is also a market leader in the European premium timber frame and dry lining business.

James Hardie Industries plc is incorporated and existing under the laws of Ireland. As an Irish plc, James Hardie is governed by the Irish Companies Act. James Hardie's principal executive offices are located at 1st Floor, Block A, One Park Place, Upper Hatch Street, Dublin 2, D02 FD79, Ireland.

Investor and Media Contact

Joe Ahlersmeyer, CFA
Vice President, Investor Relations
+1 773-970-1213
investors@jameshardie.com

Cautionary Note and Use of Non-GAAP Measures

This Earnings Release includes financial measures that are not considered a measure of financial performance under generally accepted accounting principles in the United States (GAAP), such as Adjusted Net Income, Adjusted EBIT, Adjusted EBITDA and Adjusted Diluted EPS. These non-GAAP financial measures should not be considered to be more meaningful than the equivalent GAAP measure. Management has included such measures to provide investors with an alternative method for assessing its operating results in a manner that is focused on the performance of its ongoing operations and excludes the impact of certain legacy items, such as asbestos adjustments. Additionally, management uses such non-GAAP financial measures for the same purposes. However, these non-GAAP financial measures are not prepared in accordance with GAAP, may not be reported by all of the Company's competitors and may not be directly comparable to similarly titled measures of the Company's competitors due to potential differences in the exact method of calculation. The Company is unable to forecast the comparable US GAAP financial measure for future periods due to, amongst other factors, uncertainty regarding the impact of actuarial estimates on asbestos-related assets and liabilities in future periods. For additional information regarding the non-GAAP financial measures presented in this Earnings Release, including a reconciliation of each non-GAAP financial measure to the equivalent GAAP measure, see the section titled "Non-GAAP Financial Measures" included in the Company's Earnings Presentation for the fourth quarter ended March 31, 2025.

In addition, this Earnings Release includes financial measures and descriptions that are considered to not be in accordance with GAAP, but which are consistent with financial measures reported by Australian companies, such as EBIT and EBIT margin. The Company prepares its consolidated financial statements under GAAP. The equivalent GAAP financial statement line item description for EBIT used in its consolidated financial statements is Operating income (loss). The Company provides investors with definitions and a cross-reference from the non-GAAP financial measure used in this Earnings Release to the equivalent GAAP financial measure used in the Company's consolidated financial statements. See the section titled "Non-GAAP Financial Measures" included in the Company's Earnings Presentation for the fourth quarter ended March 31, 2025.

This Earnings Release contains forward-looking statements and information that are necessarily subject to risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of James Hardie to be materially different from those expressed or implied in this release, including, among others, the risks and uncertainties set forth in Section 3 "Risk Factors" in James Hardie's Annual Report on Form 20-F for the fiscal year ended March 31, 2025; changes in general economic, political, governmental and business conditions globally and in the countries in which James Hardie does business; changes in interest rates; changes in inflation rates; changes in exchange rates; the level of construction generally; changes in cement demand and prices; changes in raw material and energy prices; changes in business strategy; the proposed AZEK merger and various other factors. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein. James Hardie assumes no obligation to update or correct the information contained in this Earnings Release except as required by law.

This earnings release has been authorized by the James Hardie Board of Directors.

Fourth Quarter FY25

Earnings Presentation



CHICAGO | DUBLIN
TUESDAY, MAY 20TH

SYDNEY
WEDNESDAY, MAY 21ST

Cautionary Disclosure Regarding Forward-Looking Statements

Statements in this communication, including statements regarding the proposed acquisition of The AZEK Company Inc. ("AZEK") by James Hardie Industries plc ("JHX"), that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Rule 175 promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934, as amended, and Rule 3b-6 promulgated thereunder, which statements involve inherent risks and uncertainties and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Examples of forward-looking statements include statements about the anticipated benefits of the proposed transaction between JHX and AZEK (the "Transaction"), including estimated synergies, and the expected timing of completion of the Transaction; statements about the Company's future performance; and statements regarding the Company's plans, objectives or goals. Words such as "believe," "anticipate," "plan," "expect," "intend," "target," "estimate," "project," "predict," "trend," "forecast," "guideline," "aim," "objective," "will," "should," "could," "likely," "continue," "may," "objective," "outlook" and similar expressions may identify forward-looking statements but are not the exclusive means of identifying such statements. Investors are cautioned not to place undue reliance on forward looking statements.

Forward-looking statements of JHX and AZEK, respectively, are based on the current expectations, estimates and assumptions of JHX and AZEK, respectively, and, because forward-looking statements address future results, events and conditions, they, by their very nature, involve inherent risks and uncertainties, many of which are unforeseeable and beyond the control of JHX or AZEK. Such known and unknown risks, uncertainties and other factors may cause actual results, performance or other achievements to differ materially from the anticipated results, performance or achievements expressed, projected or implied by forward-looking statements. These factors include risks and uncertainties relating to the Transaction, including, but not limited to, the possibility that required regulatory approvals for the Transaction or approval of the Transaction by AZEK's stockholders and other conditions to closing are not received or satisfied on a timely basis or at all; the possible occurrence of events that may give rise to a right of either or both of JHX and AZEK to terminate the merger agreement providing for the Transaction; possible negative effects of the announcement or the consummation of the Transaction on the market price of JHX's and/or AZEK's shares and/or on their respective businesses, financial conditions, results of operations and financial performance; uncertainties as to access to financing (including financing for the Transaction) on a timely basis and on reasonable terms; the impact of the additional indebtedness the Company would incur in connection with the Transaction; risks relating to the value of the JHX shares to be issued in the Transaction and the contemplated listing arrangements for JHX shares and depositary interests following the Transaction; risks relating to significant transaction costs and/or unknown liabilities; the possibility that the anticipated synergies and other benefits from the Transaction cannot be realized in full or at all or may take longer to realize than expected; risks associated with contracts containing consent and/or other provisions that may be triggered by the Transaction; risks associated with Transaction-related litigation; the possibility that costs or difficulties related to the integration of JHX's and AZEK's businesses will be greater than expected; the risk that the Transaction and its announcement could have an adverse effect on the parties' relationships with its and their employees and other business partners, including suppliers and customers; the potential for the Transaction to divert the time and attention of management from ongoing business operations; the potential for contractual restrictions under the merger agreement providing for the Transaction to adversely affect the parties' ability to pursue other business opportunities or strategic transactions; the risk of other Transaction related disruptions to the businesses, including business plans and operations, of JHX and AZEK; and the possibility that, as a result of the Transaction or otherwise, JHX could lose its foreign private issuer status and be required to bear the costs and expenses related to full compliance with rules and regulations that apply to U.S. domestic issuers. There can be no assurance that the Transaction will in fact be consummated in the manner described or at all.

Additional important factors relating to JHX that could cause actual results to differ materially from those reflected in forward-looking statements include, but are not limited to, the risks and uncertainties described in Section 3 "Risk Factors" in JHX's Annual Report on Form 20-F for the fiscal year ended March 31, 2025 (the "JHX 2025 Annual Report"); changes in general economic, political, governmental and business conditions globally and in the countries in which JHX does business; changes in interest rates; changes in inflation rates; changes in exchange rates; the level of construction generally; changes in cement demand and prices; changes in raw material and energy prices; and changes in business strategy.

These factors are not necessarily all of the factors that could cause JHX's, AZEK's or the combined company's actual results, performance or achievements to differ materially from those expressed in or implied by any of the forward-looking statements. Other factors, including unknown or unpredictable factors, could also harm JHX's, AZEK's or the combined company's results.

The foregoing discussion of risks and uncertainties is not exhaustive; other risks and uncertainties may cause actual results to differ materially from those referenced in any forward looking statements. All forward-looking statements attributable to JHX, AZEK or the combined company, or persons acting on JHX's or AZEK's behalf, are expressly qualified in their entirety by the cautionary statements set forth above. Forward looking statements in this communication speak only as of the date of this communication and are statements of then current expectations concerning future results, events and conditions. Neither JHX nor AZEK assumes any obligation to update any forward looking statements or information except as required by law. If JHX or AZEK updates one or more forward-looking statements, no inference should be drawn that JHX or AZEK will make additional updates with respect to those or other forward-looking statements. Further information regarding JHX, AZEK and factors that could affect the forward-looking statements contained herein can be found in JHX's Annual Report on Form 20-F for the fiscal year ended March 31, 2025, and in its other documents filed or furnished with the U.S. Securities and Exchange Commission ("SEC"), and in AZEK's Annual Report on Form 10-K for the fiscal year ended September 30, 2024, and in its other documents filed or furnished with the SEC.

Important Information and Where to Find It

In connection with the proposed transaction between JHX and AZEK, JHX has filed with the SEC a registration statement on Form F-4 (SEC File No. 333-286977). The registration statement includes a preliminary proxy statement/prospectus, which is a preliminary proxy statement of AZEK that also serves as a preliminary prospectus of JHX, and each party will file other documents regarding the proposed transaction with the SEC. The registration statement has not been declared effective by the SEC. Investors and security holders are urged to read the proxy statement/prospectus and other relevant documents filed with the SEC when they become available, because they contain or will contain important information. The definitive proxy statement/prospectus will be sent to AZEK's stockholders. Investors and security holders may obtain free copies of the registration statement and the proxy statement/prospectus and other documents that are filed or will be filed with the SEC by JHX or AZEK through the SEC's website at <https://www.sec.gov>. Copies of documents filed with the SEC by JHX will be available from JHX free of charge on JHX's website at jameshardie.com.au or upon request submitted to JHX by e mail addressed to investor.relations@jameshardie.com.au. Copies of documents filed with the SEC by AZEK will be available from AZEK free of charge on AZEK's website at investors.azekco.com or upon request submitted to AZEK by mail addressed to The AZEK Company Inc., Attention: Corporate Secretary, 1330 W Fulton Street #350, Chicago, Illinois 60607. The information included on, or accessible through, JHX's or AZEK's website is not incorporated by reference into this communication.

Participants in the Solicitation

JHX and certain of its directors, executive officers and other employees, and AZEK and its directors and certain of AZEK's executive officers and other employees, may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. The preliminary proxy statement/prospectus filed with the SEC as part of the registration statement includes a description of participants' direct or indirect interests, by security holdings or otherwise. Information about JHX's directors and executive officers is contained in "Section 1—Directors, Senior Management and Employees" in JHX's Annual Report on Form 20-F for the fiscal year ended March 31, 2025, filed with the SEC on May 20, 2025 and in other documents subsequently filed or furnished by JHX with the SEC. Information about AZEK's directors and executive officers is contained in "Nominees for Director," "Proposal No. 1—Election of Directors," "Corporate Governance," "Executive Officers," "Compensation Discussion and Analysis," "2024 CEO Pay Ratio Disclosure," "Pay-Versus-Performance," "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" and "Related Person Transactions" in AZEK's definitive proxy statement in connection with its 2025 annual meeting of stockholders, filed with the SEC on January 13, 2025; in AZEK's Current Report on Form 8-K (Amendment No. 1) filed with the SEC on January 24, 2025; in the Form 3 and Form 4 statements of beneficial ownership and statements of changes in beneficial ownership filed with the SEC by AZEK's directors and executive officers; and in other documents subsequently filed or furnished by AZEK with the SEC. Additional information regarding ownership of AZEK's securities by its directors and executive officers is included in such persons' SEC filings on Forms 3 and 4. The documents referenced above in this paragraph may be obtained free of charge as described above under the heading "Important Information and Where to Find It." Additional information regarding the interests of participants in the solicitation of proxies in connection with the proposed transaction will be included in the proxy statement/prospectus and other relevant materials filed with the SEC when they become available.

No Offer or Solicitation

This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Non-GAAP Financial Measures

This Earnings Presentation includes financial measures that are not considered a measure of financial performance under generally accepted accounting principles in the United States ("GAAP"). These financial measures are designed to provide investors with an alternative method for assessing our performance from on-going operations, capital efficiency and profit generation. Management uses these financial measures for the same purposes. These financial measures are or may be non-GAAP financial measures as defined in the rules of the U.S. Securities and Exchange Commission and may exclude or include amounts that are included or excluded, as applicable, in the calculation of the most directly comparable financial measures calculated in accordance with GAAP. These non-GAAP financial measures should not be considered to be more meaningful than the equivalent GAAP measure. Management has included such measures to provide investors with an alternative method for assessing its operating results in a manner that is focused on the performance of its ongoing operations and excludes the impact of certain legacy items, such as asbestos adjustments. Additionally, management uses such non-GAAP financial measures for the same purposes. However, these non-GAAP financial measures are not prepared in accordance with GAAP, may not be reported by all of the Company's competitors and may not be directly comparable to similarly titled measures of the Company's competitors due to potential differences in the exact method of calculation. For additional information regarding the non-GAAP financial measures presented in this Earnings Presentation, including a reconciliation of each non-GAAP financial measure to the equivalent GAAP measure, see slides titled "Non-GAAP Financial Measures" included in this Earnings Presentation. In addition, this Earnings Presentation includes financial measures and descriptions that are considered to not be in accordance with GAAP, but which are consistent with financial measures reported by Australian companies, such as EBIT and EBIT margin. Since the Company prepares its Consolidated Financial Statements in accordance with GAAP, the Company provides investors with definitions and a cross-reference from the non-GAAP financial measure used in this Earnings Presentation to the equivalent GAAP financial measure used in the Company's Consolidated Financial Statements. See slides titled "Non-GAAP Financial Measures" included in this Earnings Presentation.

All comparisons made are vs. the comparable period in the prior fiscal year and amounts presented are in US dollars, unless otherwise noted.

Investor Contact

Joe Ahlersmeyer, CFA
Vice President, Investor Relations
joe.ahlersmeyer@jameshardie.com

Agenda



Aaron Erter

CHIEF EXECUTIVE
OFFICER



Rachel Wilson

CHIEF FINANCIAL
OFFICER

- 1** FY25 Review and FY26 Outlook

- 2** Progress Against Key North America Strategies

- 3** Core Business Overview and Long-Term Outlook

- 4** Creating A Leading Building Products Growth Platform

- 5** Q4 FY25 Financial Results & FY26 Guidance

- 6** Q&A

Strong 2025 Lays Groundwork for Profitable Growth in 2026

FY25 Accomplishments



Winning
by Partnering
Across the Customer
Value Chain



Capturing
Material Conversion
With Our Superior
Value Proposition



Investing
in Growth & Scale
While Delivering
Robust Profitability

Achieved Solid Results
Consistent with FY25 Guidance

2.95bnsf
(Guidance 2.95bnsf+)

North America
Volume

29.4%
(Guidance 29.3%+)

North America
EBIT Margin %

\$644mm
(Guidance \$635mm+)

Total
Adjusted Net Income

FY26 Focus and Outlook



Driving
Growth Alongside
Our Customers



Accelerating
Material Conversion
of Fiber Cement



Reaffirming
Commitment to
Outperform Our
End Markets

Issuing FY26 Guidance
Consistent with Plans for Profitable Growth

**Sales and EBITDA
Growth**

In Every
Region

**North America
EBITDA Margin %**

In Line
with FY25

**Free
Cash Flow¹**

Robust Growth
vs. FY25

**Delivery of Solid Results in FY25 and Executing on Our Core Strategy into FY26
Supported By Fiber Cement's Attractive Long-Term Prospects**



JamesHardie Q4 FY25 EARNINGS PRESENTATION

1) Free Cash Flow ("FCF") is defined as net cash provided by operating activities less purchases of property, plant and equipment.

Strategies Drive FY25 Single-Family Exteriors Growth

+LSD% GROWTH IN NORTH AMERICA SINGLE-FAMILY EXTERIORS UNDERPINS MOMENTUM OF CORE STRATEGIES

Repair & Remodel

ColorPlus® Driving Growth
in Key R&R Markets



+DD%

FY25 Volume Growth
Single-Family ColorPlus
Nationally

+HSD%

5-Year Volume CAGR
Single-Family ColorPlus in
Northeast & Midwest

Revitalized ALLIANCE™
Enabling Contractor Growth



~40%

Contractors Added This Year
By Customers' Sales Rep

New Construction

Growing Share & Deepening Relationships

Meritage
Homes

M/I HOMES

CASTLEROCK
COMMUNITIES

DAVIDSON
HOMES.

David Weekley Homes

STANLEY & MARTIN
HOMES

TRUMARK HOMES

CBH HOMES

McKinley Homes

Innovating to Increase Use of Fiber Cement

Van Metre

Winning Solutions Driving Material Conversion Against Vinyl

Growth in North America Fiber Cement

Compelling Value Proposition



Demand Creation



Innovative Solutions



Unrivaled Business Support

Double-Digit Revenue Growth

- ~LSD% Market Growth
- ~4pp Outperformance
- ~MSD% ASP Growth

Substantial Material Conversion Runway

~35M

HOMES AGED 20 TO 40 YEARS OLD

~22%

OF NEW CONSTRUCTION HOMES BUILT
WITH FIBER CEMENT SIDING

Long Term Profitable Growth



+500bps Adj. EBITDA Margin

- Value Proposition
- HOS Initiatives
- Scaling for Growth

Triple Adj. EBITDA

- Robust Free Cash Flow
- Modest Capital Needs
- Low Leverage

Reaffirming Our Long-Term Opportunity and Financial Aspirations



Creating a Leading Building Products Growth Platform



A LEADING SIDING BRAND IN NORTH AMERICA & GLOBALLY



A LEADING PRO DECKING BRAND AND A LEADER IN RAILING AND PVC TRIM



Creates

a leading exterior and outdoor living growth platform



Accelerates

material conversion-led growth



Provides

customers a comprehensive solution of leading exterior brands



Delivers

best-in-class financial profile and broader shareholder base



Unlocks

significant value through higher growth and synergies

High Conviction in Commercial Synergy Realization

ENTHUSIASM ACROSS VALUE CHAIN REINFORCES OUR CONFIDENCE IN SYNERGY TARGETS



Accelerating Material Conversion Through Significant Revenue Synergy Opportunities

Focused on Delivering Quick Cost Synergy Wins

A SOLID BASELINE OF IDENTIFIED COST SYNERGIES

Breakdown of Cost Synergies By Area

Administrative

- Duplicative Back-Office Functions
- Consolidating Facilities
- Quickest Achievement




Manufacturing and Procurement

- Indirect Manufacturing & Packaging Costs
- Freight Optimization
- Services

Commercial, R&D and Marketing

- Continuous Improvement in R&D and Marketing
- Creating a Best-in-Class Aligned Sales Force

Time to Achieve Cost Synergies



\$125mm

Disciplined Integration Planning Approach Lays the Foundation for a Successful Integration and Full Cost Synergy Realization

Compelling Financial Profile Driving Value Creation

Accelerated Top Line Growth &
Tangible Commercial Synergies

+250bps

Top-Line Growth
Acceleration

\$500mm+

Run-Rate
Commercial Synergies
Within Five Years

Accelerated EBITDA Growth &
Credible Commercial Synergies

+300bps

EBITDA Growth
Acceleration

\$125mm+

Run-Rate
Cost Synergies
Within Three Years

**Strong Free Cash Flow &
Clear Path to Deleverage Post-Close**

\$1bn+

Annual Free Cash Flow¹

< 2.0x

Net Debt
Leverage²

Up to

\$500mm

Share
Repurchases³

**Delivering Significant Shareholder Value Creation
Through Higher Growth and Synergies**

Financial Key Messages



Delivered on Our FY25 Guidance



**Positioned to Outperform the Market
in FY26 and Beyond**



Planning for Profitable Growth in FY26



**Poised to Generate Robust Growth
in Free Cash Flow**



**Focused on Successful Integration
Planning and Synergy Capture to Deliver
Value to All Shareholders**



Fourth Quarter FY25 Financial Highlights

\$972mm

Net Sales

\$269mm

Adjusted EBITDA

27.6%

Adjusted EBITDA Margin

\$156mm

Adjusted Net Income

(3%)

Comparing vs.
All-Time Quarterly Record

(4%)

Comparing vs.
Record Q4 Results

(30bps)


Comparing vs.
Record Q4 Results

(10%)

Comparing vs.
Strong Q4 Results

**Solid Underlying Performance Driven by Core Strategic Successes
HOS Savings and Disciplined Cost Control Supporting Leading Profitability**

Fourth Quarter FY25 Adjusted EBITDA



**North America HOS Savings & Clutch Actions and Growth in ANZ & EU
Offset by Record Q4 Comparison and Raw Material Headwinds**



North America Fiber Cement Results



	Q4 FY25	Q4 FY24	vs. PY	Key Drivers
Net Sales (\$mm)	\$718.9	\$735.2	(2%)	<div>✓ Net Sales and volumes down modestly vs. prior year, as expected</div> <ul style="list-style-type: none"> ▪ Exteriors declined (LSD%) <ul style="list-style-type: none"> ▪ Single-Family ColorPlus +DD% ▪ Multi-Family down (22%) ▪ Interiors declined (Low-DD%)
Sales Volume	741.2 mmsf	766.3 mmsf	(3%)	
Average Net Sales Price	\$964 /msf	\$954 /msf	+1%	<div>✓ ASP growth reflects our January 2025 price increase</div>
EBIT (\$mm)	\$202.4	\$233.0	(13%)	<div>✓ Achieved EBIT margin above expectations</div> <ul style="list-style-type: none"> ▪ ~(150bps) Incremental D&A impact to EBIT margin ▪ Comparing vs. <u>4Q record</u> EBIT and margin
EBIT Margin %	28.2%	31.7%	(350bps)	
D&A (\$mm)	\$45.2	\$34.2	+32%	<div>✓ Margin drivers consistent with guidance</div> <ul style="list-style-type: none"> ▪ Unfavorable raw materials (principally pulp & cement) ▪ Investing in growth and scale while managing margins decisively ▪ Manufacturing & procurement HOS savings ▪ Unfavorable cost absorption with lower volume
EBITDA (\$mm)	\$247.6	\$267.2	(7%)	
EBITDA Margin %	34.4%	36.3%	(190bps)	

Delivered On Our Full Year Commitments Despite Softer Markets and Inflation

Asia Pacific Fiber Cement Results



	Q4 FY25	Q4 FY24	vs. PY ¹	Key Drivers
Net Sales (\$mm)	\$118.1	\$141.5	(17%)	<div>✓ Australia & New Zealand net sales up slightly in local currency</div> <ul style="list-style-type: none"> ▪ (LSD%) volume decline due to continued market softness, continued focus on material conversion strategies and Co-creation efforts ▪ Modest increase in ASP driven by recent price increases
Net Sales (A\$)			(13%)	
Net Sales (A\$) – ANZ			+LSD	
Sales Volume Sales Volume – ANZ	96.4 mmsf	139.7 mmsf	(31%) (LSD%)	
Average Net Sales Price	A\$1,723 /msf	A\$1,380 /msf	+25%	<div>✓ Increase in ASP driven by Philippines closure</div>
Adj. EBIT (\$mm)	\$36.0	\$38.5	(6%)	<div>✓ Higher margins reflect Philippines closure</div>
Adj. EBIT Margin %	30.5%	27.2%	+330bps	<div>✓ Australia & New Zealand EBIT increased +4% with margin +210bps</div> <ul style="list-style-type: none"> ▪ Capturing the value that our products demand in the market ▪ Higher raw material costs ▪ Driving HOS savings to fund growth investments ▪ Unfavorable cost absorption with lower volume
D&A (\$mm)	\$4.8	\$4.5	+7%	
EBITDA (\$mm)	\$40.8	\$43.0	(5%)	
EBITDA Margin %	34.5%	30.4%	+410bps	

Results Reflect Strong ANZ Margin Performance In Challenging Market

Europe Building Products Results



	Q4 FY25	Q4 FY24	vs. PY	Key Drivers
Net Sales (\$mm)	\$134.5	\$128.2	+5%	<div>✓ Delivered <u>record</u> sales in 4Q</div> <ul style="list-style-type: none"> Fiber Gypsum Up +7% in local currency Fiber Cement Up +14% in local currency
Net Sales (€)			+8%	
Sales Volume	207.1 mmsf	192.7 mmsf	+7%	<div>✓ High-Value Products (HVP) volume increased +LDD%</div>
Average Net Sales Price	€508 /msf	€473 /msf	+7%	<div>✓ Favorable ASP</div>
EBIT (\$mm)	\$13.3	\$13.1	+2%	<div>✓ EBIT grew despite EBIT margin contracting vs. prior year</div> <ul style="list-style-type: none"> Higher raw material and energy costs Investment in sales teams to support HVP growth Right-sizing capacity footprint
EBIT Margin %	9.9%	10.3%	(40bps)	
D&A (\$mm)	\$8.5	\$8.2	+4%	
EBITDA (\$mm)	\$21.8	\$21.3	+2%	
EBITDA Margin %	16.2%	16.7%	(50bps)	

High-Value Products Focus Drove Higher Volumes and ASP



FY26 Guidance Consistent With Planning Assumptions

FY26 Planning Assumptions Provided February 2025		FY26 Guidance
North America Net Sales	Growth vs. FY25	Up Low Single Digits %
North America EBITDA Margin %	Expansion vs. FY25	~35.0%
Total Adjusted EBITDA	Growth vs. FY25	Up Low Single Digits %
Free Cash Flow		At Least \$500mm (+30% vs. \$381mm in FY25)

Sales and EBITDA Growth In Every Region
 Maintaining Strong Margins Despite +HSD% Raw Material Inflation
 Robust Free Cash Flow Growth From Reduced Capital Expenditures




Capital Expenditures & Free Cash Flow

+30% FREE CASH FLOW GROWTH IN FY26 FROM PROFITABLE GROWTH & CAPEX REDUCTIONS

Solid Business Performance Driving Cash Generation

Cash from Operations




FY26
Cash From Operations
Growth

~+3%
vs. FY25

Well-Invested in Capacity to Service Organic Growth

Capital Expenditures




Long Term
NAFC Segment
Outlook

~6% to 7%
of Sales

Strong Free Cash Flow Growth to Fund Capital Priorities

Free Cash Flow



FY26
Free Cash Flow
Growth

+30%
vs. FY25

We Have Made Sufficient Capacity Investments to Service Demand

Creating a Leading Building Products Growth Platform


**Tremendous
Organic Growth**
in North America
Fiber Cement



**Accelerated Growth
& Cash Generation**
with the
AZEK Combination



Long-Term Shareholder Value Creation



Q&A



Aaron Erter
CHIEF EXECUTIVE
OFFICER



Rachel Wilson
CHIEF FINANCIAL
OFFICER



Non-GAAP Financial Measures

This Earnings Presentation forms part of a package of information about the company's results. It should be read in conjunction with the other parts of this package, including the 20-F and Earnings Release

Financial Measures – GAAP Equivalents

This document contains the financial statement line item EBIT, which is considered to be non-GAAP, but is consistent with the term used by Australian companies. Because we prepare our consolidated financial statements under GAAP, the equivalent GAAP financial Statement line item description used in our consolidated financial statements is Operating income (loss).

EBIT – Earnings (loss) before interest and tax

EBIT margin – EBIT margin is defined as EBIT as a percentage of net sales

Definitions

ASP – Average net sales price per msf ("ASP") – Total net sales of fiber cement and fiber gypsum products, excluding accessory sales, divided by the total volume of products sold

Free Cash Flow – Free Cash Flow ("FCF"), unless otherwise noted, is defined as net cash provided by operating activities less purchases of property, plant and equipment

Working Capital – The working capital calculation used in our cash provided by operating analysis includes the change in: (1) Accounts and other receivables, net; (2) Inventories; and (3) Accounts payable and accrued liabilities.

ROCE - Return on Capital Employed; calculated as Adjusted EBIT / Adjusted Gross Capital Employed

AICF – Asbestos Injuries Compensation Fund Ltd

bnsf – sales volume in billion standard feet, where a standard foot is defined as a square foot of 5/16" thickness

mmsf – sales volume in million standard feet, where a standard foot is defined as a square foot of 5/16" thickness

msf – sales volume in thousand standard feet, where a standard foot is defined as a square foot of 5/16" thickness

LSD – Low Single-Digits

MSD – Mid-Single Digits

HSD – High Single-Digits

DD – Double-Digits

LDD – Low Double-Digits

D&A – Depreciation & Amortization expense

Non-GAAP Financial Measures

Adjusted EBIT and Adjusted EBITDA

US\$ Millions	Quarter and Full Year Ended 31 March			
	Q4 FY25	Q4 FY24	FY25	FY24
EBIT	\$ 62.1	\$ 84.0	\$ 655.9	\$ 767.4
Asbestos related expenses and adjustments	137.6	148.5	140.5	153.3
Restructuring expenses	(7.0)	-	50.3	20.1
Merger costs	16.5	-	16.5	-
Adjusted EBIT	\$ 209.2	\$ 232.5	\$ 863.2	\$ 940.8
Net sales	971.5	1,004.9	3,877.5	3,936.3
Adjusted EBIT margin	21.5%	23.1%	22.3%	23.9%
Depreciation and amortization	59.4	48.3	216.2	185.0
Adjusted EBITDA	\$ 268.6	\$ 280.8	\$ 1,079.4	\$ 1,125.8
Adjusted EBITDA Margin	27.6%	27.9%	27.8%	28.6%

Adjusted net income

US\$ Millions	Quarter and Full Year Ended 31 March			
	Q4 FY25	Q4 FY24	FY25	FY24
Net income	\$ 43.6	\$ 55.6	\$ 424.0	\$ 510.2
Asbestos related expenses and adjustments	137.6	148.5	140.5	153.3
AICF interest income	(2.4)	(2.3)	(10.9)	(9.0)
Interest expense - Bridge Commitment	0.8	-	0.8	-
Restructuring expenses	(7.0)	-	50.3	20.1
Merger costs	16.5	-	16.5	-
Tax adjustments ¹⁾	(33.0)	(27.6)	23.1	32.9
Adjusted net income	\$ 156.1	\$ 174.2	\$ 644.3	\$ 707.5

Adjusted diluted earnings per share

	Quarter and Full Year Ended 31 March			
	Q4 FY25	Q4 FY24	FY25	FY24
Adjusted net income (US\$ Millions)	\$ 156.1	\$ 174.2	\$ 644.3	\$ 707.5
Weighted average common shares outstanding - Diluted (millions)	430.9	436.4	432.1	439.6
Adjusted diluted earnings per share	\$ 0.36	\$ 0.40	\$ 1.49	\$ 1.61

North America Fiber Cement Segment EBIT and EBITDA

US\$ Millions	Quarter and Full Year Ended 31 March			
	Q4 FY25	Q4 FY24	FY25	FY24
North America Fiber Cement Segment EBIT	\$ 202.4	\$ 233.0	\$ 840.9	\$ 921.1
North America Fiber Cement Segment net sales	718.9	735.2	2,863.3	2,891.4
North America Fiber Cement Segment EBIT margin	28.2%	31.7%	29.4%	31.9%
Depreciation and amortization	45.2	34.2	160.7	133.8
North America Fiber Cement Segment EBITDA	\$ 247.6	\$ 267.2	\$ 1,001.6	\$ 1,054.9
North America Fiber Cement Segment EBITDA Margin	34.4%	36.3%	35.0%	36.5%

Asia Pacific Fiber Cement Segment Adjusted EBIT and Adjusted EBITDA

US\$ Millions	Quarter and Full Year Ended 31 March			
	Q4 FY25	Q4 FY24	FY25	FY24
Asia Pacific Fiber Cement Segment EBIT	\$ 43.0	\$ 38.5	\$ 111.0	\$ 166.1
Restructuring expenses	(7.0)	-	50.3	-
Asia Pacific Fiber Cement Segment Adjusted EBIT	\$ 36.0	\$ 38.5	\$ 161.3	\$ 166.1
Asia Pacific Fiber Cement Segment net sales	118.1	141.5	519.9	562.8
Asia Pacific Fiber Cement Segment Adjusted EBIT margin	30.5%	27.2%	31.0%	29.5%
Depreciation and amortization	4.8	4.5	19.2	17.0
Asia Pacific Fiber Cement Segment Adjusted EBITDA	\$ 40.8	\$ 43.0	\$ 180.5	\$ 183.1
Asia Pacific Fiber Cement Segment Adjusted EBITDA Margin	34.5%	30.4%	34.7%	32.5%

Europe Building Products Segment EBIT and EBITDA

US\$ Millions	Quarter and Full Year Ended 31 March			
	Q4 FY25	Q4 FY24	FY25	FY24
Europe Building Products Segment EBIT	\$ 13.3	\$ 13.1	\$ 38.0	\$ 45.0
Europe Building Products Segment net sales	134.5	128.2	494.3	482.1
Europe Building Products Segment EBIT margin	9.9%	10.3%	7.7%	9.3%
Depreciation and amortization	8.5	8.2	32.4	29.7
Europe Building Products Segment EBITDA	\$ 21.8	\$ 21.3	\$ 70.4	\$ 74.7
Europe Building Products Segment EBITDA Margin	16.2%	16.7%	14.2%	15.5%

Non-GAAP Financial Measures

Adjusted General Corporate and Unallocated R&D costs

US\$ Millions	Quarter and Full Year Ended 31 March			
	Q4 FY25	Q4 FY24	FY25	FY24
General Corporate and Unallocated R&D costs	\$ 196.6	\$ 200.6	\$ 334.0	\$ 364.8
Restructuring expenses	-	-	-	(20.1)
Merger costs	(16.5)	-	(16.5)	-
Asbestos related expenses and adjustments	(137.6)	(148.5)	(140.5)	(153.3)
Adjusted General Corporate and Unallocated R&D costs	\$ 42.5	\$ 52.1	\$ 177.0	\$ 191.4

Adjusted interest, net

US\$ Millions	Quarter and Full Year Ended 31 March			
	Q4 FY25	Q4 FY24	FY25	FY24
Interest, net	\$ 2.9	\$ 1.9	\$ 10.3	\$ 15.3
AICF interest income	2.4	2.3	10.9	9.0
Interest expense - Bridge Commitment	(0.8)	-	(0.8)	-
Adjusted interest, net	\$ 4.5	\$ 4.2	\$ 20.4	\$ 24.3

Adjusted effective tax rate

US\$ Millions	Quarter and Full Year Ended 31 March			
	Q4 FY25	Q4 FY24	FY25	FY24
Income before income taxes	\$ 58.8	\$ 82.0	\$ 645.4	\$ 754.8
Asbestos related expenses and adjustments	137.6	148.5	140.5	153.3
AICF interest income	(2.4)	(2.3)	(10.9)	(9.0)
Interest expense - Bridge Commitment	0.8	-	0.8	-
Restructuring expenses	(7.0)	-	50.3	20.1
Merger costs	16.5	-	16.5	-
Adjusted income before income taxes	\$ 204.3	\$ 228.2	\$ 842.6	\$ 919.2
Income tax expense	15.2	26.4	221.4	244.6
Tax adjustments ¹	33.0	27.6	(23.1)	(32.9)
Adjusted income tax expense	\$ 48.2	\$ 54.0	\$ 198.3	\$ 211.7
Effective tax rate	25.9%	32.2%	34.3%	32.4%
Adjusted effective tax rate	23.6%	23.7%	23.5%	23.0%

Net Leverage Ratio

US\$ Millions	31 March	
	FY25	FY24
Numerator:		
Total principal amount of debt	\$ 1,124.0	\$ 1,129.1
Less: Cash and cash equivalents	(562.7)	(365.0)
Add: Letters of credit and bank guarantees	5.9	6.8
Total	\$ 567.2	\$ 770.9
Denominator: (Trailing 12 months)		
EBIT	\$ 655.9	\$ 767.4
Asbestos related expenses and adjustments	140.5	153.3
Restructuring expenses	50.3	20.1
Merger costs	16.5	-
Depreciation and amortization	216.2	185.0
Stock compensation - equity awards	23.0	28.2
Total	\$ 1,102.4	\$ 1,154.0
Net Leverage ratio	0.51x	0.67x



Non-GAAP Financial Measures

APAC LOCAL CURRENCY

A\$ Millions	Quarter and Full Year Ended 31 March			
	Q4 FY25	Q4 FY24	FY25	FY24
Asia Pacific Fiber Cement Segment EBIT	A\$ 68.4	A\$ 58.6	A\$ 172.7	A\$ 252.7
Restructuring expenses	(11.1)	-	73.6	-
Asia Pacific Fiber Cement Segment Adjusted EBIT	A\$ 57.3	A\$ 58.6	A\$ 246.3	A\$ 252.7
Asia Pacific Fiber Cement Segment net sales	188.1	215.2	795.0	856.3
Asia Pacific Fiber Cement Segment Adjusted EBIT margin	30.5%	27.2%	31.0%	29.5%
Depreciation and amortization	7.6	6.8	29.4	25.8
Asia Pacific Fiber Cement Segment Adjusted EBITDA	A\$ 64.9	A\$ 65.4	A\$ 275.7	A\$ 278.5
Asia Pacific Fiber Cement Segment Adjusted EBITDA Margin	34.5%	30.4%	34.7%	32.5%

Europe Building Products Segment EBIT and EBITDA

€ Millions	Quarter and Full Year Ended 31 March			
	Q4 FY25	Q4 FY24	FY25	FY24
Europe Building Products Segment EBIT	€ 12.6	€ 12.1	€ 35.4	€ 41.5
Europe Building Products Segment net sales	127.7	118.0	460.6	444.5
Europe Building Products Segment EBIT margin	9.9%	10.3%	7.7%	9.3%
Depreciation and amortization	8.1	7.6	30.2	27.4
Europe Building Products Segment EBITDA	€ 20.7	€ 19.7	€ 65.6	€ 68.9
Europe Building Products Segment EBITDA Margin	16.2%	16.7%	14.2%	15.5%

Adjusted Return on Capital Employed ("Adjusted ROCE")

US\$ Millions	Full Year Ended 31 March	
	FY25	FY24
Numerator		
Adjusted EBIT	\$ 863.2	\$ 940.8
Denominator		
Gross capital employed (GCE)	2,817.8	2,382.8
Adjustments to GCE ¹	(834.3)	(673.9)
Adjusted gross capital employed	\$ 1,983.5	\$ 1,708.9
Adjusted Return on Capital Employed	44%	55%

Free Cash Flow

US\$ Millions	Full Year Ended 31 March	
	FY25	FY24
Net cash provided by operating activities	\$ 802.8	\$ 914.2
Purchases of property, plant and equipment	(422.2)	(449.3)
Free Cash Flow	\$ 380.6	\$ 464.9



Valuation of Asbestos-Related Disease Liabilities of former James Hardie entities ("the Liable Entities") to be met by the AICF Trust

Prepared for Asbestos Injuries Compensation Fund Limited
("AICFL")

As at 31 March 2025

17 May 2025





International Towers Sydney 3
300 Barangaroo Ave
Sydney NSW 2000

PO Box H67
Australia Square NSW 1215
Australia

ABN: 91 144 686 046
Telephone: +61 2 9335 7000
Facsimile: +61 2 9335 7001
DX: 1056 Sydney
www.kpmg.com.au

17 May 2025

Bronwyn Hewish
Chief Executive Officer
Asbestos Injuries Compensation Fund Limited
Suite 202, Level 2, 56 Clarence Street
Sydney NSW 2000

Cc Rachel Wilson, Chief Financial Officer, James Hardie Industries plc
Mark Hare, Director, Department of Premier and Cabinet, The State of New South Wales
The Board of Directors, Asbestos Injuries Compensation Fund Limited

Dear Bronwyn

Valuation of Asbestos-Related Disease Liabilities of former James Hardie entities ("The Liable Entities") to be met by the AICF Trust

We are pleased to provide you with our Annual Actuarial Report relating to the asbestos-related disease liabilities of the Liable Entities which are to be met by the AICF Trust.

The report is effective as at 31 March 2025 and has taken into account claims data and information provided to us by AICFL as at 31 March 2025.

If you have any questions with respect to the contents of this report, please do not hesitate to contact us.

Yours sincerely

Neil Donlevy MA FIA FIAA
Partner, KPMG
Fellow of the Institute of Actuaries of
Australia
Fellow of the Institute of Actuaries (London)

Jefferson Gibbs BSc FIAA
Partner, KPMG
Fellow of the Institute of Actuaries of
Australia

Executive Summary

Important Note: Basis of Report

This valuation report ("the Report") has been prepared by KPMG (ABN 91 144 686 046) in accordance with an "Amended and Restated Final Funding Agreement in respect of the provision of long-term funding for compensation arrangements for certain victims of Asbestos-related diseases in Australia" (hereafter referred to as the "the Amended Final Funding Agreement") between James Hardie Industries NV (now known as James Hardie Industries plc) (hereafter referred to as "James Hardie"), James Hardie 117 Pty Limited, the State of New South Wales and Asbestos Injuries Compensation Fund Limited ("AICFL") which was signed on 21 November 2006.

This Report is intended to meet the requirements of the Amended Final Funding Agreement and values the asbestos-related disease liabilities of the Liable Entities to be met by the AICF Trust.

This Report is not intended to be used for any other purpose and may not be suitable, and should not be used, for any other purpose. Opinions and estimates contained in the Report constitute our judgment as of the date of the Report.

The information contained in this Report is of a general nature and is not intended to address the objectives, financial situation or needs of any particular individual or entity. It is provided for information purposes only and does not constitute, nor should it be regarded in any manner whatsoever as, advice and is not intended to influence a person in making a decision in relation to any financial product or an interest in a financial product. No one should act on the information contained in this Report without obtaining appropriate professional advice after a thorough examination of the accuracy and appropriateness of the information contained in this Report having regard to their objectives, financial situation and needs.

In preparing the Report, KPMG has relied on information supplied to it from various sources and has assumed that the information is accurate and complete in all material respects. KPMG has not independently verified the accuracy or completeness of the data and information used for this Report.

Except insofar as liability under statute cannot be excluded, KPMG, its executives, directors, employees and agents will not be held liable for any loss or damage of any kind arising as a consequence of any use of the Report or purported reliance on the Report including any errors in, or omissions from, the valuation models.

The Report must be read in its entirety. Individual sections of the Report, including the Executive Summary, could be misleading if considered in isolation. In particular, the opinions expressed in the Report are based on a number of assumptions and qualifications which are set out in the full Report.

Introduction

The Amended Final Funding Agreement requires the completion of an Annual Actuarial Report evaluating the potential asbestos-related disease liabilities of the Liable Entities to be met by the AICF Trust. KPMG has been retained by AICFL to provide this Annual Actuarial Report as required under the Amended Final Funding Agreement and this is detailed in our Engagement Letter dated 14 November 2024.

The Liable Entities are defined as being the following entities:

- Amaca Pty Ltd (formerly James Hardie & Coy);
- Amaba Pty Ltd (formerly Jsekarb, James Hardie Brakes and Better Brakes); and
- ABN60 Pty Ltd (formerly James Hardie Industries Ltd).

In addition, the liability for Baryulgil claims is deemed to be a liability of Amaca by virtue of the James Hardie (Civil Liability) Act 2005 (NSW). Under Part 4 of that Act, Amaca is liable for the "Marlew Asbestos Claims" or "Marlew Contribution Claims" as defined in that Act.

Our valuation is on a central estimate basis and is intended to be effective as at 31 March 2025. It has been based on claims data and information as at 31 March 2025 provided to us by AICFL.

Overview of Recent Claims Experience and comparison with previous valuation projections

In this section we compare the actual experience in 2024/25 (referred to in the following tables as "FY25 Actual") with the projections for 2024/25 that were contained within our previous valuation report at 31 March 2024. We will refer to these projections for 2024/25 as "FY25 Expected" in the tables that follow.

Claim numbers

There have been 401 mesothelioma claims reported in 2024/25, an 8% increase compared to the 373 mesothelioma claims reported in 2023/24 and 10% above expectations for 2024/25 (366 claims).

Direct claims were 3% above expectations with 9 more claims than expected. Cross claims were 31% above expectations with 26 more claims than expected.

For non-mesothelioma claims (excluding workers compensation claims), there have been 233 claims reported in 2024/25, which is a 32% increase compared to the 176 claims reported in 2023/24, primarily driven by an unusually high level of claims reporting activity in Q2 (80 claims). The other quarters showed more normal (albeit still elevated) levels of reporting activity compared with the previous year.

The following table shows the comparison of actual experience with that which had been forecast at the previous valuation. This year we have separately shown asbestosis claims split between direct claims and cross claims. We did not have separate assumptions for each of these cohorts for 2024/25.

Table E.1. Comparison of claim numbers

	FY25 Actual	FY25 Expected	Ratio of Actual to Expected (%)	FY24 Actual
Mesothelioma (direct claims)	291	282	103%	295
<60	22	15	147%	21
60-70	37	42	88%	42
70-80	116	117	99%	120
80+	112	108	104%	112
age not known	4	0	n/a	0
Mesothelioma (cross claims)	110	84	131%	78
<60	3	1	300%	1
60-70	7	12	58%	10
70-80	53	40	133%	39
80+	47	31	152%	28
age not known	0	0	n/a	0
Total	401	366	110%	373

	FY25 Actual	FY25 Expected	Ratio of Actual to Expected (%)	FY24 Actual
Asbestosis	149	102	146%	118
<i>Direct</i>	91	n/a	n/a	81
<i>Cross</i>	58	n/a	n/a	37
Lung Cancer	26	18	144%	18
ARPD & Other	43	33	130%	32
Wharf	15	6	250%	8
Workers	19	15	127%	15
Total	252	174	145%	191

Average Claim Awards

Average claims awards in 2024/25 have been higher than expectations for 60-70 year old cohort for both direct and cross mesothelioma claims, and lower than expectations for the other age cohorts.

For the other disease types, average claim sizes have been higher than expectations for asbestosis and ARPD & Other driven by a small number of larger-than-usual claims.

The following tables shows the comparison of actual experience with that which had been forecast at the previous valuation.

Table E.2. Comparison of average claim size of mesothelioma non-nil claims

	FY25 Actual (\$)	FY25 Expected (\$)	Ratio of Actual to Expected (%)	FY24 Actual (\$)
Mesothelioma (direct claims)				
<60	794,758	814,800	98%	780,289
60-70	676,446	615,300	110%	642,768
70-80	457,720	468,300	98%	440,010
80+	351,186	394,800	89%	388,363
Mesothelioma (cross claims)				
<60	0	226,800	0%	156,000
60-70	168,300	153,300	110%	218,816
70-80	74,225	106,050	70%	90,887
80+	62,957	90,300	70%	88,701
Mesothelioma Large Claims (settled)				
Number	0	3	0%	1
Average claim size	0	2,920,000	0%	2,601,560
Large claim expenditure	0	8,760,000	0%	2,601,560

Note: FY24 Actuals have been inflated (by 4%) to mid 2024/25 values

Table E.3. Comparison of average claim size of non-mesothelioma non-nil claims

	FY25 Actual (\$)	FY25 Expected (\$)	Ratio of Actual to Expected (%)	FY24 Actual (\$)
Asbestosis	171,296	152,250	113%	149,859
Direct	220,158	n/a	n/a	204,264
Cross	39,581	n/a	n/a	36,865
Lung Cancer	167,883	168,000	100%	158,387
ARPD & Other	134,204	120,750	111%	111,959
Wharf	21,853	94,500	23%	50,960
Workers	0	131,250	0%	0

Note: FY24 Actuals have been inflated (by 4%) to mid 2024/25 values

Cashflow expenditure: gross and net

Gross cashflow expenditure, at \$176.1m, was 3% below expectations.

Net cashflow expenditure, at \$166.9m, was 1% below expectations.

Table E.4. Comparison of cashflow

	FY25 Actual	FY25 Expected	Ratio of Actual to Expected	FY24 Actual
	(\$M)	(\$M)	(%)	(\$M)
Gross Cashflow	176.1	181.0	97%	177.1
Insurance and Other Recoveries	(9.3)	(12.6)	73%	(11.4)
Net Cashflow	166.9	168.4	99%	165.7

Liability Assessment

At 31 March 2025, our projected central estimate of the liabilities of the Liable Entities (the Discounted Central Estimate) to be met by the AICF Trust is \$1,472.4m (2024: \$1,457.8m).

We have not allowed for the future Operating Expenses of the AICF Trust or the Liable Entities in the liability assessment.

The following table shows a summary of our central estimate liability assessment and compares the current assessment with our previous valuation.

Table E.5. Comparison of central estimate of liabilities

	31 March 2025 \$m			31 March 2024 \$m
	Gross of insurance recoveries	Insurance recoveries	Net of insurance recoveries	Net of insurance recoveries
Total uninflated and undiscounted cashflows	1,490.3	45.1	1,445.2	1,394.3
Wage inflation allowance	398.1	6.8	391.3	399.3
Superimposed inflation allowance	133.2	2.4	130.8	133.8
Total inflated and undiscounted cashflows	2,021.6	54.3	1,967.3	1,927.4
Discounting allowance at risk-free rates	(506.0)	(11.1)	(494.9)	(469.6)
Net present value of cashflows	1,515.6	43.2	1,472.4	1,457.8

Comparison with previous valuation

In the absence of any change to the claim projection assumptions from our 31 March 2024 valuation, we would have projected a Discounted Central Estimate liability of \$1,322.5m as at 31 March 2025.

The decrease of \$135.3m relative to the valuation result at 31 March 2024 is due to:

- A decrease of \$165.4m for the impact of actual claims payments (which reduces the liability). The chart below separately shows the impact of the expected payments (a reduction of \$166.9m) and the variance between actual and expected payments (an increase of \$1.5m);
- An increase of \$53.7m for the “unwind of discount”; and
- A decrease of \$23.6m resulting from changes to the yield curve between 31 March 2024 and 31 March 2025.

Our liability assessment at 31 March 2025 of \$1,472.4m therefore represents an increase of \$149.9m arising from changes to the actuarial assumptions. The increase is principally a consequence of:


- Increases to the assumed number of mesothelioma claims for 2025/26 for both direct claims and cross claims (and all future years);
- Changes to the assumed age mix of mesothelioma claims;
- An increased allowance to the assumed number of non-mesothelioma claim numbers for 2025/26 (and all future years); and
- Increases to the incidence pattern of claims for asbestosis in future years noting the elevated experience of the last two financial years;

offset by

- Favourable nil settlement experience; and
- A reduction in the assumed average claim cost and legal cost assumptions, for both mesothelioma and non-mesothelioma claims, including the impact of setting separate assumptions for asbestosis for direct and cross claims.

The following chart shows an analysis of the change in our liability assessment from 31 March 2024 to 31 March 2025 on a discounted basis.

Figure E.1. Analysis of change in central estimate liability (discounted basis)



Note: Green bars signal that this factor has given rise to a decrease in the liability whilst light blue bars signal that this factor has given rise to an increase in the liability.

Amended Final Funding Agreement calculations

The Amended Final Funding Agreement sets out the basis on which payments will be made to the AICF Trust.

Additionally, there are a number of other figures specified within the Amended Final Funding Agreement that we are required to calculate. These are:

- Discounted Central Estimate;
- Term Central Estimate; and
- Period Actuarial Estimate.

Table E.6. Amended Final Funding Agreement calculations

	\$m
Discounted Central Estimate (net of cross-claim recoveries, Insurance and Other Recoveries)	1,472.4
Period Actuarial Estimate (net of cross-claim recoveries, gross of Insurance and Other Recoveries) comprising:	521.0
<i>Discounted value of cashflow in 2025/26</i>	<i>183.1</i>
<i>Discounted value of cashflow in 2026/27</i>	<i>174.7</i>
<i>Discounted value of cashflow in 2027/28</i>	<i>163.1</i>
Term Central Estimate (net of cross-claim recoveries, Insurance and Other Recoveries)	1,446.7

The actual funding amount due at a particular date will depend upon a number of factors, including:

- the net asset position of the AICF Trust at that time;
- the free cash flow amount of the James Hardie Group in the preceding financial year; and
- the Period Actuarial Estimate in the latest Annual Actuarial Report.

Uncertainty

Estimates of asbestos-related disease liabilities are subject to considerable uncertainty, significantly more than personal injury liabilities in relation to other causes, such as CTP or Workers Compensation claims.

It should therefore be expected that the actual emergence of the liabilities will vary from any estimate. As indicated in Figure E.2, depending on the actual out-turn of experience relative to that currently forecast, the variation could potentially be substantial.


Thus, no assurance can be given that the actual liabilities of the Liable Entities to be met by the AICF Trust will not ultimately exceed the estimates contained in this Report. Any such variation may be significant.

We have performed sensitivity testing to identify the impact of different assumptions upon the size of the liabilities. The different scenarios selected are documented at Section 11.2 of this report.

We have not included a sensitivity test for the impact of changes in discount rates although, as noted in this Report, changes in discount rates can introduce significant volatility to the Discounted Central Estimate result reported at each year-end.

We note that these sensitivity test ranges are not intended to correspond to a specified probability of sufficiency, nor are they intended to indicate an upper bound or a lower bound of all possible outcomes.

Figure E.2. Sensitivity testing results – Impact around the Discounted Central Estimate (in \$m)



The single most sensitive assumption shown in the chart is the peak period of claims reporting against the Liable Entities. Shifting the pattern of incidence by 2 years could add approximately \$279m (19%) on a discounted basis to our valuation (as shown in the above chart by the scenario labelled “mesothelioma incidence pattern”).

Table E.7. Summary results of sensitivity analysis (\$m)

	Undiscounted	Discounted
Central estimate	1,967.3	1,472.4
Low Scenario	1,555.8	1,184.1
High Scenario	3,063.0	2,183.1

Whilst the table above indicates a range around the discounted central estimate of liabilities of -\$288m to +\$711m, the actual cost of liabilities could fall outside that range depending on the actual experience.

[Executive Summary Not Report](#)

Please note that this executive summary is intended as a brief overview of our Report. To properly understand our analysis and the basis of our liability assessment requires examination of our Report in full.

Contents

Executive Summary	i
1. Scope and Purpose	1
2. Data	8
3. Valuation Methodology and Approach	11
4. Claims Experience: Mesothelioma Claim Numbers	23
5. Claims Experience: Claim numbers (non-mesothelioma)	35
6. Exposure and Latency Experience and Incidence Pattern Assumptions	39
7. Claims Experience: Average Claims and Legal Costs	52
8. Claims Experience: Nil Settlement Rates	71
9. Economic and Other Assumptions	80
10. Valuation Results	86
11. Uncertainty	94

Appendices

A Projected inflated and undiscounted cashflows (\$m)	98
B Projected inflated and discounted cashflows (\$m)	99
C Glossary of terms used in the Amended Final Funding Agreement	100



1. Scope and Purpose

1.1 Introduction

The Amended Final Funding Agreement requires the completion of an Annual Actuarial Report evaluating the potential asbestos-related disease liabilities of the Liable Entities to be met by the AICF Trust.

1.1.1 Liable Entities

The Liable Entities are defined as being the following entities:

- Amaca Pty Ltd (formerly James Hardie & Coy);
- Amaba Pty Ltd (formerly Jsekarb, James Hardie Brakes and Better Brakes); and
- ABN60 Pty Ltd (formerly James Hardie Industries Ltd).

In addition, the liability for Baryulgil claims is deemed to be a liability of Amaca by virtue of the James Hardie (Civil Liability) Act 2005 (NSW). Under Part 4 of that Act, Amaca is liable for “Marlew Asbestos Claims” or “Marlew Contribution Claims” as defined in that Act.

Baryulgil claims are discussed further in Section 5.8.

1.1.2 Personal asbestos claims

Under the Amended Final Funding Agreement, the liabilities to be met by the AICF Trust relate to personal asbestos-related disease liabilities of the Liable Entities.

The precise scope of the liabilities is documented in Section 1.2 and in Appendix C of this Report.

1.1.3 Purpose of report

KPMG has been retained by AICFL to provide an Annual Actuarial Report as required under the Amended Final Funding Agreement and this is detailed in our Engagement Letter dated 14 November 2024.

The prior written consent of KPMG is required for any other use of this Report or the information contained in it.

Our valuation is effective as at 31 March 2025 and has been based on claims data and information as at 31 March 2025 provided to us by AICFL.

1.2 Scope of report

We have been requested to provide an actuarial assessment as at 31 March 2025 of the asbestos-related disease liabilities of the Liable Entities to be met by the AICF Trust,

consistent with the terms of the Amended Final Funding Agreement.

KPMG | 1

© 2025 KPMG, an Australian partnership and a member firm of the KPMG global organisation of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organisation.

Liability limited by a scheme approved under Professional Standards Legislation.

The assessment is on a central estimate basis and is based on the claims experience as at 31 March 2025.

A "central estimate" liability assessment is an estimate of the expected value of the range of potential future liability outcomes. In other words, if all the possible values of the liabilities are expressed as a statistical distribution, the central estimate is an estimate of the mean of that distribution.

It is of note that our liability assessment:

- Relates to the Liable Entities and Marlew (in relation to Marlew Claims arising from asbestos mining activities at Baryulgil).
- Is intended to cover:
 - The amount of settlements, judgments or awards for all Personal Asbestos Claims.
 - Claims Legal Costs incurred by the AICF Trust in connection with the settlement of Personal Asbestos Claims.
- Is not intended to cover:
 - Personal injury or death claims arising from exposure to asbestos which took place outside Australia.
 - Personal injury or death claims, arising from exposure to Asbestos, which are brought in Courts outside Australia.
 - Claims for economic loss, other than any economic loss forming part of an award for damages for personal injury and/or death.
 - Claims for loss of property, including those relating to land remediation.
 - The costs of asbestos or asbestos product removal relating to asbestos or asbestos products manufactured or used by or on behalf of the Liable Entities.
- Includes an allowance for:
 - Workers Compensation claims, being claims from former employees of the Liable Entities, but only to the extent that such liabilities are not met by a Workers Compensation Scheme or Policy (see section 1.2.1).
 - Compensation to the NSW Dust Diseases Authority ("DDA") or a Workers Compensation Scheme by way of a claim by such parties for contribution or reimbursement from the Liable Entities, but only to the extent that the cost of such claims is within the limits of funding for such claims as outlined within the Amended Final Funding Agreement.
- Assumes that the product and public liability insurance policies of the Liable Entities will continue to respond to claims as and when they fall due. We have not made any allowance for the impact of any disputation concerning Insurance Recoveries, nor for any legal costs that may be incurred in resolving such disputes.
- Makes no allowance for:

- Insurance Recoveries from insurance policies placed from 1986 onwards which were placed on a “claims made” basis.
- the future Operating Expenses of the Liable Entities or the AICF Trust. Separate allowance for future Operating Expenses should be considered by the management of AICFL.
- the inherent uncertainty of the liability assessment. That is, no additional provision (or risk margin) has been included in excess of a central estimate.

Readers of this Report may refer to our previous reports which are available at www.ir.jameshardie.com.au and www.aicf.org.au.

1.2.1 Workers Compensation

Workers Compensation claims are claims made by former employees of the Liable Entities. Such past, current and future reported claims were insured with, amongst others, Allianz Australia Limited, QBE and the various State-based Workers Compensation Schemes.

Under the Amended Final Funding Agreement, the part of a future Workers Compensation claim that is met by a Workers Compensation Scheme or Policy of the Liable Entities is outside of the AICF Trust. The AICF Trust is, however, to provide for any part of a claim not covered by a Workers Compensation Scheme or Policy (e.g. as a result of the existence of limits of indemnity and policy deductibles on those policies of insurance). On this basis our liability assessment in relation to Workers Compensation claims and which relates to the AICF Trust, includes only the amount borne by the Liable Entities in excess of the anticipated recoveries due from a Workers Compensation Scheme or Policy.

In making our assessment we have assumed that the Workers Compensation insurance programme will continue to respond to claims by former employees of the Liable Entities as and when they fall due. To the extent that they were not to respond owing to (say) insurer insolvency, Insurer Guarantee Funds may be available to meet such obligations.

1.2.2 Dust Disease Authority and Other Reimbursements

The Amended Final Funding Agreement indicates that the AICF Trust is intended to meet Personal Asbestos Claims and that claims by the DDA or a Workers Compensation Scheme for reimbursement will only be met up to a certain specified limit (aggregated across the DDA and Workers Compensation Schemes), being:

- In the first financial year (2006/07) a limit of \$750,000 applied;
- In respect of each financial year thereafter, that limit is indexed annually in line with the Consumer Price Index. The annual limit for FY2026 will be \$1.25m (FY25: \$1.22m);
- There is an overall unindexed aggregate cap of \$30m;
- At 31 March 2025, AICFL has paid out \$15.78m to the DDA.

The cashflow and liability figures contained within this Report have already removed that component of any reimbursements that will not be met by the AICF Trust owing to the application of these limits and caps.

1.2.3 Risk Margins

Australian-licensed insurance companies are required to hold, and many non-insurance companies elect to hold, insurance and self-insurance claims provisions at a level above the central estimate basis to reflect the uncertainty attaching to the liability assessment and to include an allowance in respect of that uncertainty.

A risk margin is an additional amount held, above the central estimate, so as to increase the likelihood of adequacy of the provisions to meet the ultimate cost of settlement of those liabilities. We note that the Amended Final Funding Agreement envisages the ongoing financing of the AICF Trust is to be based on a “central estimate” approach and that the Annual Actuarial Report should provide a Discounted Central Estimate valuation.

Accordingly, we have made no allowance for any risk margins within this Report.

1.3 Areas of potential exposure

As identified in Section 1.2, there are other potential sources of claims exposure beyond those directly considered within this Report. However, in a number of cases they are unquantifiable even if they have the potential to generate claims. This is especially the case for those sources of future claims where there has been no evidence of claims to date.

1.3.1 General areas of potential exposure

Areas of potential changes in claims exposure we have not explicitly allowed for in our valuation include, but are not limited to:

- Future significant individual landmark and precedent-setting judicial decisions;
- Significant medical advancements;
- Unimpaired claims, i.e. claims for fear, stress, pure nervous shock or psychological illness;
- A change in the basis of compensation for asymptomatic pleural plaques for which no associated physical impairment is exhibited;
- A proliferation (compared to past and current levels of activity) of “third-wave” claims, i.e. claims arising as a result of indirect exposure such as home renovation, washing clothes of family members that worked with asbestos, or from workers involved in the removal of asbestos or the demolition of buildings containing asbestos;
- Changes in legislation, especially those relating to tort reform for asbestos sufferers. Examples include the consultation by the Law Reform Commission in Western Australia in relation to damages for gratuitous services and provisional damages;
- Introduction of new, or elimination of existing, heads of damage;
- Exemplary and aggravated or punitive damages (being damages awarded for personal injuries caused as a result of negligence or reckless conduct);
- Changes in the basis of apportionment of awards for asbestos-related diseases for claimants who have smoked;

- Changes to taxation; and
- Future bankruptcies of other asbestos claim defendants (i.e. other liable manufacturers or distributors).

Nonetheless, implicit allowance is made in respect of some of these items in the allowance for superimposed inflation included in our liability assessment. Furthermore, to the extent that some of these have emerged in past claims experience, they are reflected in our projections.

1.3.2 Third-wave claims

We have made allowance for so-called “third-wave” claims. These are defined as claims for personal injury and / or death arising from asbestos exposure during home renovations by individuals or to builders involved in such renovations. Such claims are allowed for within the projections to the extent to which they have arisen to date and to the extent our exposure model factors in these exposures in its projection.

We have not allowed for a significant additional surge in third-wave claims (over and above current levels of activity) in the future arising from renovations, but conversely we have not allowed for a tempering of those third-wave claims already included within our projection as a result of improved education of individuals as to the risks of such home renovations, or of any local Councils or State Governments passing laws in this regard. It should be noted that claims for the cost of asbestos or asbestos product removal from homes and properties or any claims for economic loss arising from asbestos or asbestos products being within such homes and properties is not required to be met by the AICF Trust.

1.4 Data reliances and limitations

KPMG has relied upon the accuracy and completeness of the data with which it has been provided. KPMG has not verified the accuracy or completeness of the data, although we have undertaken steps to test its consistency with data previously received.

However, KPMG has placed reliance on the data previously received, and currently provided, as being accurate and complete in all material respects.

1.5 Uncertainty

It must be understood that estimates of asbestos-related disease liabilities are subject to considerable uncertainty.

This is due to the fact that the ultimate disposition of future claims will be subject to the outcome of events that have not yet occurred. Examples of these events, as noted in Section 1.3, include jury decisions, court interpretations, legislative changes, epidemiological developments, medical advancements, public attitudes, potential additional third-wave exposures and social and economic conditions such as inflation.

Therefore, it should be expected that the actual emergence of the liabilities will vary, perhaps materially, from any estimate. Thus, no assurance can be given that the actual liabilities of the Liable Entities to be met by the AICF Trust will not ultimately exceed the estimates contained herein. Any such variation may be significant.

1.6 Distribution and use

The purpose of this Report is as stated in Section 1.1.

This Report should not be used for any purpose other than those specified.

This Report will be provided to the Board and management of AICFL. This Report will also be provided to the Board and management of James Hardie, the NSW Government and to EY in their capacity as auditors to both James Hardie and AICFL.

We understand that this Report will be filed with the ASX and placed on James Hardie's website in its entirety.

We understand that this Report will also be placed on AICFL's website in its entirety.

KPMG consents to this Report being made available to the above-mentioned parties and for the Report to be distributed in the manner described above.

To the extent permitted by law, neither KPMG nor its Executives, directors or employees will be responsible to any third parties for the consequences of any actions they take based upon the opinions expressed with this Report, including any use of or purported reliance upon this Report not contemplated in Section 1.2. Any reliance placed is that party's sole responsibility.

Where distribution of this Report is permitted by KPMG, the Report may only be distributed in its entirety and judgements about the conclusions and comments drawn from this Report should only be made after considering the Report in its entirety and with necessary consultation with KPMG.

Readers are also advised to refer to the "Important Note: Basis of Report" section at the front of the Executive Summary of this Report.

1.7 Date labelling convention used in this Report

In our analyses throughout this Report (unless otherwise stated), the "year" we refer to aligns with the financial year of AICFL and James Hardie and runs from 1 April to 31 March.

A "2008" notified claim would be a claim notified in the period 1 April 2008 to 31 March 2009. This might also be referred to as "2008/09" or "FY09".

Similarly, a "2024" claim settlement would be a claim settled in the period 1 April 2024 to 31 March 2025. This might also be referred to as "2024/25" or "FY25".

1.8 Author of the report

This Report is authored by Neil Donlevy, a Fellow of the Institute of Actuaries (London) and a Fellow of the Institute of Actuaries of Australia.

This Report is co-authored by Jefferson Gibbs, a Fellow of the Institute of Actuaries of Australia.

In relation to this Report, the primary regulator for Neil Donlevy is the Institute of Actuaries of Australia.

1.9 Professional standards and compliance

This Report details a valuation of the outstanding claims liabilities of entities which hold liabilities with features similar to general insurance liabilities.

In preparing this Report, we have complied with the Professional Standard 302 of the Institute of Actuaries of Australia ("PS302"), "Valuation of General Insurance Claims".

However, as we note in Section 1.2, this Report does not include an allowance for the future Operating Expenses of the AICF Trust (which are estimated by AICFL) and nor does it include any allowance for a risk margin to reflect the inherent uncertainty in the liability assessment.

1.10 Control processes and review

This valuation report and the underlying analyses have been subject to technical review and internal peer review.

The technical review focuses on ensuring that the valuation models and supporting claims experience analyses that are carried out are performed correctly and that the calculations are being correctly applied. The technical review also focuses on ensuring that the data that is being used has been reconciled insofar as possible.

Internal peer review involves a review of the approach, the methods, the assumptions selected and the professional judgments applied.

Both the technical review and internal peer review processes are applied to the Report as well as the valuation models.

1.11 Basis of preparation of Report

We have been advised by the management of AICFL to prepare the Report on a "going concern" basis (i.e. we should assume that AICFL will be able to meet any shortfall in the cost of the liabilities of the Liable Entities as they fall due).

The cashflow estimates contained in this Report assume that claims against the Liable Entities will continue to be paid in full as and when they fall due.

2. Data

2.1 Data provided to KPMG

We have been provided with the following data by AICFL:

- Claims dataset at 31 March 2025 with individual claims listings;
- Accounting transactions dataset at 31 March 2025 (which includes individual claims payment details); and
- Detailed insurance bordereaux information (being a listing of claims filed with the insurers of the Liable Entities) as at 31 March 2025.

We have allowed for the benefits of the product and public liability insurance policies of the Liable Entities based on information provided to us by AICFL relating to the insurance programme's structure, coverage and layers.

We have also considered the claims data listings which formed the basis of our previous valuation assessments. The data structures provided for the claims and accounting datasets are consistent with those provided at previous valuations.

2.2 Data limitations

We have tested the consistency of the various data sets provided to us at different valuation dates. Section 2.3 outlines the nature of the testing undertaken.

However, we have not otherwise verified the data and have instead relied on the data provided as being complete and accurate in all material respects.

We have relied upon the robustness of AICFL's internal administration and systems as to the completeness of the data provided.

Consequently, should there be material errors or incompleteness in the data, our assessment could also be affected materially.

2.3 Data reconciliation and testing

We have performed a reconciliation of the data provided at 31 March 2025 with the data provided at 31 March 2024.

We have undertaken a number of tests and reconciliations to test the accuracy of the data to the extent possible, noting the limitations outlined above.

2.3.1 Reconciliation with previous valuation's data

We have performed a reconciliation of the claims database as at 31 March 2025 with that provided at 31 March 2024.

Our findings are:

- Claims notifications: There have been no new claims reported that had a report date prior to 31 March 2024. No claims have changed their date of notification.
- Portfolio category: There has been 1 claim that has changed category to mesothelioma from workers compensation. This claim was reported in 2021/22.
- Settlement date: There have been no claims which have changed their settlement date.

Changing and developing data is not unexpected or to be considered as adverse. Indeed, changing data is common to all claims administration systems. We do not consider the number or extent of the changes noted above to be unreasonable, nor do we consider the changes to be material to the valuation.

2.3.2 Reconciliation of claims settlement amounts between claims and accounting databases

We have mapped the financial data between the claims and accounting databases into standardised groupings as follows:

Table 2.1: Grouping of financial data from claims and accounting databases

	CLAIMS DATABASE	ACCOUNTING DATABASE
Award	Damages (gross of cross-claims) plus DDB reimbursement plus Medicare (from Accounting Database)	Damages plus DDB reimbursements plus Medicare
Costs / Other	Costs plus Other less Medicare (from accounting database)	Costs plus Consulting
Defence legal costs	Defence legal costs	Defence legal costs

Note: Recovery amounts are available from the accounting database

We have compared the payment records between the claims database and the accounting database from the earliest date to the current file position.

The table below shows the results of this reconciliation for all claim transactions to date.

Table 2.2: Comparison of amounts from claims and accounting databases (\$m)

CLAIMS DATABASE		ACCOUNTING DATABASE	
Damages (gross of recoveries, excluding medicare)	2,629.4	Damages (gross of recoveries)	2,632.7
Costs	83.9	Costs	85.2
DDB	18.3	DDB	18.4
Other (inc Medicare)	6.3	Consulting	2.2
		Medicare	3.2
		Interest	1.0
Defence legal costs	271.8	Defence legal costs	272.3
Total Value	3,009.8	Total Value	3,015.0
Standardisation			
Award plus Medicare plus DDB	2,651.0	Award plus Medicare plus DDB	2,654.3
Costs / Other	86.9	Costs / Other	88.4
Defence legal costs	271.8	Defence legal costs	272.3
Total Value	3,009.8	Total Value	3,015.0

Once the standardisation has been undertaken, the two datasets reconcile closely – with differences for claim awards totalling approximately \$3.2m (31 March 2024: \$3.0m).

Our approach for each claim record has been to take the maximum value of the two databases for each claim record. This results in the following overall totals being used in our analysis:

- \$2,654.7m for the claims award component;
- \$88.7m for the costs / other component; and
- \$272.6m for the defence legal costs component.

This approach, of taking the maximum value for each claims record, may result in some minor prudence in our overall analysis although the amount of prudence is not considered to be significant in the context of the size of the potential liabilities and the underlying uncertainty in any valuation estimating future claims costs over the next 40 years or more.

2.4 Data conclusion

We have not verified the underlying data nor have we undertaken “auditing at source”. No material data issues have been identified and notified to us by the Approved Auditor of AICFL (EY) during their testing.

We have tested the data for internal consistency with the data provided at the previous valuation (31 March 2024).

Based on that testing and reconciliation, and subject to the limitations described in Section 1.4, we have formed the view that:

- Generally, the data is consistent between valuations, with any differences in the data being readily explainable;
- The financial data appears to reconcile reasonably between the two data sources (the claims dataset and the accounting transactions datasets);
- Any data issues that have emerged are not significant in relation to the size of the liabilities; and
- The data is appropriate for use for the purpose of this Report.

3. Valuation Methodology and Approach

3.1 Valuation methodology changes

We have broadly maintained the core valuation methodology adopted at our previous valuation.

The key change at this valuation is the derivation of separate assumptions for direct and cross claims for asbestosis in relation to:

- estimated future claim numbers including for the next year (2025/26) (but not including having different latency assumptions);
- average claim sizes; and
- nil settlement rates.

We have done this given the changing mix of claims for the asbestosis portfolio as between direct claims and cross claims and the materially different claim sizes and nil settlement rates. Given the recent volumes of reported asbestosis cross claims, there is now sufficient data to analyse separately between direct claims and cross claims for some of the key metrics.

We have not currently separately set assumptions for legal costs or latency assumptions for asbestosis as between direct claims and cross claims. However, depending on how experience develops at future valuations, this may be something that we might consider (albeit, especially for the latency assumptions, data volumes may still be an inhibitor to identify statistically-valid differences in the claims experience trends).

Otherwise, the most recent material change in the methodology took place at 31 March 2020 when we separated the portfolio of mesothelioma claims between direct claims and cross-claims and for each of the four age cohorts. This included deriving separate assumptions for direct claims and cross claims and for each of the four age cohorts for:

- estimated future claim numbers (including latency assumptions);
- average claim sizes (including incidence rates of large claims);
- average legal costs; and
- nil settlement rates (but only for direct and cross, without separate age-based assumptions).

3.2 Overview of current methodology

The methodology involves assessing the liabilities in two separate components, being:

- Allowance for the cost of settling claims which have already been reported but have not yet been settled ("pending claims"); and
- Allowance for the cost of settling claims which have not yet been reported ("Incurred But Not Reported" or "IBNR" claims).

For pending claims, we have used the case estimates (where available) with some adjustments to reflect the extent to which the case estimates (on average) tend to overstate the ultimate cost. For IBNR claims we have used an "average cost per claim method".

In brief, the overall methodology may be summarised as follows:

- Project the future number of claims expected to be reported in each future year by disease type (for product and public liability) and for Workers Compensation and wharf claims taking into account the expected future incidence of mesothelioma and other diseases and also the past rate of co-joining of the Liable Entities;
- Analyse past average attritional claim costs of non-nil claims in mid 2024/25 money terms. We have defined attritional claims to be claims which are less than \$1m in 2006/07 money terms. We estimate a baseline attritional non-nil average claim cost in mid 2024/25 money terms. This represents the Liable Entities' share of a claim rather than the total claim settlement;
- Analyse past historical average plaintiff/other and defendant legal costs for non-nil claim settlements;
- Analyse past historical average defendant legal costs for nil claim settlements;
- Estimate a "large claims loading" for mesothelioma claims by estimating the frequency, or incidence rate, and average claim size and legal cost sizes of such claims (being claims which are in excess of \$1m in 2006/07 money terms);
- Project the pattern and incidence of future claims settlements from the claims reporting profile projected. This is done by using a settlement pattern derived from consideration of past experience of the pattern of delay between claim reporting and claim settlement for each disease type;
- Estimate the proportion of claims which will be settled with no liability against the Liable Entities by reference to past proportions of claims settled for nil claim cost (we refer to this as the "nil settlement rate");
- Inflate average claim, plaintiff/other and defence legal costs and large claim costs to the date of settlement of claims allowing for base inflation and (where applicable) superimposed inflation;
- Multiply the claims numbers which are expected to be settled for non-nil amounts in a period by the inflated average non-nil claim costs (including the "large claims loading") and plaintiff/other and defence legal costs for that period;

- Make allowance in defence legal costs for that proportion of settled claims which are expected to be settled for no liability but for which defence costs will be incurred;
- Inflate average defence legal costs of nil claims to the date of settlement of claims allowing for base inflation;
- Multiply the claims numbers which are expected to be settled for nil amounts in a period by the inflated average defence legal costs for nil claims for that period;
- Add the expected claims costs and legal payments relating to pending claims (after allowance for the potential savings on case estimates) after making allowance for the assumed settlement pattern of pending claims;
- This gives the projected future gross cashflow for each future financial year;
- Adjust the projected gross cashflow (where applicable) for the impact of the annual and aggregate caps on DDA reimbursements;
- Estimate the recoveries resulting from cross-claims made by the Liable Entities against other parties ("cross-claim recoveries");
- Project Insurance Recoveries to establish the net cashflows;
- Discount the cashflows using a yield curve derived from yields on Commonwealth Government Fixed Interest Bonds at the valuation date to arrive at our present value liability assessment.

It should be noted that this description is an outline and is not intended to be exhaustive in consideration of all the stages we consider or all investigations we undertake. Those other stages are outlined in more detail elsewhere in this Report and readers are advised to refer to those sections for a more detailed understanding of the process undertaken. As discussed elsewhere, the liabilities are established on a central estimate basis.

3.3 Disease type and class subdivision

3.3.1 Claims records excluded from our analysis

We have excluded records that relate to cross-claims brought by the Liable Entities against other defendants. Where the cross-claim is brought as part of the main proceedings the claim is automatically counted in our analysis of the number of claims. However, where the cross-claim by the Liable Entities is severed from the main proceedings, the existence of a separate record in the claims dataset does not indicate an additional claim (or liability) against the Liable Entities. In these circumstances such records are not counted in our analysis.

We have also excluded "insurance recovery" claims records. This is because the insurance recovery record is a separate record that exists for claims records where an insurance recovery is due. In other words, the claim against the Liable Entity has already been included in our analysis and the insurance recovery record exists for operational purposes only.

3.3.2 Categories of claim

We have sub-divided the remaining claims into the following groups:

- Product and Public Liability;

- Workers Compensation, being claims by former employees of the Liable Entities; and
- Wharf claims, being claims by individuals whose occupations involved working on the docks or wharves, or where part of their exposure related to wharves.

3.3.3 Categories of disease

For product and public liability claims, we have separately analysed the individual disease types.

We have split the data by disease type for these claims because there is sufficient volume of claims to do so, because different disease types display substantially different average claim sizes, and because the incidence pattern of future notifications is expected to vary between the different disease types.

We have not divided the Workers Compensation or wharf claims data by disease type, given their low financial significance and the reduced credibility of the data if sub-divided by disease type (given the low number of claims).

For the purposes of our analysis, we have allocated each claim once and therefore to one disease only. We have selected the following order of priority, based on the relative severity of the disease:

- Mesothelioma;
- Lung cancer / Other cancer;
- Asbestosis; and then
- Asbestos-Related Pleural Disease and Other ("ARPD & Other").

This means that if a product or public liability claim has mesothelioma as one of its listed diseases, it is counted as a mesothelioma claim. If a product or public liability claim has lung cancer or other cancer as one of its listed diseases (but not mesothelioma), it is counted as a lung cancer claim. If a product or public liability claim has asbestosis as one of its listed diseases, it is only counted as asbestosis if it has no reference to mesothelioma, lung cancer or other cancer as one of its diseases.

For mesothelioma, we have also separated claims based on the age of the claimant at the date of notification of the claim. We have used four age cohorts, namely:

- <60 years of age;
- 60-70 years of age;
- 70-80 years of age; and
- >80 years of age.

We have further separated mesothelioma claims between direct claims and cross claims.

For asbestosis, at this valuation, we have separated claims between direct claims and cross claims. We have not separated this portfolio by age as the low volumes of claims in a number of the 8 age cohorts would mean identification of trends would not be statistically credible.

3.4 Numbers of future claims notifications: mesothelioma

To project the pattern of incidence of claims against the Liable Entities, we have constructed a model which utilises the following inputs:

- The current Australian population by year of birth / current age and gender;
- Standard mortality rates by age and gender. This is used to project the population by year of birth / age at each future year;
- The relative risk-exposure (or incidence rates) between males and females;
- The relative risk-exposure by age of person at time of exposure;
- The exposure to asbestos in Australia;
- The statistical distribution of the latency period from average exposure separately for direct claims and cross claims, and by age of claimant, together with the underlying parameters (the mean and the standard deviation) of the latency model.


Detailed discussion of the approach taken is documented in our 31 March 2018 Annual Actuarial Report.

3.4.1 Exposure model

We have constructed a proxy for exposure by reference to statistics showing the levels of Australian usage of asbestos. We do not have detailed individual exposure information for the Liable Entities, its products or where the products were used and how many people were exposed to those products.

However, given the market share of James Hardie over the years (through to 1987) and its relative stability, we have used a national pattern of usage as a reasonable proxy for the Liable Entities' exposure.

Figure 3.1: Consumption and production indices – Australia 1930-2002



Source: World Mineral Statistics Dataset, British Geological Survey, www.mineralsuk.com
R Virta, USGS Website Annual Yearbook

There is an implicit assumption within the use of the consumption to derive the level of future claim notifications that:

- the consumption of asbestos is directly correlated with, and is a suitable proxy for, the number (and extent of exposure) of people exposed to asbestos in any year; and
- the rate of incidence of individuals developing an asbestos-related disease arising from exposure to asbestos is the same for each exposure year and is independent of the type of asbestos used.

3.4.2 Latency model

We have continued to assume that the latency pattern (from the average date of exposure) is statistically distributed with a normal distribution.

We have derived separate latency assumptions for mesothelioma as between direct claims and cross claims. The model projection assumptions are shown in the table below.

At this valuation, we have maintained both of our mean and standard deviation latency assumptions for both direct claims and cross claims from the previous valuation.

Table 3.1: Latency assumptions for mesothelioma claims

	Direct	Cross
Mean latency	42	42
Standard deviation of latency	9	10

The analysis supporting the selection of these parameters is summarised in Section 6.

3.4.3 Calibrating the curve index to current reporting experience

We take the claim curve index and then calibrate the number of notifications in each future year by reference to the recent levels of claims reporting and the number of claims we have assumed for the 2025/26 financial year. This approach implicitly assumes that:

- The future rate of incidence of asbestos-related diseases manifesting as a result of a past exposure to asbestos will remain stable;
- The pattern of diagnosis and the delay between diagnosis and reporting remain stable;
- The “propensity to claim” by individuals will remain stable; and
- The rate of co-joining the Liable Entities in common law claims will remain stable.

Changes to any of these factors over time will result in changes to the actual pattern of incidence of claims reporting.

The claim curve index also provides us with the proportions of the total number of claims reported in each future year that relate to each of the four age groups and separately for direct claims and cross claims for mesothelioma.

Our assumptions for the base number of claims projected to be reported in 2025/26 are summarised in Section 4.6 and Section 5.7.

3.5 Incidence of claim settlements from future claim notifications

We derive a settlement pattern by analysing triangulations of the numbers of settlements and claims payments by delay from the year of notification.

From these settlement pattern analyses, we have estimated the pace at which claims notified in the future will settle, and used this to project the future number, and monetary amount, of settlements in each financial year for each disease type.

Our analysis and assumptions selected are summarised in Section 9.5.

3.6 Average claim costs of IBNR claims

3.6.1 Attritional claims

We define a large claim as one for which the award is greater than or equal to \$1m in 2006/07 money terms (which equates to approximately \$2.026m in mid 2024/25 money terms).

We define an attritional claim as a non-nil, non-large claim. We define a nil claim as one for which the award payable by the relevant Liable Entity is zero.

We have estimated the following five components to the average cost assessment:

- Average award (sometimes including plaintiff legal costs) of a non-nil “attritional” claim.
- Average plaintiff legal / other costs of a non-nil “attritional” claim.
- Average defence legal costs of a non-nil “attritional” claim.
- Average defence legal costs of a nil claim.
- Large claim awards and legal cost allowances.

All of our analyses have been constructed using past average awards, which have been inflated to mid 2024/25 money terms using a historical base inflation index (of 4% per annum). This allows for basic inflation effects when identifying trends in historical average settlements.

We then determine a prospective average cost in mid 2024/25 money terms, including an explicit allowance for overseas exposures resulting from the decision in *Talifero vs Amaca*.

Our analysis and assumptions are summarised in Section 7.

3.6.2 Large claims loading

We analyse the historical incidence rate of large claims (being measured as the ratio of the number of large claims to the total number of non-nil claims), and the average claim size and legal costs of these claims.

We use these to arrive at a “per claim” loading (being the average large claim cost multiplied by the large claim incidence rate per claim), being the additional amount we need to add to our attritional average claim size to allow for large claims.

We have derived separate incidence rate and average claim size assumptions for each of the four age groups for mesothelioma.

Our analysis and assumptions are summarised in Section 7.8.

3.6.3 Future inflation of average claim sizes

Allowance for future claim cost inflation is made. This is modelled as a combination of base inflation plus superimposed inflation. This enables us to project future average settlement costs in each future year, which can then be applied to the IBNR claims numbers as they settle in each future year.

Our analysis and assumptions in relation to claims inflation are summarised in Section 9.2.

3.7 Proportion of claims settled for nil amounts

We apply a “nil settlement rate” to the overall number of settlements to estimate the number of claims which will be settled for nil claim cost (i.e. other than in relation to defence legal costs) and those which will be settled for a non-nil claim cost.

The prospective nil settlement rate is estimated by reference to the analysis of past trends in the rate of nil settlements.

We have derived separate nil settlement rate assumptions for direct claims and cross claims for both mesothelioma and asbestosis. We do not derive separate nil settlement rate assumptions by age cohort.

Our analysis and assumptions selected are summarised in Section 8.

3.8 Pending claims

3.8.1 Definition of pending claims

At 31 March 2025, there were 534 claims for which claim awards have not yet been fully settled by the Liable Entities (297 of these are mesothelioma claims and 157 of these are asbestosis claims). Additionally, there are a number of other claims for which defence legal costs have not yet been settled, even though the awards have been settled.

3.8.2 Evaluating the liability for pending claims

The excess amount of the liability for pending claims, over the case estimates held, is what the insurance industry terms Incurred But Not Enough Reported (“IBNER”).

Depending on the case estimation procedure of a company and the nature of the liabilities, IBNER can be either positive or negative, with a negative IBNER implying that the ultimate cost of settling claims will be less than case estimates, i.e. that there is some degree of redundancy in case estimates.

3.8.3 Findings

The table below analyses the adequacy or otherwise of the previous year’s case estimates for claims reported through to 31 March 2024 relative to the current cost of those reported claims, after taking into account the 25% saving assumed on case estimates.

Table 3.2: Change in cost of claims during 2024/25 financial year (\$m) – claim award component only

Figures in \$ millions	Current year reported claims	Prior year reported claims	Total
Adopted estimates for pending claims at 31 March 2024 (undiscounted)	0.0	111.7	111.7
Paid in the year to 31 March 2025	73.9	88.1	161.9
Adopted estimates for pending claims at 31 March 2025 (undiscounted)	97.3	34.2	131.6
Incurred Cost in the financial year	171.2	10.6	181.8

The table above shows that there has been an increase of \$10.6m in the cost of claims that were reported prior to 31 March 2024.

At 31 March 2024, the prior year claims development was a decrease of \$11.4m; and at 31 March 2023, the prior year claims development was a decrease of \$0.5m.

We have maintained our assumption for the level of redundancy in case estimates on currently reported claims at 25% at this valuation given the last three years have on average been broadly in line and noting that this year's development related to a small number of claims (~20 claims) that saw a strong increase in individual reserves or in their individual final settlements relative to initial estimates.

That said, should we see further year-on-year adverse development in FY26, this assumption may require revisiting at the next valuation.

By way of illustration, a reduction in the assumed level of redundancy in case estimates from 25% to 15% would add around \$18m to the central estimate.

3.9 Insurance Recoveries

Insurance Recoveries are defined as proceeds which are estimated to be recoverable under the product and public liability insurance policies of the Liable Entities, and therefore exclude any such proceeds from a Workers Compensation Scheme or Policy in which the Liable Entities participate or which the Liable Entities hold.

In applying the insurance programme we therefore consider only the projected gross cashflows relating to product and public liability claims.

Historical analysis of the claims data suggests that approximately 97.5% of all liability claims by cost have been product liability claims.

3.9.1 Programme overview

Until 31 May 1986, the Liable Entities had in place product and public liability insurance policies that were placed on a claims occurring basis.

Product liability claims were insured under these insurance policies on an "in the aggregate" basis whilst public liability claims were insured on an "each and every loss" basis.

From 31 May 1986, the insurance policies were placed on a claims made basis in relation to asbestos-related product and public liability cover.

In summary, the insurance policies were placed as follows:

- For the period up to June 1976, the insurance policies were written on a claims occurring basis. The insurance was provided by QBE but the cover provided by these policies was commuted in June 2000. Therefore, we have assumed no future Insurance Recoveries from these policies.
- For the period from June 1976 to 31 May 1986, the insurance policies were written on a claims occurring basis; insured by Lloyds' of London, London Market insurers, Australian insurers and HIH entities.
- For the period 31 May 1986 to 31 March 1997, the insurance policies were written on a claims-made basis. For the purpose of this Report, we have made no allowance for any future Insurance Recoveries arising from these policies.

3.9.2 Modelling insurance recoveries on the claims occurring programme

Our methodology for projecting the future insurance recoveries to be collected by AICFL involves the following steps:

- Identify the current contract positions for each insurance policy year. This assumes that all monies due have been collected and does not allow for the impact of commutations that have taken place.
- Allocate the projected future gross cashflows to individual insurance policy years using an allocation basis that has been determined by reference to the exposure methodology used to project future claim numbers and also using a "period of exposure" allocation.
- This gives a projection of how the insurance programme is utilised over time.

This method allows us to:

- evaluate the total insurance recoveries due by payment year;
- determine how the insurance recoveries due will be assigned to each layer and to each insurer; and
- identify and allow for when the individual layers are projected to be fully exhausted.

We then make an additional adjustment to the projected recoveries to exclude those projected future insurance recoveries that are assigned to the participations of insurers who have already commuted their coverage with AICFL and the Liable Entities or insurers who have settled their coverage by way of a Scheme of Arrangement.

3.9.3 Commutations, HIH and Schemes of Arrangement

Where commutations have been entered into by AICFL in previous years, we have assumed that the insurance liabilities of that company to the Liable Entities have been fully discharged and no further recoveries will fall due.

Additionally, we have assumed that all monies have been paid in relation to insurance

recoveries for the claims occurring period from HH.

KPMG | 20

© 2025 KPMG, an Australian partnership and a member firm of the KPMG global organisation of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organisation.
Liability limited by a scheme approved under Professional Standards Legislation.

For the claims occurring period, where a claim filed against a company under a Scheme of Arrangement has been made, we have assumed that the insurance liabilities of that company to the Liable Entities have been fully discharged and no further recoveries will fall due.

We have made no allowance or adjustment in our valuation for any future commutations with the remaining insurers.

3.9.4 Unpaid insurance recoveries

We have not included within our liability estimate any allowance for insurance recoveries under the claims occurring period that are due but have not yet been collected.

We are advised that such monies amount to approximately \$0.6m at 31 March 2025.

These amounts are more appropriately dealt with as being debtors of AICFL.

3.9.5 Bad and doubtful debt allowance on Insurance Recoveries

We have made allowance for bad and doubtful debts on future Insurance Recoveries within our valuation by use of the default rates as shown in the table below and as applied to each insurer based on their credit rating as at 31 March 2025.

Table 3.3: Credit rating default rates by duration

Rating	Yr. 1	Yr. 2	Yr. 3	Yr. 4	Yr. 5	Yr. 6	Yr. 7	Yr. 8	Yr. 9	Yr. 10	Yr. 11	Yr. 12	Yr. 13	Yr. 14	Yr. 15
AAA	0.00%	0.03%	0.13%	0.23%	0.34%	0.44%	0.49%	0.57%	0.62%	0.67%	0.70%	0.73%	0.75%	0.81%	0.86%
AA+	0.00%	0.04%	0.04%	0.09%	0.13%	0.18%	0.23%	0.27%	0.32%	0.37%	0.43%	0.48%	0.53%	0.59%	0.65%
AA	0.02%	0.03%	0.08%	0.20%	0.33%	0.44%	0.56%	0.66%	0.74%	0.83%	0.90%	0.95%	1.04%	1.09%	1.14%
AA-	0.02%	0.07%	0.15%	0.21%	0.27%	0.36%	0.42%	0.47%	0.53%	0.59%	0.64%	0.68%	0.70%	0.73%	0.77%
A+	0.04%	0.07%	0.16%	0.27%	0.35%	0.43%	0.52%	0.61%	0.72%	0.83%	0.93%	1.04%	1.16%	1.30%	1.42%
A	0.05%	0.12%	0.19%	0.28%	0.39%	0.53%	0.68%	0.81%	0.96%	1.13%	1.27%	1.37%	1.47%	1.53%	1.66%
A-	0.05%	0.14%	0.22%	0.30%	0.42%	0.55%	0.73%	0.87%	0.97%	1.07%	1.16%	1.27%	1.37%	1.47%	1.55%
BBB+	0.09%	0.23%	0.41%	0.59%	0.79%	1.01%	1.18%	1.37%	1.60%	1.83%	2.04%	2.19%	2.36%	2.55%	2.75%
BBB	0.13%	0.33%	0.51%	0.80%	1.09%	1.38%	1.68%	1.95%	2.24%	2.50%	2.77%	2.99%	3.20%	3.32%	3.51%
NR	3.54%	6.78%	9.55%	11.79%	13.64%	15.15%	16.39%	17.41%	18.32%	19.15%	19.85%	20.44%	20.99%	21.47%	21.93%
R	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

Source: Standard & Poors' 2023 Annual Global Corporate Default Study and Rating Transitions, published April 2024.

NR relates to companies which are Not Rated

R relates to companies which have been subject to Regulatory Action regarding solvency.

3.10 Cross-claim recoveries

A cross-claim can be brought by, or against, one or more Liable Entities. Cross-claims brought against a Liable Entity ("Contribution Claims") are included in our analysis of the claims experience.

Cross-claims brought by a Liable Entity relate to circumstances where the Liable Entity seeks to join (as a cross-defendant) another party to the claim in which the Liable Entity is already joined.

Our approach in the valuation has been to separately value the rate of recovery ("cross-claims recovery rate") as a percentage of the gross award based on historical experience of such recoveries.

Our analysis and assumptions selected are summarised in Section 9.4.

3.11 Discounting cashflows

Cashflows are discounted based on yields available at the valuation date on Commonwealth of Australia fixed interest Government Bonds ("Commonwealth Government Bonds") of varying coupon rates and durations to maturity.

Our approach to the determination of the discount rates is unchanged from the approach adopted at 31 March 2024, and is:

- For years 1 to 16, zero coupon spot rates were determined by reference to the prices, coupons and durations of Commonwealth Government Bonds;
- For years 19 and onwards, we have selected a uniform long-term discount rate of 5.60% per annum (FY2024: 4.75% per annum); and
- For years 17 and 18, we have selected spot rates that "linearly interpolate" between the year-16 rate and the year-19 rate (of 5.60%).

Our selected assumptions are summarised in Section 9.3.


4. Claims Experience:

Mesothelioma Claim Numbers

4.1 Overview

The following chart shows the number of mesothelioma claims reported by year of notification.

Figure 4.1: Number of mesothelioma claims reported annually



Note: Throughout Sections 4 to 9, the date convention used in tables and charts is that (for example) 2008/09 indicates the financial year running from 1 April 2008 to 31 March 2009. Furthermore, unless clearly identifying a calendar year, the label "2008" in charts or tables would indicate the financial year running from 1 April 2008 to 31 March 2009.

For 2024/25, there were 401 mesothelioma claims reported.

This represented a 7.5% increase relative to the prior year (373 claims).

Direct claims were 291 claims, a small decrease to the prior year (295 claims) and slightly above expectations (282 claims).

Cross claims showed a material increase to 110 claims relative to the previous year (78 claims) and relative to expectations (84 claims).


4.2 External statistics on mesothelioma claims incidence

The following chart compares the total number of mesothelioma cases reported (diagnosed) nationally to the number of mesothelioma claims received by the Liable Entities.

It should be noted that the two sets of data correspond to different definitions of year and so are not directly comparable and some caution should be exercised.

The “year” is calendar year for the national cases (i.e. 2012 is the year running from 1 January 2012 to 31 December 2012); whilst for the Liable Entities it is the financial year (i.e. 2012 is the year running from 1 April 2012 to 31 March 2013).

Figure 4.2: Number of mesothelioma cases reported nationally compared to the number of claims received by the Liable Entities



Sources: Australian Cancer Incidence and Mortality book for Mesothelioma, Australian Institute of Health and Welfare, updated February 2018 for 2000-2013

Annual Report of the Australian Mesothelioma Registry for 2014 and onwards

In calendar year 2023, the number of cases diagnosed nationally (as currently reported) was 617. It should be noted there may be a considerable degree of under-reporting in the 2023 year and, to a lesser extent, the 2022 year, noting that:

- The 2018 year was first reported as 662, and this has increased to 825 (as reported in the 2023 Australian Mesothelioma Registry Report).
- The 2019 year was first reported as 659, and this has increased to 790 (as reported in the 2023 Australian Mesothelioma Registry Report).
- The 2020 year was first reported as 642, and this has increased to 816 (as reported in the 2023 Australian Mesothelioma Registry Report).


These increases in national statistics lead to a lower ratio for the number of Liable Entity claims as a percentage of the number of national cases of mesothelioma. As a consequence, the currently estimated 61% for 2023/24 may be over-stated and (if previous experience of initial under-reporting of the number of national cases were to recur) may be more in the order of 50%.

It should be noted that not all cases of mesothelioma result in a claim being brought in Common Law. Furthermore, even if a claim is brought, not all claims will involve the Liable Entities.

In relation to NSW, we have additional information from the Dust Diseases Tribunal (NSW) that indicates what proportion of common law claims the Liable Entities are joined in for NSW.

For the DDC data, the “year” is financial year (i.e. 2012 is the year running from 1 July 2012 to 30 June 2013). In contrast, in the DDT data, “year” is defined as a calendar year (i.e. 2012 is the year running from 1 January 2012 to 31 December 2012). It should be noted that the three sets of data correspond to different definitions of year and so are not directly comparable and some caution should be exercised.

Figure 4.3: Number of mesothelioma cases reported in NSW




Sources: DDC claims data: Insurance and Care NSW Annual Report 2023/24.

DDT statistics: provided by the State of New South Wales

The data would appear to indicate that the Liable Entities are not being increasingly joined in common law claims in NSW, whilst noting that there is variability from year to year (the rate of joining is typically between 60% and 70% although for 2024/25 it is currently 55%).

The chart below shows the mix of national cases by age. The data shows a broadly similar pattern to AICF’s own experience, with the proportion of cases relating to people under 70 years of age continuing to trend downward, falling below 20%.

Figure 4.4: Age profile of mesothelioma cases nationally



Sources: Australian Institute of Health and Welfare; Australian Mesothelioma Registry Report

Note: Data by age cohort for 2017 was not published in the 2017 Australian Mesothelioma Registry Report

4.3 Profile of mesothelioma claims

4.3.1 Direct claims and cross claims


The following chart shows the number of claims separately as between claims brought by claimants ('direct claims') and claims brought by other defendants ('cross claims').

There was a significant increase in cross claims in 2024/25.

This was mainly Victoria and related to Government entities and NSW primarily from one cross-claimant entity. It is unclear if this is a backlog clearance and one-off in nature or is indicative of a longer-term change.

It is noted that much of this increase took place in Q2 (37 cross claims) whilst other quarters remained above long-term run rates (they averaged 24 claims compared to a usual level of around 21 claims typically).

Figure 4.5: Number of mesothelioma claims by type of claim




4.3.2 Delay from diagnosis to notification

The chart below measures the time-lag (in days) from diagnosis of mesothelioma to notification of a claim against the Liable Entities.

Direct claims have typically taken between 5 months and 7 months to be reported after diagnosis of mesothelioma. After increasing to 8 months in 2023/24, the average lag returned to 6 months in 2024/25.

Figure 4.6: Delay from diagnosis of mesothelioma to notification of claim against the Liable Entities



4.4 Profile of mesothelioma claims: direct claims

4.4.1 Claims by State

Claims reporting for direct claims has varied between 276 and 317 claims in the last ten years.

The reductions in claim numbers in NSW in 2020/21 were offset by higher numbers of claims being lodged in Queensland (many of which are typically lodged in the DDT in NSW). This trend has since reversed.

However, 2024/25 saw a change in mix of claims by State relative to recent years with lower volumes in NSW offset by higher volumes in Victoria and SA.

SA and Victoria both saw individual instances of large numbers of claims per claimant for one or more claims. For example, 9 direct claims relating to one claimant.

Increases in Queensland claims in 2024/25 may also have been linked to the lower NSW claim volumes.

Figure 4.7: Number of mesothelioma direct claims by State




4.4.2 Age profile of claimants

The chart below shows that the primary source of growth since 2007/08 has been for claimants over the age of 70.

The last three financial years have seen some moderate reductions in the numbers of claims from the 70-80 age cohort.

There has been a strong increase in the numbers of claims from claimants 80+ over the last ten years, although it stabilised in absolute terms in 2024/25.

Figure 4.8: Number of mesothelioma direct claims by age of claimant



4.5 Profile of mesothelioma claims: cross claims

4.5.1 Claims by State

We have analysed the number of mesothelioma claim notifications by the State in which the cross claim is filed.

Figure 4.9: Number of mesothelioma cross claims by State



The high numbers of South Australia cross claims that was experienced in 2019/20 and 2020/21 has not continued in subsequent years. There were 13 claimants in 2019/20 and 10 claimants in 2020/21 where “duplicate claims” arose (i.e. 2 cross claims, or more, were lodged for each claimant).


The 2024/25 year has seen a significant increase, with 110 cross claims reported. There were increases in NSW due to one cross-claimant entity and Victoria due to Government entities most notably in Q2 (37 claims).

4.5.2 Age profile of claimants

The chart below shows the mix of claims by age cohort over time. Again, it is observed that most of the claimants are in excess of 70 years of age.

In 2024/25, there has been a significant increase in the number of claims in the 70-80 and 80+ age cohorts, while the number of claims for the 60-70 age cohort has seen a slight decrease.

Figure 4.10: Number of mesothelioma cross claims by age of claimant



4.6 Base valuation assumption for number of mesothelioma claims

The actual number of reported claims in 2024/25 for mesothelioma was 35 higher than expected (or 7%).

Direct claims (291 claims) were 9 claims above expectations (282 claims) whilst being lower than the previous year (295 claims).

Analysis indicates instances of a number of “multiple claims per claimant” having arisen in 2024/25.

Typically, there are on average about 1.1 mesothelioma claims per claimant and very few claims involve more than 2 claims for an individual claimant (and most only involve one claim per claimant). This year, we have observed instances of up to 9 claims for individual direct claimants.

Offsetting this, claim sizes would then be naturally expected to be lower, as the total compensation relating to that claimant is spread across a larger volume of claims for that claimant.

In this context, taking into account the instances of multiple claims per claimant (and not factoring into the lower implied average claim awards as a consequence), we have selected an assumption of 282 claims for 2025/26 for direct claims.

Cross claims were 26 claims above expectations (110 vs 84), and also materially above the prior year of 78 claims. As noted earlier, this primarily related to Victoria and NSW and three specific entities, and most notably in Q2 (37 claims reported).

We have set our assumption for cross claims at 96 claims, based on an average of the last three years’ experience as well as being the average experience of the three other quarters of 2024/25 (i.e. treating Q2 as a one-off at this time).

In total, we are therefore projecting 378 mesothelioma claims to be reported in 2025/26.

The table below summarises the overall assumptions and the mix assumptions by age cohort for 2025/26, as well as providing a comparison of the previous two years’ actual experience.

Table 4.1: Assumed mix of claims by age cohort and type of claim for 2025/26

	FY26 Assumption		FY25 Actual		FY24 Actual	
	Numbers	%	Numbers	%	Numbers	%
Mesothelioma (direct claims)	282		291		295	
<60	18	6.4%	22	7.6%	21	7.1%
60-70	36	12.8%	37	12.7%	42	14.2%
70-80	116	41.1%	116	39.9%	120	40.7%
80+	112	39.7%	112	38.5%	112	38.0%
age not known	0	0.0%	4	1.4%	0	0.0%
Mesothelioma (cross claims)	96		110		78	
<60	2	2.1%	3	2.7%	1	1.3%
60-70	9	9.4%	7	6.4%	10	12.8%
70-80	45	46.9%	53	48.2%	39	50.0%
80+	40	41.7%	47	42.7%	28	35.9%
age not known	0	0.0%	0	0.0%	0	0.0%

Note: percentage figures may not add exactly to 100.0% on sight, owing to the percentages being shown rounded to 1 decimal point.

4.7 Inherent uncertainties in the future number of mesothelioma claims

There remain material uncertainties in relation to the base level of claims reporting and the total future number of mesothelioma claims to be reported against the Liable Entities.

It is possible that claims reporting activity could increase next year, or that it could fall next year.

There remain uncertainties in relation to the peak period of claims reporting for mesothelioma, particularly given that 2019/20 saw the highest number of mesothelioma claims received historically, albeit primarily this was due to the extremely high level of cross-claims reporting and noting that 2024/25 has seen an increase in cross claims reported compared to the previous year.

There also remain material uncertainties as to the pace at which future claims reporting will reduce ("the decay rate") as well as the rate of co-joining of the Liable Entities in common law claims and noting the increase in multiple claims per claimant that took place in 2024/25.

Additionally, should the mix of claims by claimant age or the mix between direct claims and cross claims change relative to that currently assumed, the overall average claim sizes emerging would differ from that currently expected.

Depending on the outcome of future experience, further changes to the valuation assumptions and therefore to the valuation results may be necessary in future periods. Such changes could be material.

As a consequence of the above noted uncertainties, further volatility in relation to the valuation result should be anticipated.

Section 11 of our Report provides an indication of the sensitivity of the valuation result to the peak period of claims reporting and the decay rate of mesothelioma claims reporting after 2025/26.

5. Claims Experience: Claim numbers (non-mesothelioma)

5.1 Overview

The table below shows the number of claims reported by year of notification and by disease category.

Table 5.1: Number of claims by disease type

Notification Year	Asbestosis	Lung Cancer	ARPD & Other	Wharf	Workers
2007	171	28	43	8	46
2008	163	40	44	11	59
2009	120	40	43	3	61
2010	141	13	36	8	30
2011	110	15	36	6	30
2012	128	33	38	7	27
2013	117	26	49	15	32
2014	143	25	39	11	34
2015	91	19	30	11	29
2016	96	18	33	11	25
2017	87	25	29	8	20
2018	103	15	38	13	23
2019	137	25	32	4	21
2020	94	18	32	0	20
2021	99	18	29	0	18
2022	99	22	31	3	16
2023	118	18	32	8	15
2024	149	26	43	15	19
Pre 2007	1,012	349	369	130	1,013
2007 onwards	2,166	424	657	142	525
All Years	3,178	773	1,026	272	1,538


5.2 Asbestosis claims

In 2024/25, there were 149 asbestosis claims reported and in 2023/24 there were 118 asbestosis claims reported. Both of these observations were materially higher than the previous three years (for which experience was in the range 94 to 99 claims).

Given the change in mix of claims, as between direct asbestosis claims and cross claim asbestosis claims, we have separately analysed and selected assumptions for these two cohorts at this valuation.

The chart below shows the mix of claim by type over time.

Figure 5.1: Number of asbestosis direct claims and cross claims: 2007/08-2024/25



We have selected 72 direct claims for 2025/26 based on the average run-rate of the last six years.

We have selected 48 cross claims for 2025/26. The last four years have averaged 39 claims. The last six years have averaged 41 claims.

As such, we have assumed 120 claims for 2025/26 which would be the second highest data point since the experience of 2019/20 (137 claims).

Should the actual mix of claims between direct and cross be different to that assumed, even if claim numbers track in line with the 120 claim assumption, the impact to the valuation could be favourable (if more cross claims arise) or adverse (if more direct claims arise).

Additionally, in light of the last two years and as foreshadowed at our previous valuation, we have made changes to the future incidence pattern for asbestosis (and this will be covered in more detail in Section 6).

5.3 Lung cancer claims

In 2024/25, there were 26 lung cancer claims reported.

The last two years and three years have both averaged 22 claims and the last four years have averaged 21 claims.

We have assumed 21 lung cancer claims will be reported in 2025/26.

5.4 ARPD & Other claims

In 2024/25, there were 43 ARPD & Other claims reported.

The last two years have averaged 38 claims; the last three years have averaged 35 claims and the last four years have averaged 34 claims.

We have assumed 36 ARPD & Other claims will be reported in 2025/26.

5.5 Workers Compensation claims

In 2024/25, there were 19 Workers Compensation claims reported, and the number of claims has been showing a general progression downwards since 2009/10 (61 claims).

We have assumed 18 Workers Compensation claims will be reported in 2025/26.

It should be noted that the financial impact of this source of claim is not substantial to the Liable Entities given the proportion of claims which are settled for nil liability against the Liable Entities (typically above 95%), which results from the insurance arrangements in place.

5.6 Wharf claims

In 2024/25, there were 15 Wharf claims reported. Of this, 12 of these claims arose from 5 claimants and the awards per claim were consequently a lot lower than usual as can be observed in Section 7 of this report.

There were 8 claims reported in 2023/24, and the previous 3 years only saw 3 claims reported, all of which took place in the 2022/23 year.

We have assumed 9 wharf claims will be notified in 2025/26.

Again, the financial impact of this source of claim is not currently significant.

5.7 Summary of base claims numbers assumptions (including mesothelioma)

As outlined in Sections 4 and 5, our assumptions as to the number of claims to be reported in 2025/26 are as follows:

Table 5.2: Claim numbers experience and assumptions for 2025/26

	FY24 actual	FY25 actual	FY25 expected	FY26 assumption
Mesothelioma	373	401	366	378
Direct	295	291	282	282
Cross	78	110	84	96
Asbestosis	118	149	102	120
Direct	81	91	n/a	72
Cross	37	58	n/a	48
Lung Cancer	18	26	18	21
ARPD & Other	32	43	33	36
Wharf	8	15	6	9
Worker	15	19	15	18
Total	564	653	540	582

FY25 Expected is the assumption selected for 2024/25 in our previous valuation report.

5.8 Baryulgil

Almost half of the claims settled which relate to asbestos mining activities at Baryulgil have been settled with no liability against the Liable Entities; and for the remaining settled claims, the Liable Entities have typically borne one-third to one-half of the settlement amount, reflecting the contribution by other defendants to the overall settlement (including those which have since been placed in liquidation).

For the purposes of our valuation, we have estimated there to be 4 future claims reported, comprising 2.5 mesothelioma claims and 1.5 non-mesothelioma claims. We have assumed average claims and legal costs that are broadly in line with those described in Section 7.

Our projected liability assessment at 31 March 2025 of the additional provision (for claims not yet reported) that could potentially be required is an undiscounted liability of \$1.03m and a discounted liability of \$0.85m, all of which is deemed to be a liability of Amaca.

6. Exposure and Latency

Experience and Incidence


Pattern Assumptions

6.1 Mesothelioma claims experience

6.1.1 Exposure information from claims notified to date

We have reviewed the actual exposure information available for claims notified to date. This has been conducted by using the exposure dates stored in the claims database at an individual claim level and identifying the number of person-years of exposure in each exposure year.

Figure 6.1: Exposure (person-years) of all Liable Entities' mesothelioma claimants to date



The chart shows that, currently, the peak year of exposure for claims reported to date is in 1972.

It should be recognised that there is a degree of bias in this analysis in that the claims notified to date will tend to have arisen from the earlier periods of exposure.

Over time, we expect the right-hand side of this curve to develop and the peak year of exposure to trend towards the early-1970s to mid-1970s, and an increase in the absolute level at all periods of exposure as more claims are notified and the associated exposures from

these are included in the analysis.


The relatively low level of exposure from 1987 onwards is not unexpected given that all asbestos products ceased being manufactured by the Liable Entities by 1987. The exposure after that date likely results from usage of products already produced and sold before that date.

The chart above is a cumulative chart of the position to date and does not show trends in the allocation of claims to exposure years over time.

For example, one would expect that more recently reported claims should be associated with, on average, later exposures; and that claims reported in future years would continue that trend towards later exposure periods.

To understand better these trends, we have analysed the spread of claimants' exposures for each past claim report year.

Figure 6.2: Exposure (person years) of all mesothelioma claimants to date by report year and exposure period




As can be seen in the chart above, there has been a general increasing shift towards the exposure period after 1970, evident by the downwards trends in the chart from left to right indicating that an increasing proportion of the claimants' exposure relates to more recent exposure periods.

For example, pre-1970 exposures made up approximately 45% of mesothelioma claims exposures in 2007/08 but around 26% of claims exposures in 2024/25.

We would expect that such a trend (towards claims emerging from later exposure periods) should continue for some time to come.

The following chart then performs the same analysis but is based on the year of first exposure of a claimant (as opposed to spreading all of the exposure across each year in which claimants were exposed). A much lower proportion (less than 5%) of claims relate to pure post-1986 exposures.

Figure 6.3: Exposure (person years) of all mesothelioma claimants to date by report year and exposure period based on first year of exposure




6.2 Mesothelioma: direct claims

6.2.1 Latency period of reported claims

We have analysed the actual latency period of the reported claims of the Liable Entities. In the charts that follow, we have measured the average actual latency period from the average date of exposure to the date of notification of a claim.

The chart below shows the average latency observed for mesothelioma claims and the 25th percentile and 75th percentile observations.


Figure 6.4: Latency of mesothelioma direct claims



The observed average latency period from the average exposure is currently approximately 48 years for direct claims, increasing at an average rate of 0.5 years for each passing year.

The observed average latency of claims reported in future report years should also be expected to show a further upward trend in the coming years.

Figure 6.5: Latency distribution of mesothelioma direct claims




Our latency model assumes a “normal distribution” and the chart seems to (in broad terms) support that assumption at this time.

For direct claims, the mean latency to date is 40.5 years, the median latency to date is 41 years, and the mode of the latency is 42 years. The standard deviation to date is 9.0 years.

The following chart shows how the average reported latencies vary between each of the age groups.

Figure 6.6: Latency of mesothelioma direct claims by age of claimant





Our latency model for mesothelioma direct claims from first exposure assumes a mean latency of 42 years and a standard deviation of 9 years.

6.2.2 Overall future incidence pattern and IBNR claim numbers

The following chart shows the pattern of future notifications which have resulted from the application of our methodology.

Figure 6.7: Projected future claim notifications for mesothelioma direct claims






6.2.3 Assumed change in future mix of claims by claimant age

We have assumed a mix of direct claims by claimant age for 2025/26 as follows:

- 6.4% (18 claims) for ages less than 60,
- 12.8% (36 claims) for ages 60-70,
- 41.1% (116 claims) for ages 70-80,
- 39.7% (112 claims) for ages over 80.

The following chart shows the change in mix of claims by claimant age over time both historically and projected into the future periods.

Figure 6.8: Mix of claims by claimant age for mesothelioma direct claims




6.3 Mesothelioma: cross claims

6.3.1 Latency period of reported claims

We have analysed the actual latency period of the reported claims of the Liable Entities. In the charts that follow, we have measured the average actual latency period from the average date of exposure to the date of notification of a claim.


The chart below shows the average latency observed for mesothelioma claims and the 25th percentile and 75th percentile observations.

Figure 6.9: Latency of mesothelioma cross claims



The observed average latency period from the average exposure is currently approximately 49 years for cross claims, and although it has decreased from the previous year, it is generally increasing at about 0.5 years for each passing year.

Figure 6.10: Latency distribution of mesothelioma cross claims




Our latency model assumes a “normal distribution” and the chart seems to (in broad terms) support that assumption at this time, whilst noting that smaller claim numbers will lead to more volatility (and a lower ‘goodness of fit’).

For cross claims, the mean latency to date is 42.5 years, the median latency is 43 years and the mode of the latency is 44 years. The standard deviation to date is around 10.4 years.

The following chart shows how the average reported latencies vary between each of the age groups.

Figure 6.11: Latency of mesothelioma cross claims by age of claimant




Note: There were no claims for the <60 age cohort in 2020/21. As a result, the chart displays a “linear interpolation” between the 2019/20 and 2021/22 data points.

Our latency model for mesothelioma cross claims from first exposure assumes a mean latency of 42 years and a standard deviation of 10 years.

6.3.2 Overall future incidence pattern and IBNR claim numbers

The following chart shows the pattern of future notifications which have resulted from the application of our methodology.

Figure 6.12: Projected future claim notifications for mesothelioma cross claims



6.3.3 Assumed change in future mix of claims by claimant age


We have assumed a mix of cross claims by claimant age for 2024/25 as follows:

- 2.1% (2 claims) for ages less than 60,
- 9.4% (9 claims) for ages 60-70,
- 46.9% (45 claims) for ages 70-80,
- 41.6% (40 claims) for ages over 80.

The following chart shows the change in mix of claims by claimant age over time both historically and projected into the future periods.

historically and projected into the future periods.

Figure 6.13: Mix of claims by claimant age for mesothelioma cross claims



6.4 Non-mesothelioma experience

6.4.1 Latency period of reported claims

The trend in latency periods for other disease types is shown in the following charts.

Figure 6.14: Latency of asbestosis claims




Figure 6.15: Latency of lung cancer claims





Figure 6.16: Latency of ARPD & Other claims



The average observed latency periods for the other disease types show a more surprising trend, appearing to be longer than epidemiological literature has tended to suggest.

A summary of our underlying latency assumptions by disease type are shown below. The mean and standard deviation values quoted are applied to a normal distribution model.

Table 6.1: Assumed underlying latency distribution parameters from average date of exposure to date of notification

	Mean latency (years)	Standard deviation of latency (years)
Asbestosis	35	8
Lung Cancer	35	10
ARPD & Other	32	10
Wharf	n/a	n/a
Workers compensation	n/a	n/a

These assumptions are unchanged from the previous valuation.

6.4.2 Modelled assumptions for peak year of claim incidence

Based on the application of our exposure model and our latency model, and the assumptions contained explicitly or implicitly within those models, the peak year of notification of claims reporting against the Liable Entities for each disease type (excluding mesothelioma) is modelled to be as follows:

Table 6.2: Modelled peak year of claim notifications

	Current valuation	Previous valuation
Asbestosis	2008/09	2008/09
Lung Cancer	2010/11	2010/11
ARPD & Other	2007/08	2007/08
Wharf	2008/09	2008/09

These modelled assumptions are unchanged.

However, in light of the emerging experience relating to asbestosis over the last two years, we have judgmentally 'pushed out' the claims incidence pattern by three years.

We note that whilst the "modelled peak" derived from our model is as shown above, this does not automatically translate to, nor does it imply that, the "highest claims reporting year" will be those years. This is because variation from year to year is expected due to normal 'statistical variation' in claim numbers.


6.4.3 Projected incidence patterns

We have projected the future number of claim notifications from the curve we have derived using our exposure model and our latency model.

We have applied this curve to the base number of claims we have estimated for each disease type for 2025/26 as summarised in Section 5.7.

The following chart shows the pattern of future notifications which have resulted from the application of our exposure and latency model and the recalibration of the curve to our revised expectations of claims reporting activity for 2025/26.

Figure 6.17: Projected future claim notifications for other disease types



7. Claims Experience: Average Claims and Legal Costs

7.1 Overview

We have analysed the average claim awards, average plaintiff/other costs and average defendant legal costs by disease type in arriving at our valuation assumptions.

The table below shows how the average settlement cost for non-nil attritional (i.e. non-large) claims has varied by settlement year. All data have been converted into mid 2024/25 money terms using a historical base inflation index of 4% per annum.

We refer to these amounts as “inflated average attritional awards” in the charts and tables that follow.

The average amounts shown hereafter relate to the average amount of the contribution made by the Liable Entities and does not reflect the total award payable to the plaintiff unless this is clearly stated to be the case.

Table 7.1: Average attritional non-nil claim award (inflated to mid 2024/25 money terms)

Settlement Year	Mesothelioma	Asbestosis	Lung Cancer	ARPD & Other	Wharf	Workers Compensation
2007	439,689	152,434	213,830	91,910	92,147	509,237
2008	499,041	160,589	158,085	167,665	270,940	103,014
2009	445,427	180,391	182,821	158,948	106,018	180,935
2010	452,852	147,321	237,659	125,002	64,599	0
2011	476,894	181,812	208,205	162,539	126,695	1,498,566
2012	469,419	196,161	187,261	139,044	56,332	136,088
2013	480,217	151,437	159,672	149,801	159,819	30,789
2014	446,679	147,021	203,862	106,694	118,455	103,617
2015	419,212	143,185	165,585	146,266	191,826	0
2016	377,979	107,450	55,848	99,974	50,497	0
2017	398,780	137,891	153,982	87,603	103,522	318,017
2018	406,110	118,103	81,818	144,209	70,008	0
2019	406,942	132,403	102,196	166,595	119,969	60,833
2020	346,530	155,159	159,361	141,277	76,120	0
2021	407,618	168,636	188,816	96,538	0	0
2022	384,318	156,601	186,679	75,321	0	270
2023	388,546	149,859	158,387	111,959	50,960	0
2024	403,561	171,296	167,883	134,204	21,853	0

7.2 Mesothelioma claims

7.2.1 Claim sizes for 2024/25 by claim type and age of claimant

The following table shows the comparison of the average cost of claims settled in 2024/25 for direct and cross claims, split by age cohort.

This table demonstrates the significant difference between the average costs of claims between direct claims and cross claims.

This also explains why the separation of the mesothelioma category between direct claims and cross claims is important if the mix of claims by number is, or has been, changing.

Table 7.2: Average attritional awards (inflated to mid 2024/25 money terms) for direct and cross claims by age of claimant for claims settled in 2024/25

Age	Direct Claims				Cross Claims			
	# settled (non-nil)	Average Claim Size	Mar24 val assumption inflated to 2024/25	Actual / Expected	# settled (non-nil)	Average Claim Size	Mar24 val assumption inflated to 2024/25	Actual / Expected
<60	30	794,758	814,800	98%	0	0	226,800	0%
60 - 70	39	676,446	615,300	110%	5	168,300	153,300	110%
70 - 80	109	457,720	468,300	98%	45	74,225	106,050	70%
80+	98	351,186	394,800	89%	21	62,957	90,300	70%
Overall	276	487,434	500,637	97%	71	77,517	104,719	74%

7.2.2 Additional allowance for mesothelioma claims for the potential costs from overseas exposures (*Talifero vs Amaca*)

We have made an allowance of \$6,000 per mesothelioma claim (in mid 2024/25 money terms).


This amount has been applied across all mesothelioma claims, both direct claims and cross claims), to allow for the potential costs arising from overseas exposures consequent to the decision in *Talifero vs Amaca*. This adjustment is already included in the mesothelioma assumptions shown later in this section.

Our per-claim adjustment is only applied to mesothelioma claims.

7.2.3 Mesothelioma: direct claims experience and assumptions

The charts below show the average claim size by age cohort since 2007/08 for direct mesothelioma claims.


Figure 7.1: Average attritional awards (inflated to mid 2024/25 money terms) for <60 years age cohort



For claimants under the age of 60:

- The average size for 2024/25 was \$795,000.
- The last three years have averaged \$802,000; the last four years have averaged \$798,000; the last five years have averaged \$761,000, the last six years have averaged \$759,000; the last seven years have averaged \$766,000.
- We have therefore selected an assumption of \$796,000, inclusive of the \$6,000 Talifero adjustment.


Figure 7.2: Average attritional awards (inflated to mid 2024/25 money terms) for 60-70 years age cohort



For claimants aged 60-70:

- The average size for 2024/25 was \$676,000.
- The last three years have averaged \$655,000; the last four years have averaged \$621,000; the last five years have averaged \$605,000, the last six years have averaged \$588,000; the last seven years have averaged \$583,000.
- Given the recent upward trends for the last three years, we have given greater weight to the more recent years. Our selected assumption is set half-way between the previous assumption and the 2024/25 experience.
- We have therefore selected an assumption of \$646,000, inclusive of the \$6,000 Talifero adjustment.


Figure 7.3: Average attritional awards (inflated to mid 2024/25 money terms) for 70-80 years age cohort



For claimants aged 70-80:

- The average size for 2024/25 was \$458,000.
- The last three years have averaged \$453,000; the last four years have averaged \$465,000; the last five years have averaged \$466,000; the last six years have averaged \$469,000; the last seven years have averaged \$467,000.
- This segment is the largest segment by both number of claims and total expenditure.
- We have therefore selected an assumption of \$466,000, inclusive of the \$6,000 Talifero adjustment.

Figure 7.4: Average attritional awards (inflated to mid 2024/25 money terms) for 80+ years age cohort




For claimants aged 80+:

- The average size for 2024/25 was \$351,000.
- The last three years have averaged \$371,000; the last four years have averaged \$387,000; the last five years have averaged \$378,000; the last six years have averaged \$379,000; the last seven years have averaged \$378,000.
- We have therefore selected an assumption of \$381,000, inclusive of the \$6,000 Talifero adjustment.

7.2.4 Mesothelioma cross claims experience and assumptions

The charts below show the average claim size by age cohort since 2007/08 for cross claims.


Figure 7.5: Average attritional awards (inflated to mid 2024/25 money terms) for <60 years age cohort



For claimants under the age of 60:

- There were no claims settled in 2024/25.
- There are typically between 1 and 4 claims in this age cohort. As such, the claim size experience can be volatile from year to year depending on the specific circumstances of a small number of claims.
- We have therefore selected an assumption of \$206,000, inclusive of the \$6,000 Talifero adjustment, whilst noting this assumption is not material to the overall valuation given the small number of claims typically reported for this cohort.


Figure 7.6: Average attritional awards (inflated to mid 2024/25 money terms) for 60-70 years age cohort



For claimants aged 60-70:

- The average size for 2024/25 was \$168,000. There were only 5 claims settled in this cohort and the average size was influenced by one sizable claim.
- The last three years have averaged \$149,000; the last four years have averaged \$129,000; the last five years have averaged \$122,000; the last six years have averaged \$117,000; the last seven years have averaged \$130,000.
- We have taken a longer-term view noting the smaller numbers of claims in this age group.
- We have therefore selected an assumption of \$156,000, inclusive of the \$6,000 Talifero adjustment.


Figure 7.7: Average attritional awards (inflated to mid 2024/25 money terms) for 70-80 years age cohort



For claimants aged 70-80:

- This segment is the largest by volume and by total expenditure for mesothelioma cross claims.
- The average size for 2024/25 was \$74,000.
- The last three years have averaged \$81,000; the last four years have averaged \$84,000; the last five years have averaged \$81,000; the last six years have averaged \$86,000; the last seven years have averaged \$92,000.
- We have therefore selected an assumption of \$91,000, inclusive of the \$6,000 Talifero adjustment.

Figure 7.8: Average attritional awards (inflated to mid 2024/25 money terms) for 80+ years age cohort



For claimants aged 80+:


- The average size for 2024/25 was \$63,000.
- The last three years have averaged \$78,000; the last four years have averaged \$74,000; the last five years have averaged \$77,000; the last six years have averaged \$80,000; the last seven years have averaged \$82,000.
- We have therefore selected an assumption of \$86,000, inclusive of the \$6,000 Talifero adjustment.

7.3 Asbestosis claims

For asbestosis, it can be seen from Table 7.1 that the period since 2007/08 has had volatile average claim size experience.

Given we have now separated out direct and cross claims for asbestosis claims, in the charts that follow we show the aggregated experience and then the different experience for direct claims and cross claims over time.

Figure 7.9: Average awards (inflated to mid 2024/25 money terms) and number of non-nil claims settlements for asbestosis claims (aggregated for direct and cross claims)



As noted earlier in this report, we are now setting assumptions for direct claims and cross claims separately.

Figure 7.10: Average awards (inflated to mid 2024/25 money terms) for direct and cross claims for asbestosis



In considering the future average claim size assumption for direct claims we note the following:

- The three year-average has been \$215,000; the four-year average has been \$218,000; the five-year average has been \$221,000.
- The 7-year average was \$207,000.
- The experience in 2024/25 has been \$220,000.

Taking all of these factors into consideration, we have assumed a future average claim size assumption of \$215,000. We did not have a separate assumption for asbestosis direct claims at the previous valuation.

In considering the future average claim size assumption for cross claims we note the following:


- The three year-average has been \$35,000; the four-year average has been \$36,000; the five-year average has been \$37,000.
- The 7-year average was \$39,000.
- The experience in 2024/25 has been \$39,000.

Taking all of these factors into consideration, we have assumed a future average claim size assumption of \$38,000. We did not have a separate assumption for asbestosis cross claims at the previous valuation.

7.4 Lung cancer claims

The average award for lung cancer claims has exhibited some volatility in the past ten years, although this is not unexpected given the small volume of claim settlements (approximately 10 to 30 claims per annum).

Figure 7.11: Average awards (inflated to mid-2024/25 money terms) and number of non-nil claims settlements for lung cancer claims



The experience in 2021/22 and 2022/23 were each impacted by one unusually large claim, which materially impacts the observed average claim size given there are typically between 10 and 15 non-nil claim settlements.

The average of the past three years is \$170,000; the average of the past four years is \$173,000 and the average of the past five years is \$170,000.


The average award in 2024/25 was \$168,000.

Taking all of the above factors into consideration, we have adopted a valuation assumption of \$170,000 in mid 2024/25 money terms.

7.5 ARPD & Other claims

The average award size has shown considerable volatility over time.

Figure 7.12: Average awards (inflated to mid 2024/25 money terms) and number of non-nil claims settlements for ARPD & Other claims



The average of the past three years is \$107,000; the average of the past four years is \$104,000 and the average of the past five years is \$112,000.


The average award in 2024/25 was \$134,000, owing to a small number of larger-than-usual claim settlements.

Taking all of the above factors into consideration, we have adopted a valuation assumption of \$120,000 for ARPD & Other claims in mid 2024/25 money terms.

7.6 Workers Compensation claims

The average award for non-nil Workers Compensation claims has shown a large degree of volatility, reflecting the small number of non-nil claims.

Figure 7.13: Average awards (inflated to mid 2024/25 money terms) and number of non-nil claims settlements for Workers Compensation claims



It should be noted that the high average claim size in 2011/12 is due to one claim of \$900,000 (in 2011/12 values). Furthermore, we understand that this claim payment was recovered from the workers compensation insurer at a later date.

Taking all of the above factors into consideration, we have adopted a valuation assumption of \$125,000 in mid 2024/25 money terms.


This assumption is not material to the overall liability given the high proportion of claims (in excess of 95%) which are settled with no retained liability against the Liable Entities.

7.7 Wharf claims

For wharf claims, the average of the past three years has been \$35,000; the average of the past four years has also been \$35,000 and the average of the past five years has been \$42,000.

The experience in 2008/09 was impacted by one large claim of almost \$600,000 (in 2008/09 values).

Figure 7.14: Average awards (inflated to mid 2024/25 money terms) and number of non-nil claims settlements for wharf claims



At this valuation, we have adopted a valuation assumption of \$75,000 in mid 2024/25 money terms.

Given the small volume of wharf claims, this assumption is not financially significant to the overall results.

7.8 Mesothelioma large claim size and incidence rates

There have been 79 mesothelioma claims settled with awards in excess of \$1m in 2006/07 money terms.

There has only ever been one cross claim that has been a large claim (settled in 2000/01). Given this, the assumed large claim incidence rate for cross claims has been set at 0% for all age cohorts.

The following analysis is therefore only applicable for direct claims.

In selecting a large claim incidence rate or an expected annual number of large claims for direct claims, we have analysed the number of large claims by year of notification, separately for each of the four age groups. We have also shown the incidence rate of large claims for each of the age groups.

Figure 7.15: Number of large claims settled by year of notification





Figure 7.16: Large claims incidence rate by age of claimant



There have been no large claims settled to date for claimants over the age of 80.

We have assumed a future large claim incidence rate of 9.00% for claimants under 60 years of age, 1.00% for claimants between 60 and 70 years of age, and 0.10% for claimants between 70 and 80 years of age.

For the average large claim size, we have adopted a valuation assumption of \$2.89m in mid 2024/25 money terms and we have adopted the same average claim size for all age groups.

This is based on analysis that shows small variation in average claim size for large claims between claimants in each of the age cohorts

The actual incidence of, and settlement of, large claims is not readily predictable and therefore deviations will occur from year to year due to random fluctuations because of the small numbers of large claims (between 0 and 8 large claims per annum).

7.9 Summary average claim cost assumptions

The following table provides a summary of our average claim cost assumptions at this valuation, and those assumed at the previous valuation.

Table 7.3: Summary average claim cost assumptions

	Current Valuation	Previous Valuation	% change
Mesothelioma: Direct <60	796,000	814,800	-2%
Mesothelioma: Direct 60-70	646,000	615,300	5%
Mesothelioma: Direct 70-80	466,000	468,300	0%
Mesothelioma: Direct 80+	381,000	394,800	-3%
Mesothelioma: Cross <60	206,000	226,800	-9%
Mesothelioma: Cross 60-70	156,000	153,300	2%
Mesothelioma: Cross 70-80	91,000	106,050	-14%
Mesothelioma: Cross 80+	86,000	90,300	-5%
Asbestosis	144,200	152,250	-5%
Direct	215,000	n/a	n/a
Cross	38,000	n/a	n/a
Lung Cancer	170,000	168,000	1%
ARPD & Other	120,000	120,750	-1%
Wharf	75,000	94,500	-21%
Workers Compensation	125,000	131,250	-5%
Mesothelioma Large Claims (award only) (direct claims)	Average Size: \$2.89m. Direct frequency: 9.00% (<60), 1.00% (60-70), 0.1% (70-80)	Average Size: \$2.92m. Direct frequency: 10.00% (<60), 1.00% (60-70), 0.1% (70-80)	

Note: Both the current valuation assumption and the previous valuation assumption are expressed in mid 2024/25 money terms.

Note: For mesothelioma, the current and previous valuation assumptions include an allowance of \$6,000 for the decision in Talifero vs Amaca.

Note: We have shown the weighted average nil settlement rate for the current valuation for asbestosis which is based on a 60% direct / 40% cross claims mix. We did not have separate assumptions for direct and cross claims for asbestosis at the previous valuation.


7.10 Defence legal costs

7.10.1 Non-nil claims

The average defence legal costs for non-nil claims by settlement year have been relatively stable over the last ten years for mesothelioma, asbestosis and ARPD & Other, albeit showing some general downward drift over time.

The average defence costs for lung cancer have shown a greater degree of variability, although this is not unexpected given the small volume of claim settlements (approximately 10 to 30 claims per annum).

Figure 7.17: Average defence legal costs (inflated to mid 2024/25 money terms) for non-nil claims settlements by settlement year



Note: The chart does not include average defence costs for Wharf and Worker claims due to the smaller number of claims involved and the variability that exists as a consequence.

7.10.2 Large claims

The average inflated defence legal costs across all large claims to date has been \$200,000 although this has generally been trending downwards over time, although this has reversed in the last three years, whilst noting small volumes of settlements in recent years.

Noting the small number of claims in any year, and that legal costs will depend on the complexity of matters in relation to these claims, we have allowed for defence legal costs of \$105,000 per large claim having regard to more recent experience.

7.10.3 Nil claims


The average defence legal costs for nil claims by settlement year has been volatile for all disease types.

For mesothelioma, the volatility is a consequence of low nil settlement rate, meaning that there may be 20 to 30 nil claims in any year.

For the other disease types, the number of nil claims might typically be of the order of 5 to 10

claims per annum for each disease type (excluding workers compensation).

Figure 7.18: Average defence legal costs (inflated to mid 2024/25 money terms) for nil claims settlements by settlement year



Note: The chart does not include average defence costs for Wharf and Worker claims due to the smaller number of claims involved and the variability that exists as a consequence.

7.11 Summary average defendant legal costs assumptions

The following table provides a summary of our defendant legal costs assumptions at this valuation, and those assumed at the previous valuation.

We have adopted different legal cost assumptions for mesothelioma for the four age groups and separately for direct and cross claims, based on analysis which indicates there is variation (which in part will be related to the average size of claims in each age group and claim type).

Table 7.4: Summary average defendant legal costs assumptions

	Current Valuation		Previous Valuation	
	Non Nil Claims	Nil Claims	Non Nil Claims	Nil Claims
Mesothelioma: Direct <60	37,000	23,000	34,320	23,920
Mesothelioma: Direct 60-70	31,000	23,000	30,160	23,920
Mesothelioma: Direct 70-80	27,000	17,000	26,000	17,680
Mesothelioma: Direct 80+	23,000	12,000	21,840	11,440
Mesothelioma: Cross <60	24,000	11,000	24,960	10,400
Mesothelioma: Cross 60-70	22,000	11,000	22,880	10,400
Mesothelioma: Cross 70-80	17,000	11,000	17,680	10,400
Mesothelioma: Cross 80+	15,000	11,000	15,600	10,400
Asbestosis	23,000	6,000	21,840	6,240
Lung Cancer	26,000	6,000	26,000	10,400
ARPD & Other	26,000	5,000	24,960	10,400
Wharf	21,000	5,000	19,760	5,200
Workers Compensation	16,000	1,000	16,640	1,040
Mesothelioma Large	105,000	0	109,200	0

Note: Both the current valuation assumption and the previous valuation assumption are expressed in mid 2024/25 money terms.

8. Claims Experience: Nil Settlement Rates

8.1 Overview

We have analysed the nil settlement rates, being the number of nil settlements expressed as a percentage of the total number of settlements (nil and non-nil).

We have shown the nil rate for mesothelioma both in aggregate and separately for each of direct claims and cross claims.

Table 8.1: Nil settlement rates


Settlement Year	Mesothelioma	Asbestosis	Lung Cancer	ARPD & Other	Wharf	Workers Compensation	Meso: Direct	Meso: Cross
2007	13%	9%	31%	19%	72%	85%	7%	31%
2008	8%	9%	24%	13%	0%	95%	4%	25%
2009	8%	8%	29%	2%	14%	83%	8%	12%
2010	6%	6%	41%	14%	0%	100%	7%	4%
2011	10%	7%	32%	11%	0%	67%	5%	27%
2012	9%	15%	23%	20%	40%	99%	4%	23%
2013	3%	8%	3%	13%	20%	99%	1%	10%
2014	9%	11%	16%	8%	9%	97%	4%	24%
2015	7%	6%	25%	8%	8%	100%	3%	20%
2016	20%	13%	57%	16%	9%	100%	4%	23%
2017	8%	16%	59%	7%	9%	88%	4%	22%
2018	5%	15%	17%	5%	22%	100%	2%	14%
2019	6%	9%	32%	20%	0%	96%	3%	14%
2020	3%	7%	14%	6%	0%	100%	1%	8%
2021	7%	3%	45%	3%	0%	100%	3%	20%
2022	7%	8%	20%	7%	0%	95%	3%	16%
2023	6%	8%	0%	0%	11%	100%	3%	16%
2024	9%	6%	9%	15%	0%	100%	5%	20%

Note: Mesothelioma cross claims nil settlement rate for 2016/17 was 55%. This has been restated in the above table to 23%, reflecting the removal of 54 Queensland statutory recovery claims that were closed for nil in that year.

8.2 Mesothelioma claims

Nil settlement rates vary between direct claims and cross claims as shown in the chart below.

Figure 8.1: Mesothelioma nil settlement rate for direct claims and cross claims



In considering the future nil settlement rate assumption for direct claims, we observe:

- The nil settlement rate for the past three years has averaged 4.1%, for the past four years has averaged 3.7% and for the past five years has averaged 3.3%. The five-year average was particularly impacted by the 1.5% nil rate in 2020/21.
- The nil settlement rate for 2024/25 was 5.5%, an increase from the previous year (3.5% nil settlement rate).
- The average nil settlement rate from 2007/08 to 2024/25 has been 3.9%.

Taking all of these factors into consideration, we have assumed a future nil settlement rate of 4.0%, an increase from the previous valuation assumption of 3.5%.

In considering the future nil settlement rate assumption for cross claims, we observe:

- The nil settlement rate for the 2016/17 year of 55% was due to 54 Queensland statutory recovery claims being closed at nil cost in December 2016. Our chart has removed these as they were a one-off correction.
- The nil settlement rate for the past three years has averaged 17.3%, for the past four years has averaged 18.0% and for the past five years has averaged 15.8%.
- The nil settlement rate for 2024/25 was 20.2%, an increase from the previous year (15.7% nil settlement rate).
- The average nil settlement rate from 2007/08 to 2024/25 has been 18.2%.

Taking all of these factors into consideration, we have assumed a future nil settlement of 17.0%, an increase from the previous valuation assumption of 16.0%.

The nil settlement rate assumptions have been applied equally to all age groups.

The 100 settlement rate assumptions have been applied equally to all age groups.

8.3 Asbestosis claims

As with mesothelioma, the historical asbestosis nil settlement rate has been volatile. As noted earlier in this report, we have now separated out our assumptions for each of direct and cross claims.

In the charts below, we show firstly the aggregated experience and then the separate experience for direct claims and cross claims over time.

Figure 8.2: Asbestosis nil claims experience (aggregated)





Figure 8.3: Asbestosis nil settlement rate for direct claims and cross claims



In considering the future nil settlement rate assumption for direct claims we note the following:

- The nil settlement rate for the past three years has averaged 3.3%, for the past four years has averaged 2.9% and for the past five years has averaged 2.6%.
- The 7-year average was 3.6%.
- The average rate since 2007 has been 4.7%.
- The nil settlement rate for 2024/25 was 3.1%.

Taking all of these factors into consideration, we have assumed a future nil settlement rate of 3.5%. We did not have a separate assumption for direct claims at the previous valuation.

In considering the future nil settlement rate assumption for cross claims we note the following:


- The nil settlement rate for the past three years has averaged 14.5%, for the past four years has averaged 12.8% and for the past five years has averaged 13.4%. The averages are particularly impacted by the 2021/22 data point.
- The 7-year average was 15.5%.
- The average rate since 2007 has been 18.3%
- The nil settlement rate for 2024/25 was 11.5%.

Taking all of these factors into consideration, and noting the smaller volumes of claims settled historically, we have taken a longer-term average for our assumption. As such, we have assumed a future nil settlement rate of 16.0%. We did not have a separate assumption for cross claims at the previous valuation.

8.4 Lung cancer claims

Given the small volumes of claims, volatility in the nil settlement rate for lung cancer claims is to be expected.

Figure 8.4: Lung cancer nil claims experience



In considering the future nil settlement rate assumption, we note the following:


- The nil settlement rate for the past three years has averaged 10%, for the past four years has averaged 18% and for the past five years has averaged 18%. All of these averages have been impacted by the 0% nil settlement rate observed in 2023/24.
- The nil settlement rate for 2024/25 was 9%.

Taking all of these factors into consideration, we have assumed a future nil settlement rate of 18%, a reduction from the previous valuation assumption of 20%.

8.5 ARPD & Other claims

As with other disease types, there has been significant volatility in the historical nil settlement rate, given the low numbers of claims for this disease.

Figure 8.5: ARPD & Other nil claims experience



The nil settlement rate for the past three years has averaged 8%, for the past four years has averaged 7% and for the past five years has averaged 6%. All of these averages have been impacted by the 0% nil settlement rate in 2023/24.

The nil settlement rate for 2024/25 was 15%.


We have selected 8% as our nil settlement rate assumption an increase from the previous valuation assumption of 7%.

8.6 Workers Compensation claims

The nil settlement rates for Workers Compensation claims have been high and reflect the portion of claims whose costs are fully met by a Workers Compensation Scheme or Policy. The proportion of such claims which are fully met by insurance has been relatively stable since 1997/98, typically varying between 80% and 100%.

The nil settlement rate has been in excess of 90% for nine out of the past ten years, and it has been above 80% for ten out of the past ten years.

Figure 8.6: Workers Compensation nil claims experience



We have selected 96% as our nil settlement rate assumption, unchanged from our previous valuation assumption.


The overall financial impact of this assumption is not material given the small number of claims reported annually.

8.7 Wharf claims

During the past thirteen years, the nil settlement rate has exhibited considerably volatility for wharf claims, varying between 0% and 40%.

The nil settlement rate for the past three years has averaged 5%, for the past four years it has averaged 5% and for the past five years it has averaged 4%.

Figure 8.7: Wharf nil claims experience



Noting the small number of claims being reported generally and being assumed to be reported in future years, we have selected a nil settlement rate assumption of 0%, unchanged from our previous valuation assumption.

Given the low volume of claims activity for wharf claims, this assumption is highly subjective but is also not material to the overall liability assessment.

8.8 Summary assumptions

The following table provides a summary of our nil settlement rate assumptions at this valuation, and those assumed at the previous valuation.

Table 8.2: Summary nil settlement rate assumptions

	Current Valuation	Previous Valuation
Mesothelioma: Direct	4.0%	3.5%
Mesothelioma: Cross	17.0%	16.0%
Asbestosis	8.5%	8.0%
Direct	3.5%	n/a
Cross	16.0%	n/a
Lung Cancer	18.0%	20.0%
ARPD & Other	8.0%	7.0%
Wharf	0.0%	0.0%
Workers Compensation	96.0%	96.0%

Note: We have shown the weighted average nil settlement rate for the current valuation for asbestosis which is based on a 60% direct / 40% cross claims mix. We did not have separate assumptions for direct and cross claims for asbestosis at the previous valuation.

9. Economic and Other Assumptions

9.1 Overview

The two main economic assumptions required for our valuation are:

- The underlying claims inflation assumptions adopted to project the future claims settlement amounts and related costs.
- The discount rate adopted for the present value determinations.

We also discuss the basis of derivation of other valuation assumptions, being:

- The cross-claim recovery rate; and
- The pattern of settlement of future reported claims and pending claims.

9.2 Claims inflation

We are required to make assumptions about the future rate of inflation of claims costs.

We have adopted a standard Australian actuarial claims inflation model for liabilities of the type considered in this report that is based on:

- An underlying, or base, rate of general economic inflation relevant to the liabilities, in this case based on wage/salary (earnings) inflation; and
- A rate of superimposed inflation, i.e. the rate at which claims costs inflation exceeds base inflation.

9.2.1 Base inflation

We have adopted a long-term base (wage) inflation assumption of 3.50% per annum, unchanged from our assumption at 31 March 2024.

In maintaining this long-term assumption at 31 March 2025, we have had regard to the current level of annualised wage inflation (3.5% at 31 December 2024, down from 4.3% at December 2023) and noting that our wage inflation assumption is intended to be a long-term assumption.

Wage inflation in Australia has averaged approximately 3.1% per annum for the period 2000-2024.

Consumer Price Inflation was reported as 2.4% at 31 December 2024, down from 4.1% at December 2023.

9.2.2 Superimposed inflation

Superimposed inflation is a term commonly used by Australian actuaries to measure the rate at which average claims costs escalate in excess of a base (usually wage) inflation measure.

As a result, superimposed inflation is a “catch-all” for a range of potential factors affecting claims costs, including (but not limited to):

- Courts making compensation payments in relation to new heads of damage;
- Courts changing the levels of compensation paid for existing heads of damage;
- Advancements in medical treatments – for example, this could lead to higher medical treatment costs (e.g. the cost of the use of new drug treatments);
- Allowance for medical costs to rise faster than wages because of the use of enhanced medical technologies;
- Changes in retirement age – this would increase future economic loss awards;
- Changes in the relative share of the liability to be borne by the Liable Entities’ (which we refer to as “the contribution rate”) and which might result from changes in the number of defendants joined in claims;
- Changes in the mix of claims costs by different heads of damage; and
- Changes in the mix of claimants by age of claimant.

Additionally, superimposed inflation also captures those characteristics of claims experience which might have different relative claim sizes but which are currently modelled in aggregate (rather than explicitly and separately modelled). This includes factors such as:

- Changes in the mix of claims between direct and cross claims (if the future pattern of incidence changes relative to that currently assumed);
- Changes in the mix of claims between renovator and non-renovator claims; and
- Changes in the mix of claims by the numbers of defendants to each claim.

Whilst the future rate of superimposed inflation is uncertain, and not predictable from one year to the next, it is of note that the average claim costs appear to have been relatively stable in recent years (after adjusting for wage inflation) and that, if anything, average claim sizes have trended downwards generally. As discussed elsewhere in this report, this reflects the changing mix of claimants by claimant age (shifting towards older claimants).

Furthermore, the emergence of new or expanding heads of damage does not tend to proceed smoothly but progresses in “steps”, depending on the outcome of legislative and other developments.

We have reviewed the rate of inflation of claims costs by settlement year for the period from 2000/01 to 2024/25 for mesothelioma direct claims and cross claims separately, and separately for each age cohort.

We have assessed this by analysing inflated claim costs and therefore the following table measures the trend in the rate of superimposed inflation.

Table 9.1: Annualised rate of superimposed inflation for mesothelioma claims cohorts for various averaging periods

Period	Direct				Cross				Weighted by \$ spend
	<60	60-70	70-80	80+	<60	60-70	70-80	80+	
2000-2024	-0.2%	1.1%	0.9%	0.5%		3.9%	n/a	-0.3%	0.7%
2001-2024	-0.4%	-0.3%	0.0%	-1.4%		5.4%	n/a	n/a	-0.5%
2002-2024	-0.7%	0.6%	0.1%	-0.9%		-3.8%	-5.4%	-2.7%	-0.5%
2003-2024	-0.7%	1.2%	-0.1%	-0.2%		-0.7%	-3.8%	-4.6%	-0.2%
2004-2024	-0.6%	1.0%	0.0%	-0.1%		0.4%	-1.5%	-4.3%	-0.1%
2005-2024	-0.2%	1.1%	0.1%	-0.5%		0.5%	-3.7%	-5.4%	-0.2%
2006-2024	-0.6%	1.6%	0.4%	0.7%		-1.7%	-2.3%	-1.2%	0.4%
2007-2024	0.0%	1.5%	0.7%	0.0%		-1.5%	-3.7%	-1.0%	0.4%
2008-2024	-0.5%	1.2%	0.3%	-0.8%		1.2%	-2.2%	-3.0%	-0.1%
2009-2024	0.4%	0.7%	0.6%	-0.1%		-1.1%	-4.7%	0.0%	0.2%
2010-2024	0.7%	0.6%	0.2%	-1.1%		0.2%	-3.2%	-4.4%	-0.3%
2011-2024	-0.8%	1.3%	0.1%	-1.1%		-3.6%	-1.3%	-6.8%	-0.4%
2012-2024	0.2%	0.6%	-1.1%	-1.4%		1.8%	-4.2%	-4.7%	-0.9%
2013-2024	-2.6%	0.7%	-0.6%	-1.2%		2.1%	-5.2%	-3.5%	-0.9%
2014-2024	-0.7%	1.1%	0.9%	-1.4%		2.8%	-5.0%	-7.7%	-0.3%
2015-2024	0.8%	1.5%	0.1%	-0.3%		-0.8%	-5.0%	-6.1%	0.0%
Maximum	0.8%	1.6%	0.9%	0.7%		5.4%	-1.3%	0.0%	0.7%
Minimum	-2.6%	-0.3%	-1.1%	-1.4%		-3.8%	-5.4%	-7.7%	-0.9%

Note: The red shading in the above table indicates those data points with values exceeding 1.0% per annum superimposed inflation (being our selected valuation assumption).

Note: We have removed the <60 cohort for cross claims from the analysis given no claims were settled in the 2024/25 year.

The weighted average (being the right-hand column of the table) is derived by weighting the individual rates of inflation within each cohort by the current level of spend across the 8 cohorts.

The analysis above does not show a material prevalence of annualised rates of superimposed inflation above 1.0% per annum in the eight buckets nor depending on which averaging periods are selected.

The high average claim size for the 60-70 age cohort for direct claims and for cross claims in 2024/25, which we have explained the factors behind, leads to most averaging periods for that cohort having an annualised rate of superimposed inflation above 1%.

The actuarial approach for this report is to take an average view for superimposed inflation to be applied over the long-term, noting that there will necessarily be deviations from this average on an annual basis and that cashflows are projected for the next 40 or more years.

Weighing all of the evidence together, we have adopted an assumed long-term rate of future superimposed inflation of claims awards of 1.00% per annum, unchanged from our previous valuation assumption.

This assumption is applied to the claim awards for all categories of claim and age cohorts.

The outcome of this assumption is a "superimposed inflation allowance" of approximately \$80m on a discounted central estimate basis and approximately \$130m on an inflated and undiscounted central estimate basis.


9.3 Discount rates: Commonwealth bond zero coupon yields

We have calculated the zero coupon yield curve at 31 March 2025 underlying the prices, coupons and durations of Commonwealth Government Bonds for the purpose of discounting the liabilities for this report.

The use of such discount rates is consistent with standard Australian actuarial practice for such liabilities, is in accordance with the Institute of Actuaries of Australia's Professional Standard PS302 and is also consistent with our understanding of the Australian accounting standards.

The chart below shows the assumptions for the current valuation and the previous valuation.

Figure 9.1: Zero coupon yield curve by duration




At this valuation, the long-term yield has increased from 4.75% to 5.60% per annum.

9.4 Cross claim recovery rates

The following chart shows how the experience of cross claim recoveries has varied over the last fourteen years, both in monetary terms and expressed as a percentage of gross payments.

Figure 9.2: Cross claim recovery experience



Cross claim recoveries reduced year on year from 2012/13 to 2015/16, both in absolute terms and as a percentage of gross payments.

The four years from 2017/18 to 2020/21 were broadly stable at around \$7m and falling to around \$5m per annum in 2021/22 to 2022/23. The 2023/24 year had fallen further to \$3m and for the 2024/25 year, has slightly increased to \$3.3m.

In light of the average rate of recovery over the last six years, and the lower level of recoveries both in dollar terms and percentage terms in the last three years, we lowered our assumption to 3.00% at 31 March 2024. We have maintained this assumption at 31 March 2025 based on the average experience of the last six years.

However, should the rate of cross-claim recovery rate not show signs of further increases, it may be necessary to lower this assumption further at future valuations.

By way of illustration, a 50 basis point reduction in the assumed cross claim recovery rate would add approximately \$8m to the discounted central estimate.

9.5 Settlement Patterns

Triangulation methods are used to derive the past pattern of settlement of claims and are used in forming a view on future settlement patterns.

The following triangles provide an illustrative example of how we perform this:

Figure 9.3: Settlement pattern derivation for mesothelioma claims: paid as % of ultimate cost

Yr of Notification	0	1	2	3	4	5	6	7	8	9	10	11	12
2006	61.7%	63.7%	67.6%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2007	53.3%	57.1%	66.5%	99.8%	99.8%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2008	67.3%	68.5%	97.7%	99.2%	99.9%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2009	57.8%	68.0%	92.9%	99.4%	99.6%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2010	71.7%	66.4%	96.7%	99.9%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2011	57.1%	66.9%	96.1%	99.7%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2012	55.7%	67.7%	96.7%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2013	65.3%	94.9%	99.6%	99.8%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2014	65.8%	96.0%	96.6%	99.5%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2015	65.5%	96.2%	96.4%	99.7%	99.8%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2016	57.3%	98.2%	99.2%	99.9%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2017	55.8%	97.2%	96.9%	99.9%	99.9%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2018	56.1%	97.1%	96.2%	99.4%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2019	58.9%	93.2%	97.3%	99.4%	99.4%	99.4%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2020	46.2%	91.4%	95.5%	98.0%	99.1%	99.1%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2021	52.0%	94.7%	97.4%	97.7%	97.7%	97.7%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2022	50.3%	92.5%	96.3%										
2023	42.5%	88.0%											
2024	47.5%												

Figure 9.4: Settlement pattern derivation for non-mesothelioma claims: paid as % of ultimate cost

Yr of Notification	0	1	2	3	4	5	6	7	8	9	10	11	12
2006	22.7%	72.0%	91.0%	94.7%	99.4%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2007	28.9%	83.1%	93.0%	99.6%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2008	26.1%	84.5%	95.6%	97.3%	99.7%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2009	43.4%	77.7%	94.1%	95.9%	96.1%	97.5%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2010	26.1%	84.7%	95.7%	97.4%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2011	36.8%	90.1%	99.8%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2012	38.2%	87.9%	97.1%	98.0%	98.5%	98.7%	98.7%	98.7%	98.7%	100.0%	100.0%	100.0%	100.0%
2013	28.4%	84.2%	95.6%	97.8%	99.0%	99.9%	99.9%	99.9%	99.9%	100.0%	100.0%	100.0%	100.0%
2014	32.7%	90.6%	97.2%	98.8%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2015	46.8%	89.8%	95.9%	99.6%	99.6%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2016	22.7%	74.4%	91.4%	94.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2017	38.9%	92.3%	97.6%	98.9%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
2018	21.0%	81.8%	94.0%	96.9%	99.7%	99.7%	99.7%	99.7%	99.7%	100.0%	100.0%	100.0%	100.0%
2019	24.7%	84.7%	98.0%	99.4%	99.8%	99.8%	99.8%	99.8%	99.8%	100.0%	100.0%	100.0%	100.0%
2020	32.3%	79.5%	85.1%	96.4%	98.4%	98.4%	98.4%	98.4%	98.4%	100.0%	100.0%	100.0%	100.0%
2021	28.7%	79.9%	94.4%	97.1%	97.1%	97.1%	97.1%	97.1%	97.1%	100.0%	100.0%	100.0%	100.0%
2022	24.9%	78.4%	82.2%										
2023	23.8%	79.5%											
2024	23.8%												

We have estimated the settlement pattern for future claim reporting as follows:

Table 9.2: Settlement pattern of claims awards by delay from claim reporting

Delay (years)	Mesothelioma	Non-mesothelioma
0	49.0%	24.5%
1	43.0%	55.0%
2	5.0%	8.5%
3	1.5%	9.5%
4	1.0%	1.0%
5	0.5%	1.0%
6	0.0%	0.5%
7	0.0%	0.0%
8	0.0%	0.0%
9	0.0%	0.0%

The assumed settlements patterns have been modified (lengthened) slightly since the previous valuation.

For mesothelioma, we have adopted one pattern because analysis of the average time to settlement for each of the four age groups was not materially different to the overall average time to settlement.

10. Valuation Results

10.1 Central estimate liability

At 31 March 2025, our projected central estimate of the liabilities of the Liable Entities (the Discounted Central Estimate) to be met by the AICF Trust is \$1,472.4m (2024: \$1,457.8m).

We have not allowed for the future Operating Expenses of the AICF Trust or the Liable Entities in the liability assessment.

The following table shows a summary of our central estimate liability assessment and compares the current assessment with our previous valuation.

Table 10.1: Comparison of central estimate of liabilities

	31 March 2025 \$m			31 March 2024 \$m
	Gross of insurance recoveries	Insurance recoveries	Net of insurance recoveries	Net of insurance recoveries
Total uninflated and undiscounted cashflows	1,490.3	45.1	1,445.2	1,394.3
Wage inflation allowance	398.1	6.8	391.3	399.3
Superimposed inflation allowance	133.2	2.4	130.8	133.8
Total inflated and undiscounted cashflows	2,021.6	54.3	1,967.3	1,927.4
Discounting allowance at risk-free rates	(506.0)	(11.1)	(494.9)	(469.6)
Net present value of cashflows	1,515.6	43.2	1,472.4	1,457.8

10.2 Comparison with previous valuation

In the absence of any change to the claim projection assumptions from our 31 March 2024 valuation, we would have projected a Discounted Central Estimate liability of \$1,322.5m as at 31 March 2025.

The decrease of \$135.3m relative to the valuation result at 31 March 2024 is due to:

- A decrease of \$165.4m for the impact of actual claims payments (which reduces the liability). The chart below separately shows the impact of the expected payments (a reduction of \$166.9m) and the variance between actual and expected payments (an increase of \$1.5m);
- An increase of \$53.7m for the “unwind of discount”; and
- A decrease of \$23.6m resulting from changes to the yield curve between 31 March 2024 and 31 March 2025.

Our liability assessment at 31 March 2025 of \$1,472.4m therefore represents an increase of \$149.9m arising from changes to the actuarial assumptions. The increase is principally a consequence of:


- Increases to the assumed number of mesothelioma claims for 2025/26 for both direct claims and cross claims (and all future years);
- Changes to the assumed age mix of mesothelioma claims;
- An increased allowance to the assumed number of non-mesothelioma claim numbers for 2025/26 (and all future years); and
- Increases to the incidence pattern of claims for asbestosis in future years noting the elevated experience of the last two financial years;

offset by

- Favourable nil settlement experience; and
- A reduction in the assumed average claim cost and legal cost assumptions, for both mesothelioma and non-mesothelioma claims, including the impact of setting separate assumptions for asbestosis for direct and cross claims.

The following chart shows an analysis of the change in our liability assessment from 31 March 2024 to 31 March 2025 on a discounted basis.

Figure 10.1: Analysis of change in central estimate liability (discounted basis)



Note: Green bars signal that this factor has given rise to a decrease in the liability whilst light blue bars signal that this factor has given rise to an increase in the liability.

10.3 Comparison of valuation results since 30 September 2006

We have analysed how our valuation results have changed since the Initial Report (as defined in the Amended Final Funding Agreement) at 30 September 2006.

The table below shows the results over time.

We have used the inflated and undiscounted results as the comparison. We consider this to be the most appropriate assessment as it removes the impacts of changes in discount rates and the “unwind of the discount”.

Table 10.2: Comparison of net undiscounted valuation results since 30 September 2006

	FY2007	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012	FY 2013	FY 2014	FY 2015	FY 2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Valuation result at end of previous financial year	3,169	2,811	3,027	3,124	2,906	2,861	2,525	2,513	2,805	2,743	2,427	2,200	2,381	2,219	2,215	2,034	2,004	1,921	1,927
Net payments made (actual)	-32	-55	-93	-86	-76	-76	-85	-113	-121	-129	2	-124	-143	-142	-139	-149	-147	-166	-167
Expected valuation result (no actuarial changes)	3,137	2,756	2,934	3,038	2,830	2,585	2,439	2,400	2,684	2,614	2,429	2,076	2,238	2,077	2,076	1,885	1,857	1,755	1,760
Actual valuation at end of financial year	2,811	3,027	3,124	2,906	2,861	2,525	2,513	2,805	2,743	2,427	2,200	2,381	2,219	2,215	2,034	2,004	1,921	1,927	1,967
Impact of actuarial valuation changes	-326	271	190	-132	-169	-50	74	405	59	-187	-229	305	-19	138	-42	119	64	173	207
Cumulative changes since 30 September 2006	-326	-55	135	3	-166	-226	-152	253	312	125	-104	201	182	320	278	397	461	633	840

Note: For FY2007, the starting valuation (\$3,169m) is the valuation at 30 September 2006, not the valuation at 31 March 2006.

The table shows that whilst there have been ten years where there have been increases and eight years where there have been decreases arising from changes to actuarial valuation assumptions, over the period from 30 September 2006 to 31 March 2024 the valuation has increased by approximately \$840m (26% of the valuation contained in the Initial Report).

The valuation impact at 31 March 2025 has been an increase of approximately \$207m, primarily due to the impact of the higher mesothelioma claim numbers being assumed into the future.

In terms of net cashflows, actual net payments of \$2,042m (including commutation receipts of \$191m) have been made since 30 September 2006. This compares with an estimate of \$2,104m projected for the same period (1 October 2006 to 31 March 2025) in the valuation at 30 September 2006.

Some of the commutation receipts are in relation to payments that would otherwise have been projected to be due after 31 March 2025.


Gross cashflows over the same period have been \$74m (3.0%) above those projected in the valuation at 30 September 2006 (\$2,511m vs \$2,437m) with \$72m of this having arisen in the last two years as a consequence of the higher mesothelioma claim numbers being reported as compared to that assumed in our September 2006 valuation.

10.4 Cashflow projections

10.4.1 Historical cashflow expenditure

The following chart shows the historical expenditure by the Liable Entities relating to asbestos-related claim settlements since the formation of AICFL.

Figure 10.2: Historical claim-related expenditure of the Liable Entities (\$m)




Gross cashflow payments in the 12 months to 31 March 2025 were \$176.1m (2024: \$177.1m). This was \$4.9m (3%) lower than the gross cashflow projected for 2024/25 in our 31 March 2024 valuation (\$181.0m).

Net cashflow payments in the 12 months to 31 March 2025 were \$166.9m (2024: \$165.7m). This was \$1.5m (1%) lower than the net cashflow projected for 2024/25 in our 31 March 2024 valuation report (\$168.4m).

10.4.2 Future cashflow projections: current and previous valuation

The following chart shows the projected net cashflows underlying our current valuation and the projected net cashflow projection underlying our previous valuation at 31 March 2024.

Figure 10.3: Annual cashflow projections – inflated and undiscounted (\$m)



Given the extremely long-tailed nature of asbestos-related liabilities, a small change in an individual assumption can have a significant impact upon the cashflow profile of the liabilities.

10.5 Amended Final Funding Agreement calculations

The Amended Final Funding Agreement sets out the basis on which payments will be made to the AICF Trust.

Additionally, there are a number of other figures specified within the Amended Final Funding Agreement that we are required to calculate. These are:

- Discounted Central Estimate;
- Term Central Estimate; and
- Period Actuarial Estimate.

Table 10.3: Amended Final Funding Agreement calculations

	\$m
Discounted Central Estimate (net of cross-claim recoveries, Insurance and Other Recoveries)	1,472.4
Period Actuarial Estimate (net of cross-claim recoveries, gross of Insurance and Other Recoveries) comprising:	521.0
<i>Discounted value of cashflow in 2025/26</i>	<i>183.1</i>
<i>Discounted value of cashflow in 2026/27</i>	<i>174.7</i>
<i>Discounted value of cashflow in 2027/28</i>	<i>163.1</i>
Term Central Estimate (net of cross-claim recoveries, Insurance and Other Recoveries)	1,446.7

The actual funding amount due at a particular date will depend upon a number of factors, including:

- the net asset position of the AICF Trust at that time;
- the free cash flow amount of the James Hardie Group in the preceding financial year; and
- the Period Actuarial Estimate in the latest Annual Actuarial Report.

10.6 Insurance Recoveries

Our liability valuation has made allowance for a discounted central estimate of Insurance Recoveries of \$43.2m.

This estimate is comprised as follows:

Table 10.4: Insurance recoveries at 31 March 2025

\$m	Undiscounted central estimate	Discounted central estimate
Gross liability (net of cross claim recoveries)	2,021.6	1,515.6
Product liability recoveries	46.0	37.2
Bad and doubtful debt allowance (product)	(0.4)	(0.2)
Public liability recoveries	8.7	6.3
Bad and doubtful debt allowance (public)	(0.1)	(0.0)
Insurance recovery asset	54.3	43.2
Net liability	1,967.3	1,472.4
Insurance recovery rate	2.7%	2.9%
Bad and doubtful debt rate	0.8%	0.7%
Value of Insurance Policies per Facility Agreement		36.9

The combined bad and doubtful debt rate is 0.7% on a discounted basis (2024: 0.7%).

The AICF Facility Agreement requires the Approved Actuary to calculate the discounted central estimate value of certain Insurance Policies, being those specified in Schedule 5 of the AICF Facility Agreement.

At 31 March 2025, the discounted central estimate of the Insurance Policies, as specified in Schedule 5 of the AICF Facility Agreement, is \$36.9m (2024: \$39.8m).

11. Uncertainty

11.1 Overview

There is uncertainty involved in any valuation of the liabilities of an insurance company or a self-insurer. The sources of such uncertainty include, but are not limited to:

- Parameter error – this is the risk that the parameters and assumptions chosen ultimately prove not to be reflective of future experience.
- Model error – this is the risk that the model selected for the valuation of the liabilities ultimately proves not to be adequate for the projection of the liabilities.
- Legal and social developments – this is the risk that the legal environment in which claims are settled changes relative to its current and historical position thereby causing significantly different awards.
- Future actual rates of inflation being different from that assumed.
- The general economic environment being different from that assumed.
- Potential sources of exposure – this is the risk that there exist sources of exposure which are as yet unknown or unquantifiable, or for which no liabilities have yet been observed, but which may trigger future claims.

In the case of asbestos liabilities, these uncertainties are exacerbated by the extremely long latency period from exposure to onset of disease and notification of a claim. Asbestos-related claims often take in excess of 40 years from original exposure to become notified and then settled, compared with an average delay from exposure to settlement of 4-5 years for many other compensation-type liabilities such as Comprehensive Third-Party injury liabilities or other Workers Compensation liabilities.

Specific forms of uncertainty relating to asbestos-related disease liabilities include:

- The difficulty in quantifying the extent and pattern of past asbestos exposures and the number and incidence of the ultimate number of lives that may be affected by asbestos related diseases arising from such past asbestos exposures;
- The timing of the peak level and future pattern of incidence of claims reporting for mesothelioma;
- The propensity of individuals affected by diseases arising from such exposure to file common law claims against defendants;
- The extent to which the Liable Entities will be joined in such future common law claims;
- The mix of claimants by age, in particular noting the shift towards older claimants and which has had a downwards effect on average claim sizes in recent years;

which has had a downward effect on average claim sizes in recent years,

- The mix of mesothelioma claims between direct claims and cross claims;
- The fact that the ultimate severity of the impact of the disease and the quantum of the claims that will be awarded will be subject to the outcome of events that have not yet occurred, including:
 - medical and epidemiological developments, including those relating to life expectancy in general;
 - court interpretations;
 - legislative changes;
 - changes to the form and range of benefits for which compensation may be awarded ("heads of damage");
 - public attitudes to claiming;
 - the potential for future procedural reforms in NSW and other States affecting the legal costs incurred in managing and settling claims;
 - potential third-wave exposures; and
 - social and economic conditions such as inflation.

11.2 Sensitivity testing

As we have noted above, there are many sources of uncertainty. Actuaries often perform "sensitivity testing" to identify the impact of different assumptions on future experience, thereby providing an indication of the degree of parameter error risk to which the valuation assessment is exposed.

Sensitivity testing may be considered as being a mechanism for testing "what will the liabilities be if instead of choosing [x] for assumption [a] we choose [y]?" It is also a mechanism for identifying how the result will change if experience turns out different in a particular way relative to that which underlies the central estimate expectations. As such, it provides an indication of the level of variability inherent in the valuation.

We have performed some sensitivity tests of the results of our central estimate valuation. We have sensitivity tested the following factors:

- **number of claims notified:** 10% above and below our central estimate assumption.
- **average claim cost of a non-nil claim:** 5% above and below our central estimate assumption.
- **nil settlement rate:** 2 percentage points above and below our central estimate assumption.
- **superimposed inflation:** 1 percentage point above and below our central estimate assumption (of 1% per annum) over all future years.
- **mesothelioma incidence pattern:** we have tested the impact of shifting out the pattern of incidence by two further years.

There are other factors which influence the liability assessment and which could be sensitivity tested, including:

- The cross-claim recovery rate;
- The variation in timing of claim notifications (but with no change in the overall number of notifications); and
- The pattern and delay of claim settlements from claim notification.

We have not sensitivity tested these factors, viewing them as being of less financial significance individually.

We have not sensitivity tested the value of Insurance Recoveries as uncertainties typically relate to legal risk and disputation risk, and it is not possible to parameterise a sensitivity test in an informed manner.

We have not included a sensitivity test for the impact of changes in discount rates although, as noted in this Report, changes in discount rates can introduce significant volatility to the Discounted Central Estimate result reported at each year-end.

11.3 Results of sensitivity testing

The chart below shows the impact of various individual sensitivity tests on the Discounted Central Estimate of the liabilities, and of a combined sensitivity test of a number of factors.

Although we have tested multiple scenarios of each assumption, one cannot gauge an overall potential range by simply adding these tests together. Accordingly, we have prepared a range based on a combination of factors.

Figure 11.1: Sensitivity testing results – Impact around the Discounted Central Estimate (in \$m)





Figure 11.2: Sensitivity testing results – Impact around the undiscounted central estimate (in \$m)



The single most sensitive assumption shown in the chart is the incidence pattern of mesothelioma claims reporting against the Liable Entities. Shifting the pattern of incidence by 2 years could add approximately \$279m (19%) on a discounted basis to our valuation (as shown in Figure 11.1 by the scenario labelled “mesothelioma incidence pattern”).

Table 11.1: Summary results of sensitivity analysis (\$m)

	Undiscounted	Discounted
Central estimate	1,967.3	1,472.4
Low Scenario	1,555.8	1,184.1
High Scenario	3,063.0	2,183.1

Whilst the table above indicates a range around the discounted central estimate of liabilities of -\$288m to +\$711m, the actual cost of liabilities could fall outside that range depending on the actual experience.

We further note that these sensitivity test ranges are not intended to correspond to a specified probability of sufficiency nor are they intended to indicate an upper bound or a lower bound of all possible outcomes.

A Projected inflated and undiscounted cashflows (\$m)

Payment Year	Mesothelioma Claims	Asbestos Claims	Lung Cancer Claims	ARPD & Other Claims	Legal and Other Costs	Workers Compensation Claims	Workers Compensation Legal and Other Costs	Wharf Claims	Wharf Legal and Other Costs	Banyulil Recoveries	Cross Claim Recoveries	Gross	Insurance	Net
2025 / 2026	142.5	19.8	3.5	4.0	20.5	0.1	0.0	0.9	0.2	0.2	5.1	186.6	8.3	178.4
2026 / 2027	145.4	16.7	3.0	3.9	19.5	0.1	0.0	0.7	0.2	0.1	5.1	184.7	6.0	178.7
2027 / 2028	142.2	15.5	2.8	3.6	18.4	0.1	0.0	0.6	0.2	0.1	4.9	178.6	6.1	172.5
2028 / 2029	134.2	15.3	2.8	3.6	17.1	0.1	0.0	0.6	0.2	0.1	4.7	169.2	6.0	163.2
2029 / 2030	124.8	14.0	2.5	3.2	15.7	0.1	0.0	0.6	0.1	0.1	4.4	156.7	5.8	150.9
2030 / 2031	116.0	12.9	2.3	2.8	14.5	0.1	0.0	0.5	0.1	0.1	4.0	145.3	3.2	142.0
2031 / 2032	105.1	11.6	2.1	2.5	13.1	0.1	0.0	0.4	0.1	0.1	3.7	131.3	2.8	128.5
2032 / 2033	94.4	10.1	1.8	2.1	11.8	0.0	0.0	0.4	0.1	0.1	3.3	117.5	2.0	115.5
2033 / 2034	84.8	9.0	1.6	1.8	10.6	0.0	0.0	0.3	0.1	0.0	2.9	105.3	1.6	103.6
2034 / 2035	75.6	7.9	1.4	1.5	8.9	0.0	0.0	0.3	0.1	0.0	2.6	93.1	1.5	91.6
2035 / 2036	67.0	6.8	1.2	1.3	7.8	0.0	0.0	0.2	0.1	0.0	2.3	82.1	1.4	80.7
2036 / 2037	58.9	5.9	1.0	1.0	6.8	0.0	0.0	0.2	0.0	0.0	2.0	72.0	1.3	70.7
2037 / 2038	51.5	5.0	0.8	0.9	5.9	0.0	0.0	0.2	0.0	0.0	1.8	62.7	1.1	61.5
2038 / 2039	44.8	4.3	0.7	0.7	5.0	0.0	0.0	0.1	0.0	0.0	1.5	54.2	1.0	53.2
2039 / 2040	38.8	3.6	0.6	0.6	4.3	0.0	0.0	0.1	0.0	0.0	1.3	46.7	0.9	45.8
2040 / 2041	33.5	3.0	0.5	0.5	3.7	0.0	0.0	0.1	0.0	0.0	1.1	40.1	0.8	39.3
2041 / 2042	28.9	2.5	0.4	0.4	3.1	0.0	0.0	0.1	0.0	0.0	1.0	34.3	0.7	33.6
2042 / 2043	24.8	2.0	0.3	0.3	2.6	0.0	0.0	0.1	0.0	0.0	0.8	29.3	0.6	28.7
2043 / 2044	21.3	1.6	0.3	0.2	2.2	0.0	0.0	0.0	0.0	0.0	0.7	25.0	0.5	24.4
2044 / 2045	18.2	1.3	0.2	0.2	1.9	0.0	0.0	0.0	0.0	0.0	0.6	21.2	0.5	20.8
2045 / 2046	15.6	1.0	0.2	0.1	1.6	0.0	0.0	0.0	0.0	0.0	0.5	18.0	0.4	17.6
2046 / 2047	12.8	0.8	0.1	0.1	1.3	0.0	0.0	0.0	0.0	0.0	0.4	14.8	0.3	14.4
2047 / 2048	10.2	0.6	0.1	0.1	1.0	0.0	0.0	0.0	0.0	0.0	0.3	11.7	0.3	11.4
2048 / 2049	8.0	0.5	0.1	0.1	0.8	0.0	0.0	0.0	0.0	0.0	0.3	9.2	0.2	9.0
2049 / 2050	6.3	0.4	0.1	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.2	7.2	0.2	7.0
2050 / 2051	4.9	0.3	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.2	5.6	0.1	5.5
2051 / 2052	3.9	0.2	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	4.4	0.1	4.3
2052 / 2053	3.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	3.4	0.1	3.3
2053 / 2054	2.4	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	2.7	0.1	2.6
2054 / 2055	1.9	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	2.1	0.1	2.0
2055 / 2056	1.5	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	1.6
2056 / 2057	1.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	1.2
2057 / 2058	0.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0
2058 / 2059	0.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.8
2059 / 2060	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.6
2060 / 2061	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.5
2061 / 2062	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.4
2062 / 2063	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.3
2063 / 2064	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1
2064 / 2065	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2065 / 2066	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2066 / 2067	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2067 / 2068	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2068 / 2069	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2069 / 2070	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2070 / 2071	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2071 / 2072	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2072 / 2073	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TOTAL	1,628.0	173.1	30.4	35.4	200.5	0.8	0.3	6.5	1.7	1.0	56.2	2,021.6	54.3	1,967.3

B Projected inflated and discounted cashflows (\$m)

Payment Year	Mesothelioma Claims	Asbestosis Claims	Lung Cancer Claims	ARPD & Other Claims	Legal and Other Costs	Workers Compensation Claims	Workers Compensation Legal and Other Costs	Wharf Claims	Wharf Legal and Other Costs	Baryulgil	Cross Claim Recoveries	Gross	Insurance	Net
2025 / 2026	139.9	19.5	3.5	3.9	20.1	0.1	0.0	0.8	0.2	0.2	5.0	183.1	8.1	175.0
2026 / 2027	137.6	15.8	2.9	3.7	18.5	0.1	0.0	0.7	0.2	0.1	4.8	174.7	5.7	169.0
2027 / 2028	129.9	14.1	2.6	3.3	16.8	0.1	0.0	0.6	0.2	0.1	4.5	163.1	5.5	157.6
2028 / 2029	118.0	13.4	2.4	3.1	15.1	0.1	0.0	0.5	0.1	0.1	4.1	148.8	5.3	143.6
2029 / 2030	105.3	11.8	2.1	2.7	13.2	0.1	0.0	0.5	0.1	0.1	3.7	132.3	4.9	127.4
2030 / 2031	93.6	10.5	1.9	2.3	11.7	0.1	0.0	0.4	0.1	0.1	3.3	117.3	2.6	114.7
2031 / 2032	80.9	8.9	1.6	1.9	10.1	0.0	0.0	0.3	0.1	0.0	2.8	101.1	2.2	98.9
2032 / 2033	69.1	7.4	1.3	1.5	8.7	0.0	0.0	0.3	0.1	0.0	2.4	86.1	1.5	84.6
2033 / 2034	59.0	6.2	1.1	1.2	7.4	0.0	0.0	0.2	0.1	0.0	2.0	73.3	1.1	72.1
2034 / 2035	50.0	5.2	0.9	1.0	5.9	0.0	0.0	0.2	0.0	0.0	1.7	61.5	1.0	60.5
2035 / 2036	42.0	4.3	0.7	0.8	4.9	0.0	0.0	0.1	0.0	0.0	1.4	51.5	0.9	50.6
2036 / 2037	35.0	3.5	0.6	0.6	4.0	0.0	0.0	0.1	0.0	0.0	1.2	42.8	0.8	42.0
2037 / 2038	29.0	2.8	0.5	0.5	3.3	0.0	0.0	0.1	0.0	0.0	1.0	35.3	0.6	34.7
2038 / 2039	23.9	2.3	0.4	0.4	2.7	0.0	0.0	0.1	0.0	0.0	0.8	29.0	0.5	28.4
2039 / 2040	19.6	1.8	0.3	0.3	2.2	0.0	0.0	0.1	0.0	0.0	0.7	23.6	0.5	23.2
2040 / 2041	16.1	1.4	0.2	0.2	1.8	0.0	0.0	0.0	0.0	0.0	0.5	19.2	0.4	18.8
2041 / 2042	13.1	1.1	0.2	0.2	1.4	0.0	0.0	0.0	0.0	0.0	0.4	15.6	0.3	15.3
2042 / 2043	10.7	0.9	0.1	0.1	1.1	0.0	0.0	0.0	0.0	0.0	0.4	12.6	0.3	12.3
2043 / 2044	8.7	0.7	0.1	0.1	0.9	0.0	0.0	0.0	0.0	0.0	0.3	10.2	0.2	9.9
2044 / 2045	7.0	0.5	0.1	0.1	0.7	0.0	0.0	0.0	0.0	0.0	0.2	8.2	0.2	8.0
2045 / 2046	5.7	0.4	0.1	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.2	6.6	0.1	6.4
2046 / 2047	4.4	0.3	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	5.1	0.1	5.0
2047 / 2048	3.3	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	3.8	0.1	3.7
2048 / 2049	2.5	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	2.8	0.1	2.8
2049 / 2050	1.8	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	2.1	0.1	2.1
2050 / 2051	1.4	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	1.5
2051 / 2052	1.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	1.1
2052 / 2053	0.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.8
2053 / 2054	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.6
2054 / 2055	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.5
2055 / 2056	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.3
2056 / 2057	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.2
2057 / 2058	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2
2058 / 2059	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1
2059 / 2060	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1
2060 / 2061	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1
2061 / 2062	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1
2062 / 2063	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2063 / 2064	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2064 / 2065	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2065 / 2066	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2066 / 2067	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2067 / 2068	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2068 / 2069	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2069 / 2070	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2070 / 2071	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2071 / 2072	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
2072 / 2073	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TOTAL	1,211.6	133.5	23.7	28.1	152.6	0.7	0.2	5.2	1.4	0.8	42.1	1,515.6	43.2	1,472.4

C Glossary of terms used in the Amended Final Funding Agreement

The following provides a glossary of terms which are referenced in the Amended Final Funding Agreement and upon which we have relied in preparing our report.

The operation of these definitions cannot be considered in isolation but instead need to be considered in the context of the totality of the Amended Final Funding Agreement.

AICF means the trustee of the Asbestos Injuries Compensation Fund from time to time, in its capacity as trustee, initially being Asbestos Injuries Compensation Fund Limited.

These terms also need to be read in conjunction with the Deed of Amendment dated 19 December 2017 which added a new clause (13.4A) and which is effective from 1 January 2018.

AICF Funded Liability means:

- (a) any Proven Claim;
- (b) Operating Expenses;
- (c) Claims Legal Costs;
- (d) any claim that was made or brought in legal proceedings against a Former James Hardie Company commenced before 1 December 2005;
- (e) Statutory Recoveries within the meaning and subject to the limits set out in the Amended Final Funding Agreement;
- (f) a claim or category of claim which James Hardie and the NSW Government agree in writing is a "AICF Funded Liability" or a category of "AICF Funded Liability".

but in the cases of paragraphs (a), (c) and (d) excludes any such liabilities or claims to the extent that they have been recovered or are recoverable under a Worker's Compensation Scheme or Policy.

Claims Legal Costs means all costs, charges, expenses and outgoings incurred or expected to be borne by AICF or the Former James Hardie Companies, in respect of legal advisors, other advisors, experts, court proceedings and other dispute resolution methods in connection with Personal Asbestos Claims and Marlew Claims but in all cases excluding any costs included as a component of calculating a Proven Claim.

Concurrent Wrongdoer in relation to a personal injury or death claim for damages under common law or other law (excluding any law introduced or imposed in breach of the restrictions on adverse regulatory or legislative action against the James Hardie Group under the Amended Final Funding Agreement, and which breach has been notified to the NSW Government in accordance with Amended Final Funding Agreement), means a person whose acts or omissions, together with the acts or omissions of one or more Former James Hardie Companies or Marlew or any member of the James Hardie Group (whether or not together with any other persons) caused, independently of each other or jointly, the damage or loss to another person that is the subject of that claim.

Contribution Claim means a cross-claim or other claim under common law or other law (excluding any law introduced or imposed in breach of the restrictions on adverse regulatory or legislative action against the James Hardie Group under the Amended Final Funding Agreement, and which breach has been notified to the NSW Government in accordance with Amended Final Funding Agreement):

- (a) for contribution by a Concurrent Wrongdoer against a Former James Hardie Company or a member of the James Hardie Group in relation to facts or circumstances which give rise to a right of a person to make a Personal Asbestos Claim or a Marlew Claim; or
- (b) by another person who is entitled under common law (including by way of contract) to be subrogated to such a first mentioned cross-claim or other claim;

Discounted Central Estimate means the central estimate of the present value (determined using the discount rate used within the relevant actuarial report) of the liabilities of the Former James Hardie Companies and Marlew in respect of expected Proven Claims and Claims Legal Costs, calculated in accordance with the Amended Final Funding Agreement.

Excluded Claims are any of the following liabilities of the Former James Hardie Companies:

- (i) personal injury or death claims arising from exposure to Asbestos outside Australia;
- (ii) personal injury or death claims arising from exposure to Asbestos made outside Australia;
- (iii) claims for economic loss (other than any economic loss forming part of the calculation of an award of damages for personal injury or death) or loss of property, including those relating to land remediation and/or Asbestos or Asbestos products removal, arising out of or in connection with Asbestos or Asbestos products manufactured, sold, distributed or used by or on behalf of the Liable Entities;
- (iv) any Excluded Marlew Claim;
- (v) any liabilities of the Liable Entities other than AICF Funded Liabilities.

Excluded Marlew Claim means a Marlew Claim:

- (a) covered by the indemnities granted by the Minister of Mineral Resources under the deed between the Minister, Fuller Earthmoving Pty Limited and James Hardie Industries Limited dated 11 March 1996; or
- (b) by a current or former employee of Marlew in relation to an exposure to Asbestos in the course of such employment to the extent:
 - (i) the loss is recoverable under a Worker's Compensation Scheme or Policy; or

- (ii) the Claimant is not unable to recover damages from a Marlew Joint Tortfeasor in accordance with the Marlew Legislation;
- (c) by an individual who was or is an employee of a person other than Marlew arising from exposure to Asbestos in the course of such employment by that other person where such loss is recoverable from that person or under a Worker's Compensation Scheme or Policy; or
- (d) in which another defendant (or its insurer) is a Marlew Joint Tortfeasor from whom the plaintiff is entitled to recover compensation in proceedings in the Dust Diseases Tribunal, and the Claimant is not unable to recover damages from that Marlew Joint Tortfeasor in accordance with the Marlew Legislation.

Former James Hardie Companies means Amaca, Amaba and ABN 60.

Insurance and Other Recoveries means any proceeds which may reasonably be expected to be recovered or recoverable for the account of a Former James Hardie Company or to result in the satisfaction (in whole or part) of a liability of a Former James Hardie Company (of any nature) to a third party, under any product liability insurance policy or public liability insurance policy or commutation of such policy or under any other contract, including any contract of indemnity, but excluding any such amount recovered or recoverable under a Worker's Compensation Scheme or Policy.

Liable Entities see Former James Hardie Companies.

Marlew means Marlew Mining Pty Ltd (in liquidation), ACN 000 049 650, previously known as Asbestos Mines Pty Ltd.

Marlew Claim means, subject to the limitation on Statutory Recoveries, a claim which satisfies one of the following paragraphs and which is not an Excluded Marlew Claim:

- (a) any present or future personal injury or death claim by an individual or the legal personal representative of an individual, for damages under common law or other law (excluding any law introduced or imposed in breach of the restrictions on adverse regulatory or legislative action against the James Hardie Group under the Amended Final Funding Agreement, and which breach has been notified to the NSW Government in accordance with the Amended Final Funding Agreement) which:
 - (i) arose or arises from exposure to Asbestos in the Baryulgil region from Asbestos Mining Activities at Baryulgil conducted by Marlew, provided that:
 - A. the individual's exposure to Asbestos occurred wholly within Australia; or
 - B. where the individual has been exposed to Asbestos both within and outside Australia, the amount of damages included in the Marlew Claim shall be limited to the amount attributable to the proportion of the exposure which caused or contributed to the loss or damage giving rise to the Marlew Claim which occurred in Australia;
 - (ii) is commenced in New South Wales in the Dust Diseases Tribunal; and

- (iii) is or could have been made against Marlew had Marlew not been in external administration or wound up, or could be made against Marlew on the assumption (other than as contemplated under the Marlew legislation) that Marlew will not be in the future in external administration;
- (b) any claim made under compensation to relatives legislation by a relative of a deceased individual (or personal representative of such a relative) or (where permitted by law) the legal personal representative of a deceased individual in each case where the individual, but for such individual's death, would have been entitled to bring a claim of the kind described in paragraph (a); or
- (c) a Contribution Claim relating to a claim described in paragraphs (a) or (b).

Marlew Joint Tortfeasor means any person who is or would be jointly and severally liable with Marlew in respect of a Marlew Claim, had Marlew not been in external administration or wound up, or on the assumption that Marlew will not in the future be, in external administration or wound up other than as contemplated under the Marlew Legislation.

Payable Liability means any of the following:

- (a) any Proven Claim (whether arising before or after the date of this deed);
- (b) Operating Expenses;
- (c) Claims Legal Costs;
- (d) any liability of a Former James Hardie Company to the AICFL, however arising, in respect of any amounts paid by the AICFL in respect of any liability or otherwise on behalf of the Former James Hardie Company;
- (e) any claim that was made or brought in legal proceedings against a Former James Hardie Company commenced before 1 December 2005;
- (f) if regulations are made pursuant to section 30 of the Transaction Legislation and if and to the extent the AICFL and James Hardie have notified the NSW Government that any such liability is to be included in the scope of Payable Liability, any liability of a Former James Hardie Company to pay amounts received by it from an insurer in respect of a liability to a third party incurred by it for which it is or was insured under a contract of insurance entered into before 2 December 2005; and
- (g) Statutory Recoveries within the meaning and subject to the limits set out in the Amended Final Funding Agreement,

but in the cases of paragraphs (a), (c) and (e) excludes any such liabilities or claims to the extent that they have been recovered or are recoverable under a Worker's Compensation Scheme or Policy.

Period Actuarial Estimate means, in respect of a period, the central estimate of the present value (determined using the discount rate used in the relevant actuarial report) of the liabilities of the Former James Hardie Companies and Marlew in respect of expected Proven Claims and Claims Legal Costs (in each case which are reasonably expected to become payable in that period), before allowing for Insurance and Other Recoveries, calculated in accordance with the Amended Final Funding Agreement.

Personal Asbestos Claim means any present or future personal injury or death claim by an individual or the legal personal representative of an individual, for damages under common law or under other law (excluding any law introduced or imposed in breach of the restrictions on adverse regulatory or legislative action against the James Hardie Group under the Amended Final Funding Agreement, and which breach has been notified to the NSW Government under the Amended Final Funding Agreement) which:

- (a) arises from exposure to Asbestos occurring in Australia, provided that:
 - (i) the individual's exposure to Asbestos occurred wholly within Australia; or
 - (ii) where the individual has been exposed to Asbestos both within and outside Australia, damages included in the Marlew Claim shall be limited to the amount attributable to the proportion of the exposure which caused or contributed to the loss or damage giving rise to the Personal Asbestos Claim which occurred in Australia;
- (b) is made in proceedings in an Australian court or tribunal; and
- (c) is made against:
 - (i) all or any of the Liable Entities; or
 - (ii) any member of the James Hardie Group from time to time;
- (d) any claim made under compensation to relatives legislation by a relative of a deceased individual (or personal representative of such a relative) or (where permitted by law) the legal personal representative of a deceased individual in each case where the individual, but for such individual's death, would have been entitled to bring a claim of the kind described in paragraph (a); or
- (e) a Contribution Claim made in relation to a claim described in paragraph (a) or (b)

but excludes all claims covered by a Worker's Compensation Scheme or Policy.

Proven Claim means a proven Personal Asbestos Claim in respect of which final judgment has been given against, or a binding settlement has been entered into by, a Former James Hardie Company, to the extent to which that entity incurs liability under that judgment or settlement, or a Proven Marlew Claim.

Statutory Recoveries means any statutory entitlement of the NSW Government or any Other Government or any governmental agency or authority of any such government ("Relevant Body") to impose liability on or to recover an amount or amounts from any person in respect of any payments made or to be made or benefits provided by a Relevant Body in respect of claims (other than as a defendant or in settlement of any claim, including a cross-claim or claim for contribution).

Term means the period

- (i) from the date on which the principal obligations under the Amended Final Funding Agreement will commence to 31 March 2045,
- (ii) as may be extended in accordance with the terms of the Amended Final Funding Agreement.

Term Central Estimate means the central estimate of the present value (determined using the discount rate used in the relevant Annual Actuarial Report) of the liabilities of the Former James Hardie Companies and Marlew in respect of expected Proven Claims and Claims Legal Costs (in each case reasonably expected to become payable in the relevant period) after allowing for Insurance and Other Recoveries during that period, from and including the day following the end of the Financial Year preceding that Payment Date up to and including the last day of the Term (excluding any automatic or potential extension of the Term, unless or until the Term has been extended).

Workers Compensation Scheme or Policy means any of the following:

- (a) any worker's compensation scheme established by any law of the Commonwealth or of any State or Territory;
- (b) any fund established to cover liabilities under insurance policies upon the actual or prospective insolvency of the insurer (including without limitation the Insurer Guarantee Fund established under the Worker's Compensation Act 1987 (NSW)); and
- (c) any policy of insurance issued under or pursuant to such a scheme.





